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Abstract 
Breast cancer remains the most common malignant disease in women worldwide. 
Despite the advantages of early detection and improved treatments, studies into the 
mechanisms that initiate and drive breast cancer progression are still required. Recent 
studies have identified RUNX1, which is an essential transcription factor for 
hematopoiesis, is one of the most frequently mutated genes in breast cancer patients. 
However, the role of RUNX1 in the mammary gland is understudied. 
    In this dissertation, we examined the role of RUNX1 in both normal mammary epithelial 
and breast cancer cells. Our in vitro studies demonstrated that RUNX1 inhibits epithelial 
to mesenchymal transition (EMT), migration, and invasion, reflecting its tumor suppressor 
activity, which was confirmed in vivo.  Moreover, RUNX1 also contributes significantly to 
inhibition of the phenotypes of breast cancer stem cells (CSC), which is responsible for 
metastasis and tumor relapse.  We showed that Runx1 overexpression reduces the 
tumorsphere formation and cancer stem cell population. Overall, our studies provide 
mechanistic evidence for RUNX1 repression of EMT in mammary cells, anti-tumor activity 
in vivo and regulation of CSC-like properties in breast cancer.  
Our results highlight crucial roles for RUNX1 in preventing epithelial to mesenchymal 
transition and tumor progression in breast cancer. This RUNX1 mediated mechanism 
points to novel intervention strategies for early stage breast cancer.  
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Chapter I Introduction 
1.1 Mammary Gland Biology and Breast Cancer   
1.1.1 Breast cancer overview 
Breast cancer is the most commonly diagnosed cancer in women worldwide (~30% 
of new cancer diagnoses). Approximately 1 in 8 women in the USA will develop 
invasive breast cancer during their lifespan. In 2017, about 252,000 new invasive 
breast cancer cases are expected to be diagnosed in the U.S (Siegel, Miller et al. 
2016).  In the past few decades, significant advances in early detection and 
treatment of breast cancer have greatly improved the overall 5-year survival rate 
for breast cancer patients with an increase from 35% in 1960’s to 89% in 2016 
(Miller, Siegel et al. 2016). Despite this progress, breast cancer remains the 
second leading cause of cancer-related death in American women. About 40,000 
women in the USA are expected to die due to breast cancer in 2017 alone (Siegel, 
Miller et al. 2016).  Worldwide, half-a-million women die from breast cancer each 
year. Therefore, further studies into the mechanisms that initiate and drive breast 
cancer progression are still needed. A greater understanding of these mechanisms 
will provide new potential targets for improved therapies. 
 
1.1.2 Breast cancer molecular subtypes  
Breast cancer is either ductal or lobular, with the ductal type compositing the 
majority of cases (40%-75%) (Bombonati and Sgroi 2011). Ductal breast 
carcinoma progression can be further divided into 4 progressive stages based on 
	 2	
histology: flat epithelial atypia (benign lesion), atypical hyperplasia (precancerous 
lesion), ductal carcinoma in situ (DCIS), and invasive ductal carcinoma (IDC, which 
is highly aggressive and metastatic) (Bombonati and Sgroi 2011). However, 
patients exhibit considerable heterogeneity in clinical responses even amongst the 
same stage, indicating the need for a new classification method (Polyak 2007, 
Rivenbark, O’Connor et al. 2013).  In the past two decades, using the gene 
expression portrait including the expression of estrogen receptor (ER), the 
progesterone receptor (PR) and the human epidermal growth factor receptor-
related protein (HER2), breast cancer is characterized into 6 distinct molecular 
subtypes, summarized in Table 1.1, including four major subtypes: Luminal A, 
Luminal B, Basal like, Her2 enriched, and two unusual subtypes: Claudin-low and 
normal-breast (Sørlie, Perou et al. 2001, Sørlie, Tibshirani et al. 2003, Prat, Parker 
et al. 2010, Eroles, Bosch et al. 2012) .  
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Table 1.1 Features of molecular subtypes of breast cancer. 
 
Luminal A 
The luminal A subtype comprises 50–60% of all diagnosed breast tumors and is 
therefore the most common subtype (Eroles, Bosch et al. 2012). It is characterized 
by high expression of ER-activated genes that are typically expressed in the 
luminal epithelial lining in the mammary ducts (Sørlie, Perou et al. 2001). Luminal 
A tumors usually have a low histological grade, and lower expression of 
proliferation related genes. In particular, the immunohistochemistry profile of the 
luminal A subtype is characterized by expression of ER, PR, Bcl-2, GATA3 and 
cytokeratin CK8/18, and an absence of HER2 and Ki67 expression (Eroles, Bosch 
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et al. 2012).  This subtype of breast cancer has a higher incidence of metastasis 
to bone (18.7% of total patients) compared to other sites such as nervous system, 
liver and lungs, which together represent less than 10% of metastatic sites (Eroles, 
Bosch et al. 2012).  Luminal A patients have a generally good prognosis with a 
metastatic rate of 27.8% which is significantly lower than that of other subtypes 
(Kennecke, Yerushalmi et al. 2010).  The treatment of this subtype is mainly based 
on hormonal treatment in postmenopausal patients, and selective estrogen 
receptor modulators like Tamoxifen, a competitive inhibitor of the estrogen 
receptor binding to its ligands (Guarneri and Conte 2009).  
Luminal B  
The luminal B group makes up 10–20% of all breast cancers and has a higher 
histological grade, greater proliferative rate, and an aggressive phenotype with a 
worse prognosis compared with the Luminal A subtype (Colleoni, Rotmensz et al. 
2012). Similar to the Luminal A subtype, the Luminal B subtype also expresses ER, 
but with a higher expression of proliferation genes, such as Ki67 and cyclin-B1, 
and growth factor receptors EGFR and HER2. Bone is also the most common site 
of metastasis (30%), together with a high metastasis rate in other organs such as 
the liver (13.8%) (Eroles, Bosch et al. 2012). Luminal B tumors are treated with 
Tamoxifen and aromatase inhibitors, which inhibits the generation of estrogen. 
However, the worse prognosis compared to luminal A tumors underlines the need 
of new therapeutic options for this subgroup (Bosch, Eroles et al. 2010).  
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Basal-like   
The basal-like subtype accounts for 10% to 20% of breast cancer cases (Bosch, 
Eroles et al. 2010). Basal-like tumors typically express genes characteristic of 
mammary myoepithelial cells, including Cytokeratins CK5 and CK17, P-cadherin, 
Caveolin 1/2, Nestin, CD44, Vimentin and EGFR (Nielsen, Hsu et al. 2004). 
Meanwhile genes characteristic of the luminal epithelium, such as CK8/18 and Kit, 
are lower in these tumors (Eroles, Bosch et al. 2012). Clinically, basal-like tumors 
are characterized by their larger size, higher grade, presence of necrosis, pushing 
borders of invasion, and frequent invasion of the lymph node (Livasy, Karaca et al. 
2005, Bosch, Eroles et al. 2010). One of the most relevant features of this subtype 
is the lack of expression of the three key receptors in breast cancer: estrogen 
receptor, progesterone receptor and HER2. For this reason the basal-like group 
overlaps with triple-negative breast cancer (TNBC) (Eroles, Bosch et al. 2012). 
Compared with luminal subtypes, basal-like tumors frequently have a worse 
prognosis and a higher relapse rate in the first 3 years (Dent, Trudeau et al. 2007).  
Molecularly, basal-like tumors have a high rate of p53 mutation and often carry a 
germ-line mutation in BRCA1 (Sørlie, Tibshirani et al. 2003).  Metastatic relapse 
of the basal-like subtype commonly occurs in visceral organs, such as lung, central 
nervous system and lymph nodes (Kennecke, Yerushalmi et al. 2010).   
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HER2 positive  
HER2 positive tumors represent 15-20% of breast cancers. They are characterized 
by a high expression of the HER2 gene and other genes associated with the HER2 
pathway (Eroles, Bosch et al. 2012). These tumors are highly proliferative, with a 
high histological grade and frequent p53 mutations (Montemurro, Di Cosimo et al. 
2013). Clinically, the HER2-positive subtype is a poor prognosis subtype, while the 
introduction of anti-HER2 treatment has significantly improved survival in both 
primary and metastatic disease (Slamon, Leyland-Jones et al. 2001).   
Claudin-low 
The Claudin-low subtype is the newest defined subtype, which was identified in 
2007 (Herschkowitz, Simin et al. 2007). It is characterized by having low 
expression of tight junction and intercellular adhesion genes, including Claudin-3, 
-4, -7, Occludin and E-cadherin (Eroles, Bosch et al. 2012).  The gene expression 
profile of this subtype is similar to that of the basal subtype, as both have low Her2 
and luminal gene expression (Parker, Mullins et al. 2009, Prat, Parker et al. 2010).  
In contrast to the basal subtype, however, the Claudin-low subtype expresses a 
set of 40 immune response-related genes, indicating high infiltration of immune 
system cells (Hennessy, Gonzalez-Angulo et al. 2009, Prat, Parker et al. 2010, 
Sabatier, Finetti et al. 2014).  Additionally, this subtype is also enriched in genes 
associated with epithelial-mesenchymal transition and cancer stem cell 
phenotypes (Eroles, Bosch et al. 2012).  These tumors show poor long-term 
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prognosis and are not sensitive to neoadjuvant chemotherapy (Prat, Parker et al. 
2010, Prat and Perou 2011).  
Normal Breast Subtype 
The normal-breast subtype accounts for about 5-10% of breast carcinomas (Eroles, 
Bosch et al. 2012). This subtype expresses genes associated with adipose tissues 
and has an intermediate prognosis between luminal and basal-like subtypes. 
Tumors from this subtype are occasionally inappropriately classified as triple-
negative as they do not express ER, PR and HER. However, this subtype differs 
from the basal-like subtype, as they are negative for CK5 and EGFR expression 
(Eroles, Bosch et al. 2012).  There are some contradictory views of this subtype, 
as some researchers question its existence as they consider it a technical artifact 
due to contamination from normal breast tissue (Weigelt, Mackay et al. 2010). The 
knowledge regarding the molecular mechanism and treatment is inadequate for 
this subtype due to its rarity and the technical artifact hypothesis.  
 
1.1.3 The origin of breast cancer and breast cancer subtypes 
As discussed above, breast cancer is not a single disease, but is composed of 
distinct subtypes associated with different clinical outcomes. Understanding this 
heterogeneity is key for developing targeted therapy and preventive intervention.  
The roots of breast cancer heterogeneity lie in the developmental hierarchy of the 
normal mammary gland, which contains both luminal and basal cell lineages 
(Skibinski and Kuperwasser 2015). It has been speculated for a long time that 
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accumulation of specific mutations in a particular cell type of the normal mammary 
epithelium generates transformed multi-potent cells, which then give rise to a 
specific breast cancer subtype (Smalley and Ashworth 2003). The molecular 
features of each subtype mirror the characteristics of the normal cell type of their 
origin. For example, mammary stem cells are thought to be the cell-of-origin for 
basal-like breast cancer based on their shared features such as expression of 
basal cytokeratin and low expression of hormone receptors (Polyak 2007). While 
Luminal A tumors are thought to be derived from relatively well-differentiated cells 
of the ER+ lineage, Luminal B tumors are believed to develop from less 
differentiated luminal progenitors (Polyak 2007). However, this hypothesis has 
been recently challenged using in vivo lineage tracing. In this method, particular 
cell types from the mammary gland, such as mammary stem cells, luminal 
progenitors and basal progenitor cells, have been identified using different cell 
surface markers (Summarized in Fig. 1.1) (Visvader and Stingl 2014, Skibinski and 
Kuperwasser 2015). Comparison of the gene expression signature of these 
lineages with breast cancer subtypes has suggested that one lineage may give 
rise to the multiple subtypes (Lim, Vaillant et al. 2009). Luminal progenitors likely 
serve as the origin of both luminal and basal-like breast cancers (Lim, Vaillant et 
al. 2009, Prat and Perou 2011); whereas the basal progenitor signature is most 
closely aligned with the expression profile of the Claudin-low subtype (Lim, Vaillant 
et al. 2009). This observation was confirmed by studies of the origin of BRCA-1 
associated breast cancer.  Different strategies have all demonstrated that BRCA-
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1 associated basal-like breast cancer is derived from luminal progenitor cells (Lim, 
Vaillant et al. 2009, Molyneux, Geyer et al. 2010, Proia, Keller et al. 2011, Bai, 
Smith et al. 2013).  
Still, it remains an open question as to why luminal progenitor cells can give rise 
to both luminal and basal subtypes. One explanation is that the luminal progenitor 
population itself is heterogeneous (e.g., with respect to estrogen receptor 
expression) (Booth and Smith 2006, Shehata, Teschendorff et al. 2012).  Another 
hypothesis is based on the striking finding that 80% of basal-like breast tumors 
carry p53 mutations. An early loss of p53 may cause genome instability thereby 
allowing the acquisition of secondary mutations. The cells with p53 and secondary 
mutations may gain a competitive advantage over neighboring clones with regard 
to proliferation, migration and invasion, which are also features of basal-like breast 
cancer (Skibinski and Kuperwasser 2015). Currently the origin of Her2-positive 
breast cancer remains unclear. Better understanding of the etiology and biology of 
each subtype will enhance the precision of diagnosis and treatment of women with 
different forms of breast cancer.  
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Figure 1.1 Schematic model of mammary epithelial hierarchy and 
potential relationship with breast tumor subtypes.  Cell surface 
markers used for the isolation of epithelial cell populations from the 
mouse mammary gland are indicated. The four major tumor types are 
shown linked to their closest normal epithelial cell type. Basal-like 
subtype could originate through mutation of p53 and BRCA1 in the 
luminal progenitor cells.  
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1.1.4 Cell line models used in breast cancer studies 
The first breast cancer cell line, BT-20, was established in 1958 (Lasfargues and 
Ozzello 1958). Later more breast cancer cell lines were generated, such as the 
MDA series generated by MD Anderson Cancer Center. One of such cell line, 
MDA-MB-231, the highly metastatic breast cell line generated in 1973	(Cailleau, 
Young et al. 1974), is widely used to identify genes and pathways that regulate 
metastasis to different sites	(Kang, Siegel et al. 2003, Minn, Gupta et al. 2005, Bos, 
Zhang et al. 2009). The most commonly used breast cancer cell line in the world 
is MCF-7, which was also established in 1973 at the Michigan Cancer Foundation	
(Soule, Vazquez et al. 1973).  MCF-7 cells have high expression of estrogen 
receptor (ER), which makes them very sensitive to hormone and thus an ideal 
model to study hormone response	(Levenson and Jordan 1997).  Currently there 
are more 100 breast cancer cell lines available from ATCC. Based on their gene 
expression profiles, they have been grouped into different subtypes of breast 
cancer (Neve, Chin et al. 2006, Prat, Karginova et al. 2013). Breast cell line models 
are widely used to identify molecular mechanisms, test treatment response both in 
vitro and in xenograft models	(Holliday and Speirs 2011).  
    Another breast cell line model used in this dissertation is the MCF10 cell line 
series. MCF10A cells are considered to be a normal-like mammary epithelial cell, 
which was obtained from a patient with benign fibrocystic disease (Soule, Maloney 
et al. 1990). It is a spontaneously immortalized, non-malignant breast cell line. The 
MCF10A cell line is the founder of a progressively more aggressive family of breast 
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cancer lines named MCF10 series. These cell lines include MCF10AT1, which is 
a premalignant cell line derived from MCF10A by overexpressing the H-Ras 
oncogene (Dawson, Wolman et al. 1996), a set of highly aggressive and metastatic 
MCF10CA cell lines (including MCF10CA1a), which gained the capability of 
metastasis after in vivo passage of MCF10AT (Santner, Dawson et al. 2001). While 
MCF10A cells cannot form tumors in vivo, MCF10AT can form tumors with an 
incidence of about 25% and MCF10CA1a always forms tumors after subcutaneous 
injection into nude mice (Dawson, Wolman et al. 1996, Santner, Dawson et al. 
2001). Therefore, the MCF10 cell line series provides a useful model to assess the 
progression of breast cancer. 
 
1.2 The Runx Family  
1.2.1 Runx family overview 
Runx proteins, which function as lineage-specific transcription factors, regulate cell 
differentiation, proliferation and growth (Reviewed in (Coffman 2003)).  Runx 
proteins are also known as acute myeloid leukemia (AML), core-binding factor 
(CBF) or Polyoma enhancer-binding protein-2α (PEBP2α) family (Ito 2004). The 
Runx proteins share a highly conserved Runt domain with 128 amino acids in the 
N-terminus (Ogawa, Maruyama et al. 1993). This Runt homology domain is 
responsible for DNA binding and hetero-dimerization with Core Binding Factor 
(CBF-b), which stabilizes the protein complex.  The Runx-CBF-b complex binds to 
a consensus sequence within the DNA (PyGPyGGTPy;Py- cytosine or thymine) 
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(Melnikova, Crute et al. 1993)	(Ogawa, Maruyama et al. 1993). A nuclear targeting 
sequence, located on the C-terminal end of the Runt domain, is essential for proper 
nuclear localization (Kanno, Kanno et al. 1998). Although Runx proteins are 
primarily located in nucleus, in some cell types, Runx proteins are found partly in 
cytoplasm sequestered by STAT5, which is usually elevated in cancer cells 
(Ogawa, Satake et al. 2008).  
    All Runx family members also have a conserved C-terminal region, which is a 
sub-nuclear matrix-targeting signal (NMTS)	(Zeng, McNeil et al. 1998, Zaidi, Javed 
et al. 2001). The NMTS in Runx proteins is a 30-35 amino acid sequence, 
responsible for sub-nuclear localization to distinct nuclear sites for specific gene 
regulation (Zeng, van Wijnen et al. 1997, Zeng, McNeil et al. 1998, Zaidi, Javed et 
al. 2001, Stein, Lian et al. 2007).  The NMTS organizes the multiple complexes of 
Runx proteins with different classes of co-regulatory factors, such as SMAD family 
members. Runx proteins also have PY and VWRPY motifs for protein-protein 
interaction with other transcription factors (Aronson, Fisher et al. 1997, Javed, Guo 
et al. 2000, Lian, Javed et al. 2004, Zaidi, Young et al. 2005, Westendorf 2006, 
Chuang, Ito et al. 2013). 
    In almost all species, Runx function has been shown to be dependent on its 
binding to CBF-b, which increases specificity and affinity of Runx protein binding 
to their target genes (Golling, Li et al. 1996, Adya, Castilla et al. 2000, Kagoshima, 
Nimmo et al. 2007). Sedimentation equilibrium measurement was performed to 
confirm that Runx, CBF-b and DNA form a complex in a 1:1:1 stoichiometry (Tang, 
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Crute et al. 2000). The affinity of Runx for DNA or Runx-CBF-b for DNA has also 
been measured using electromobility shift assay (EMSA) and an isothermal 
titration calorimetric assay (Crute, Lewis et al. 1996, Huang, Crute et al. 1998, 
Tang, Crute et al. 2000). Both measurements have shown a significant 
enhancement (6 to 10-fold) of Runx-DNA binding affinity in the presence of CBF-
b (Crute, Lewis et al. 1996, Huang, Crute et al. 1998, Tang, Crute et al. 2000). In 
addition to CBF-b, Runx factors also bind with co-activators (e.g., p300) or co-
repressors (e.g., Groucho) depending on the cellular context (Aronson, Fisher et 
al. 1997, Javed, Guo et al. 2000, Coffman 2003, Durst and Hiebert 2004, Chuang, 
Ito et al. 2013, Ito, Bae et al. 2015). This complex and dynamic ability allows Runx 
factors to engage in diverse functions and regulatory mechanisms (Coffman 2003).  
 
1.2.2 Structure of Runx 
The structure of the Runt domain has been determined, using X-ray 
crystallography and NMR, to be a member of the s-type Ig fold DNA binding 
domains (Berardi, Sun et al. 1999, Nagata, Gupta et al. 1999). Other members 
include NF-kB, NFAT, STAT1 and p53 (Berardi, Sun et al. 1999, Nagata, Gupta et 
al. 1999). The structure of Runx-CBF-b-DNA complex was later solved using X-
ray crystallography (Warren, Bravo et al. 2000, Bravo, Li et al. 2001, Tahirov, 
Inoue-Bungo et al. 2001). As shown in Figure 1.2, the structure reveals that the 
Runt domain contacts with both DNA major and minor grooves, and the C-terminal 
region of the Runt domain establishes sequence-specific DNA-contacts. On the 
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other hand, CBF-b does not make any contacts with DNA but induces a 
conformational change in the Runt domain to allosterically facilitate binding 
between Runx factors and DNA (Tahirov and Bushweller 2017). Mutagenesis 
studies also identified that residues at the C-terminus of Runt domain (T169, D171, 
R174 and R177 in human RUNX1) are the key amino acids, essential for forming 
the complex between Runx and CBF-b and DNA (Li, Yan et al. 2003). In breast 
cancer patients, several RUNX1 mutations have been identified in Runt domain. 
These mutations, such as D171 and R174, are located at the interface of the Runt 
domain and DNA (Fig. 1.2 Red residues), suggesting that loss of Runx binding on 
target genes will cause disease. In addition to breast cancer, mutations in the 
interface of DNA/Runx or CBF-b/Runx binding have been documented in patients 
with either RUNX1 related leukemia or RUNX2 related Cleidocranial Dysplasias 
(CCD), respectively (Otto, Kanegane et al. 2002, Mangan and Speck 2011).    
The Runt domain is evolutionary conserved in metazoans suggesting that Runx 
proteins have conserved functions through different species. Because Runx genes 
are highly context dependent and partially redundant within vertebrates, the use of 
invertebrate animal models with simple genetic background such as Drosophila 
melanogaster or Caenorhabditis elegans (C.elegans) can help us find an ancestral 
function of Runx.  
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Figure 1.2 Structure of the CBF-b: Runt domain: DNA complex.  
Ribbon representation shows CBF-b in purple, the Runt domain in green, 
and the DNA in blue. RUNX1 mutations identified in breast cancer 
patients are shown in red. For clarity, the structure is shown in two 
different orientations, rotated by 90 degrees relative to one another. The 
image was rendered from PDB code 1H9D. The mutations are clearly 
seen in the DNA binding domain suggesting a loss of RUNX1 function in 
breast cancer. Association of loss function of RUNX1 and breast cancer 
progression is studied in Chapter II,III and IV.  
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1.2.3 Evolutionary role of Runx  
    Evolutionarily, Runx genes have been identified in all metazoans and 
unexpectedly in the unicellular amoeboid halozoan Capsaspora owczarzaki, 
suggesting the Runx family is involved in fundamental biological processes (Sebé-
Pedrós, de Mendoza et al. 2011). The role of Runx genes have been intensively 
studied in the invertebrate animal models Drosophila melanogaster (Dm), 
Strongylocentrotus purpuratus (Sp) and Caenorhabditis elegans. The mechanisms 
obtained from these models can give us a hint of Runx function in mammals, 
especially in human.  
     In the fruit fly, Drosophila melanogaster, there are four Runx genes (Rennert, 
Coffman et al. 2003, Bao and Friedrich 2008). The most well studied Runx family 
member is runt, which was identified for its function in development. DmRunt is 
one of the five pair-rule genes, which regulate the spatial expression of other pair 
rule genes and segment polarity genes (Nusslein-Volhard and Wieschaus 1980, 
Gergen and Wieschaus 1985). Deletion of DmRunt results in the loss of larval 
segments and consequently, smaller than wild-type flies (Gergen and Wieschaus 
1985). In addition, DmRunt also plays a role in sex determination and 
neurogenesis (Gergen and Butler 1988, Kania, Bonner et al. 1990, Duffy and 
Gergen 1991, Duffy, Kania et al. 1991, Canon and Banerjee 2000). Another Runx 
family member studied in Drosophila is lozenge (lz), which is required for eye 
development and hematopoiesis (Canon and Banerjee 2000). The function of two 
other Runx genes, CG34145 (RunxA) and CG42267 (RunxB) remains unclear. 
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However, it has been shown that RunxB is involved in the control of cell survival 
(Boutros, Kiger et al. 2004).  
   In Caenorhabditis elegans, the single Runx homolog, rnt-1, also plays an 
essential role during development (Hughes and Woollard 2017). It regulates the 
balance between proliferation/self-renewal and differentiation in the lateral 
neuroectodermal seam cells (Kagoshima, Sawa et al. 2005, Nimmo, Antebi et al. 
2005, Xia, Zhang et al. 2007). The seam cells are multi-potent stem cell-like cells 
formed during C.elegans embryogenesis (Sulston and Horvitz 1977). Rnt-1 is 
expressed in seam cells during embryogenesis and throughout larval development 
and functions to regulate their division (Braun and Woollard 2009).  Consequently, 
in rnt-1 mutant worms, the number of seam cells is reduced from 16 to an average 
of 13 per worm (Kagoshima, Sawa et al. 2005, Nimmo, Antebi et al. 2005). 
Importantly, overexpression of rnt-1 leads to hyper-proliferation and expansion of 
seam cells (Kagoshima, Sawa et al. 2005, Kagoshima, Nimmo et al. 2007). As a 
result, rnt-1 overexpression mutant worms develop massive hyperplasia leading 
to a tumor-like appearance of the seam cell tissue, which normally forms a straight 
line of cells at each side of the worm (Kagoshima, Nimmo et al. 2007).  
    There are two Runx genes in sea urchin S. purpuratus, but only one of them, 
SpRunt-1, is expressed (Braun and Woollard 2009). SpRunt-1 is expressed in 
various tissues during embryogenesis and transiently in adult coelomocytes upon 
challenging their immune system (Coffman, Kirchhamer et al. 1996, Pancer, Rast 
et al. 1999, Robertson, Dickey et al. 2002, Fernandez-Guerra, Aze et al. 2006). 
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During embryogenesis, spRunt-1 regulates the expression of transcription factors 
and other markers of terminal differentiation in all major tissues (Robertson, 
Coluccio et al. 2008). SpRunt-1 activates the WNT signaling pathway thereby 
positively regulating cell proliferation (Minokawa, Wikramanayake et al. 2005, 
Robertson, Coluccio et al. 2008).   
    The role of Runx genes as the master regulator specifying lineage was further 
studied in the more complex vertebrate animal models. Runx1 is expressed in 
hematopoietic progenitors in Zebrafish and Xenopus where it controls stem cell 
differentiation (Tracey, Pepling et al. 1998, Kalev-Zylinska, Horsfield et al. 2002, 
Burns, Traver et al. 2005).  Runx1 is also required for neuronal development in 
Xenopus (Park, Hong et al. 2012).  In both fish and frogs, Runx2 is required for 
chondrogenesis and is detected in developing bones (Flores, Tsang et al. 2004, 
Flores, Lam et al. 2006, Kerney, Gross et al. 2007).  
In summary, evidence gathered utilizing different animal models from 
invertebrate to vertebrate, separated by millions of years of evolution, helps build 
a picture of Runx genes as key transcription factors. This work further highlights 
their function in lineage determination and fine-tuning the balance between cell 
proliferation and differentiation. These Runx functions identified in lower animal 
models are also found in mammalian cells.  In the next section, the role of each 
Runx factor during normal development in mammalian systems is reviewed.   
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1.3 The Runx Family and Development in Mammals  
1.3.1 Overview 
In mammals, the Runx family is composed of three genes, Runx1, Runx2, 
and Runx3. Each of these genes is transcribed from two promoters, a distal P1 
promoter and a proximal P2 promoter (Ghozi, Bernstein et al. 1996, Fujiwara, 
Tagashira et al. 1999, Drissi, Luc et al. 2000, Bangsow, Rubins et al. 2001). All 
Runx proteins play essential roles in both normal developmental processes and 
diseases. Runx1 is essential for hematopoiesis (Okuda, van Deursen et al. 1996), 
Runx2 is required for osteoblast maturation and osteogenesis (Otto, Thornell et al. 
1997), and Runx3 is involved in gastrointestinal, neurogenesis of the dorsal root 
ganglia and T-cell differentiation (Inoue, Ozaki et al. 2002, Levanon, Bettoun et al. 
2002, Li, Ito et al. 2002).  Deletion of any of the Runx genes is lethal in mice.   For 
example, Runx1 loss causes embryonic lethality due to major defects in the 
formation of the fetal liver and hemorrhaging in the central nervous system by 
embryonic day 12.5 (E12.5) (Okuda, van Deursen et al. 1996, Wang, Stacy et al. 
1996). Furthermore, mice bearing a homozygous mutation in Runx2 die just after 
birth due to an inability to breathe, presumably caused by complete lack of 
ossification (Otto, Thornell et al. 1997). The concept of fundamental core 
mechanism(s) for Runx protein function in development has been posited, 
however no single common machinery that governs the development of different 
tissues has been identified. Instead, Runx proteins utilize multiple spatiotemporal 
mechanisms to regulate development of different tissues depending on tissue type 
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or age. In this section, I will discuss the role of each Runx protein in tissue 
development.  
 
1.3.2 Runx1 
Runx1 is widely considered as the master regulator of developmental 
hematopoiesis (Okuda, van Deursen et al. 1996, Yzaguirre, de Bruijn et al. 2017). 
The process of hematopoiesis begins with primitive hematopoiesis, where a limited 
number of blood lineages (erythrocyte progenitors, erythrocyte/ megakaryocyte 
progenitors and primitive macrophages) that sustain early embryonic development 
are produced primarily from the yolk sac (Palis, Robertson et al. 1999, Xu, 
Matsuoka et al. 2001, Ferkowicz and Yoder 2005, Tober, Koniski et al. 2007). 
Runx1 is expressed in the mesodermal masses in this yolk sac, and in the primitive 
hematopoietic cells with the exception of primitive erythrocyte progenitor cells 
(North, Gu et al. 1999, Georges Lacaud, Lia Gore et al. 2002).  Although, Runx1 
is not considered to be required for primitive hematopoiesis, in its absence, all 
three primitive hematopoietic lineages are affected. Without Runx1, primitive 
macrophages are absent (Georges Lacaud, Lia Gore et al. 2002, Li, Chen et al. 
2005), the number of megakaryocytes is reduced (Potts, Sargeant et al. 2014), 
and primitive erythrocytes are abnormal in function with decreased expression of 
the erythroid marker Ter118 and the transcription factors EKLF and Gata1 (Castilla, 
Wijmenga et al. 1996, Yokomizo, Hasegawa et al. 2008). Therefore, Runx1 plays 
an essential role in primitive hematopoiesis. 
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    After primitive hematopoiesis, endothelial cells undergo a process known as 
definitive hematopoiesis, which constitutes the second and third waves of blood 
development (Yzaguirre, de Bruijn et al. 2017). During this stage of development, 
hematopoietic stem cells (HSCs) are formed (Chen, Mao et al. 2014). HSCs have 
long-term repopulation capacity and the ability to produce any of the hematopoietic 
lineages (Bryder, Rossi et al. 2006). Definitive hematopoietic cells are derived from 
a subset of epithelial cells called hemogenic endothelium (HE) cells, which are part 
of the interior lining of blood vessels in the embryo (Swiers, Rode et al. 2013). HE 
cells are a transitional population that undergoes an endothelial to hematopoietic 
transition (EHT) to transform into hematopoietic progenitors and stem cells (Kissa 
and Herbomel 2010). Runx1 is indispensable for definitive hematopoiesis and a 
critical transcription factor regulating such processes by suppressing the 
endothelial transcriptional program and initiating the hematopoietic program (North, 
Gu et al. 1999, Yokomizo, Ogawa et al. 2001, Chen, Yokomizo et al. 2009, Lancrin, 
Mazan et al. 2012, de Bruijn and Dzierzak 2017).  In the absence of Runx1, no 
definitive HSCs are formed (Okuda, van Deursen et al. 1996, Wang, Stacy et al. 
1996). On the other hand, in Runx1 heterozygous mutant embryos, definitive 
hematopoiesis is suppressed and the spatial and temporal developments of HSCs 
are changed (Wang, Stacy et al. 1996, Cai, de Bruijn et al. 2000, Mukouyama, 
Chiba et al. 2000). Depletion of Runx1 within specific tissues or developmental 
stages in mice demonstrated that Runx1 expression is required specifically in 
endothelial cells for de novo generation of HSCs, but is not essential for the 
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renewal and survival of HSCs thereafter (Chen, Yokomizo et al. 2009, Yzaguirre, 
de Bruijn et al. 2017). Even so, Runx1 is still required for lineage-specific 
differentiation and homeostasis. For instance, Runx1 is necessary for 
megakaryocytic maturation and differentiation of B-cells and T-cells in mouse bone 
marrow (Ichikawa, Asai et al. 2004, Seo, Ikawa et al. 2012, Niebuhr, Kriebitzsch et 
al. 2013).  
    Runx1 may function in embryogenesis at an even earlier stage than 
hematopoiesis. In human embryonic stem cells, RUNX1 is transiently expressed 
during early mesendodermal differentiation, which starts at E 5.5 day (Wang and 
Chen 2016), by promoting an epithelial to mesenchymal transition in a 
Transforming growth factor beta (TGF-b) dependent manner (VanOudenhove, 
Medina et al. 2016).  In addition to its role in defining hematopoietic lineages, 
Runx1 is also involved in the development of other tissues including hair follicles, 
bone, nervous system, mammary gland and muscle (Yamashiro, Åberg et al. 2002, 
Lian, Balint et al. 2003, Osorio, Lee et al. 2008, Hoi, Lee et al. 2010, Kanaykina, 
Abelson et al. 2010, van Bragt, Hu et al. 2014, Sokol, Sanduja et al. 2015, 
Umansky, Gruenbaum-Cohen et al. 2015). It has been well documented that 
Runx1 modulates the developmental activation and proliferation of hair follicle cells 
(Osorio, Lee et al. 2008).  The formation of hair follicle stem cells requires constant 
interaction between epithelial and mesenchymal cells, which both require RUNX1 
expression (Raveh, Cohen et al. 2006, Osorio, Lee et al. 2008, Sennett and Rendl 
2012).  In epithelial cells, depletion of Runx1 delays the formation of hair follicles 
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due to the lack of hair follicle cell emergence (Osorio, Lee et al. 2008, Osorio, Lilja 
et al. 2011). However, the function of Runx1 in this cell type appears dispensable, 
as the defects are overcome with time (Osorio, Lilja et al. 2011). Loss of Runx1 in 
mesenchymal cells during embryogenesis affects the integrity of hair follicle 
formation. It has been shown that mesenchymal cells still mature into hair follicles 
after knockout of Runx1 in mice, but with enormous sebaceous cysts that do not 
contain the bulb and bulge region at the first hair cycle (Osorio, Lilja et al. 2011). 
Besides embryogenesis, Runx1 is also crucial for regulating the hair cycle at the 
transition into adult skin homeostasis. Runx1 directly promotes the proliferation of 
hair follicle stem cells and loss of RUNX1 delays the activation of stem cells into 
the cell cycle (Osorio, Lee et al. 2008, Hoi, Lee et al. 2010, Scheitz, Lee et al. 
2012). Recently it has been discovered that RUNX1 is also essential for mammary 
gland development as will be discussed later (see Section 1.5.1).   
 
1.3.3 Runx2 
Bone development occurs through two independent processes termed 
intramembranous and endochondral ossification (Berendsen and Olsen 2015). For 
intramembranous bone development, flat bones are directly formed by osteoblasts, 
which are differentiated from mesenchymal cells (Berendsen and Olsen 2015).  
Runx2 is the first transcription factor required for osteoblast differentiation (Komori 
2010, Komori 2017). Osteoblasts are completely absent in Runx2-/- mice, which 
indicates that Runx2 is required for the differentiation of mesenchymal stem cells 
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into osteoblasts (Komori, Yagi et al. 1997, Otto, Thornell et al. 1997). Runx2 also 
activates the bone commitment transcription factor SP7 and bone matrix proteins 
including Spp1, Col1a1, IBSP and Bglap2 (Ducy, Zhang et al. 1997, Sato, Morii et 
al. 1998, Harada, Tagashira et al. 1999, Lee, Kim et al. 2000, Stein, Lian et al. 
2004). After mesenchymal stem cell differentiation into osteoblasts, Runx2 
expression is decreased, and abnormally maintaining Runx2 expression inhibits 
osteoblast maturation (Liu, Toyosawa et al. 2001, Geoffroy, Kneissel et al. 2002, 
Kanatani, Fujita et al. 2006). For the formation of long bones, endochondral 
ossification requires maturation of chondrocytes at the center of the bone, known 
as the diaphysis. Terminally differentiated chondrocytes undergo apoptosis and 
are then replaced by mesenchymal cells. These mesenchymal cells later 
differentiate into osteoblasts (Berendsen and Olsen 2015). In Runx2-/- mice, 
chondrocyte maturation is severely inhibited and mechanistically Runx2 up-
regulates chondrocyte maturation through the activation of osteoblast 
differentiation (Komori, Yagi et al. 1997, Inada, Yasui et al. 1999, Komori 2017).   
    Recently, evidence has demonstrated that Runx2 is also involved in 
hematopoiesis. Runx2 expression is at an even higher level than Runx1 in 
hematopoietic stem cells; however the level of Runx2 sharply decreases during 
myeloid differentiation (Kuo, Zaidi et al. 2009). This loss of Runx2 expression is 
necessary for myeloid progenitor differentiation, as ectopic expression of Runx2 
blocked differentiation in in vitro assays (Kuo, Zaidi et al. 2009). Besides myeloid 
differentiation, Runx2 is also involved in regulating lymphoid lineage	 (Stewart, 
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Terry et al. 1997). Runx2 is expressed at the earliest stage of thymocyte 
development and forced expression of Runx2 slows down T cell development, 
resulting in an expansion of double-negative and CD8 immature single-positive 
cells (Satake, Nomura et al. 1995, Vaillant, Blyth et al. 2002, Blyth, Vaillant et al. 
2010). Moreover, Ehrhardt et al. showed that Runx2 expression is enriched in a 
subpopulation of memory B cells and therefore might be involved in B-cell 
differentiation (Ehrhardt, Hijikata et al. 2008). In addition to bone development and 
hematopoiesis, Runx2 is also expressed in prostate, testis, vascular endothelium 
and ovary where its function in these tissues remains unclear (Sun, Vitolo et al. 
2001, Jeong, Jin et al. 2008, Blyth, Vaillant et al. 2010).  The reason why bone-
specific factor Runx2 is found in hematopoietic stem cells and other tissue lineages 
is still unclear. It could potentially be related to mitotic bookmarking functions of 
Runx factors (Young, Hassan et al. 2007, Young, Hassan et al. 2007).   
 
1.3.4 Runx3  
Like Runx1 and Runx2, Runx3 has also been shown to be involved in development 
(Inoue, Shiga et al. 2008). Runx3-/- mice exhibit ataxia due to improper function of 
several important organs, including dorsal root ganglia, natural killer cells, and 
CD8+ T cells (Inoue, Ozaki et al. 2002, Levanon, Bettoun et al. 2002, Taniuchi, 
Osato et al. 2002, Durst and Hiebert 2004, Chen, de Nooij et al. 2006). In addition 
to neuronal defects, Runx3-null mice develop gastric hyperplasia and die shortly 
after birth due to starvation (Li, Ito et al. 2002). These data indicate a possible role 
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of Runx3 in regulating development of the gastric epithelium (Li, Ito et al. 2002). 
Conversely, this phenotype was not observed in another Runx3 knockout mouse 
(Levanon, Brenner et al. 2003, Levanon, Bernstein et al. 2011). The reason for this 
discrepancy is still unclear, but could be a result of different genetic backgrounds 
and/or antibodies used in these studies (Ito 2012, Levanon, Negreanu et al. 2012).  
    In summary, all three Runx proteins are essential for normal development in 
multiple tissues and have diverse roles in proliferation, differentiation and cell 
lineage commitment. In the original studies, all Runx-null mice are lethal. The 
advancement of new tissue-specific CRISPR/Cas9 technology may find novel 
developmental roles for this conserved Runx family in the future.   
 
1.4 The Runx Family in Cancer  
1.4.1 Overview 
As discussed, all three Runx proteins are involved in the development of multiple 
tissues. Therefore, the precise regulation and integrity of these factors is 
necessary for normal function. Deregulation of Runx functions causes many 
diseases and cancers. One such example, mutation of RUNX2, causes a 
hypomorphic allele and results in a congenital disorder in skeletal development 
named Cleidocranial Dysplasia (CCD) (Otto, Kanegane et al. 2002, Matheny, 
Speck et al. 2007) . In this section, I will give examples of how dysfunction of Runx 
proteins causes diseases and cancer. 
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1.4.2 Runx1 
RUNX1 was first cloned in 1991 at the breakpoints on chromosome 21 in leukemia 
(Miyoshi, Shimizu et al. 1991). Later it was discovered that a RUNX1 fusion protein, 
RUNX1-ETO (AML1-ETO), is generated by a translocation between chromosomes 
8 and 21 (t8:21) (Miyoshi, Shimizu et al. 1991, Erickson, Gao et al. 1992, Miyoshi, 
Kozu et al. 1993).  RUNX1-ETO leads to leukemia and is the most common genetic 
alteration in acute myeloid leukemia (AML), especially within the M2 subtype of 
AML (Lin, Mulloy et al. 2017, Sood, Kamikubo et al. 2017). This subtype is 
associated with younger age and relatively good prognosis (Lin, Mulloy et al. 2017). 
The RUNX1-ETO fusion protein contains the N-terminal 177 amino acids of 
RUNX1, including the entire Runt DNA-binding domain, fused in frame with almost 
the entire ETO protein. ETO contains four evolutionarily conversed domains 
termed nervy homology regions (NHR), which mediates homodimerization of 
RUNX1-ETO (Davis, McGhee et al. 2003, Liu, Cheney et al. 2006, Kwok, Zeisig et 
al. 2009, Yan, Ahn et al. 2009). Like RUNX1, RUNX1-ETO regulates gene 
expression by forming complexes with diverse proteins and gains the ability to form 
complexes with aberrant partners compared with the wild-type RUNX1. For 
instance, RUNX1-ETO forms a co-repressor complex with nuclear receptor co-
repressor (NCOR1), histone deacetylase (HDAC1), and SIN3A/HDAC at the ETO 
NHR domain (Gelmetti, Zhang et al. 1998, Lutterbach, Westendorf et al. 1998, 
Wang, Hoshino et al. 1998, Amann, Nip et al. 2001, Davis, McGhee et al. 2003, 
Lin, Mulloy et al. 2017). RUNX1-ETO also interacts with E proteins through the 
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NHR domain to inhibit E-protein-induced transcriptional activation (Zhang, Kalkum 
et al. 2004).  It has also been reported that in physiological conditions, p300 and 
PRMT bind weakly to RUNX1-ETO forming a transcription co-activation complex 
to dynamically regulate target gene expression (Sun, Wang et al. 2013).  
Dominant-negative inhibition of native RUNX1 function may therefore be the 
central mechanism for RUNX1-ETO induced leukemogenesis (Goyama and 
Mulloy 2011). However, surprisingly, RUNX1-ETO also requires some activities of 
the native RUNX1 to promote leukemogenesis, as RUNX1 is a member of the 
RUNX1-ETO transcription complex (Li, Wang et al. 2016) .   
    In addition to the t(8:21) translocation, more than 50 other chromosomal 
translocations affect RUNX1. Most of them are related to leukemia, but only about 
half of the partner genes have been identified among these translocations (Etienne 
De Braekeleer 2011). Other common translocations include t(12;21) in pediatric 
acute lymphoblastic leukemia (ALL), known as TEL-RUNX1 (Jamil, Theil et al. 
2000); and t(3:21) in therapy related AML and myelodysplastic syndrome (MDS), 
known as RUNX1-MECOM (Yang, Cho et al. 2012).  
    RUNX1 somatic mutations are also detected in approximately 3% of pediatric 
and 15% of adult AML patients. Adult AML is associated with older age and worse 
prognosis.  These leukemic cells generally have a growth advantage over the 
hematopoietic progenitor cells with defects in differentiation due to mutated 
RUNX1 (Tang, Hou et al. 2009, Greif, Konstandin et al. 2012, Mendler, Maharry et 
al. 2012, Schuback, Arceci et al. 2013, Skokowa, Steinemann et al. 2014).  RUNX1 
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is also one of the most frequently mutated genes in MDS and ALL, about 10% and 
25% respectively (Speck and Gilliland 2002, Bejar, Stevenson et al. 2011, 
Grossmann, Kern et al. 2011, Mullighan 2012, Papaemmanuil, Gerstung et al. 
2013, Haferlach, Nagata et al. 2014).  
    In summary, RUNX1 is a major player in hematologic malignancies. It is a key 
regulator of hematopoiesis, and maintains a proper balance between proliferation 
and differentiation.  Therefore, the high frequency of loss-of-function somatic point 
mutations or translocations in multiple subtypes of leukemia result in the 
repression of RUNX1 normal function and initiation of leukemogenesis. Several 
companies including Invitae and NEO genomics provide screening of RUNX1 
mutations in leukemia patients to evaluate prognosis and select therapeutic 
strategy.  
    Besides its impact on leukemia, Runx1 is either over- or under-expressed in 
many solid tumors, implying that Runx1 either promotes or represses epithelial 
cancers depending on the cellular context (Scheitz and Tumbar 2013). For 
example, Runx1 is identified as a tumor promoter in ovarian and skin cancers and 
tumor suppresses tumor growth in prostate cancer (Scheitz, Lee et al. 2012, Keita, 
Bachvarova et al. 2013, Takayama, Suzuki et al. 2015). The involvement of Runx1 
in skin cancer was first discovered in a chemically induced mouse model. Loss of 
Runx1 significantly decreases the number of skin tumors formed (Hoi, Lee et al. 
2010).  Using lineage tracing, it has been shown that the Runx1-expressing hair 
follicle stem cells are the origin of these chemically induced skin tumors (Scheitz, 
	 31	
Lee et al. 2012).  Mechanistically, in skin cancer Runx1 maintains an 
active/phosphorylated form of the oncogene STAT3, and thus increases cell 
survival, proliferation and invasion (Scheitz, Lee et al. 2012).   
 
1.4.3 Runx2 and Runx3  
In contrast with RUNX1, which has opposing functions in different cancer types, 
RUNX2 has been well documented to be an oncogene (Chuang, Ito et al. 2017). 
For example, Runx2 functions as an oncogene in lymphoma, where it is a frequent 
target for viral insertion in T-cell lymphomas (Stewart, Terry et al. 1997, Blyth, 
Vaillant et al. 2006). In osteosarcoma, increased RUNX2 expression is also 
associated with tumorigenicity, metastasis, lower survival and poor prognosis by 
directly activating PI3K/AKT pathways (Martin, Zielenska et al. 2011, Cohen-Solal, 
Boregowda et al. 2015). Up-regulation of RUNX2 has been linked to bone 
metastasis in multiple epithelial cancer types including colon, breast, prostate and 
thyroid cancer (Pratap, Javed et al. 2005, Akech, Wixted et al. 2010, Chimge, 
Baniwal et al. 2011, Niu, Kondo et al. 2012, Cohen-Solal, Boregowda et al. 2015).  
RUNX2 contributes to metastatic events through regulation of bone metastatic-
related genes, such as osteopontin, bone sialoprotein, matrix metalloproteinases, 
and activation of signaling pathways including WNT and TGF-b (Pratap, Lian et al. 
2006).  Meanwhile RUNX3 is also involved in multiple solid tumors and functions 
as a tumor suppressor in the majority of the cases (reviewed in (Chuang and Ito 
2010, Chen, Wang et al. 2014, Chen, Liu et al. 2016) ) . 
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1.5 RUNX1 in Mammary Gland development and Breast Cancer  
1.5.1 Mammary gland development and hierarchy 
The mammalian mammary gland is a highly dynamic organ that undergoes 
profound changes in structure and function during the reproductive cycle and 
pregnancy (Richert, Schwertfeger et al. 2000, Hennighausen and Robinson 2005, 
Watson and Khaled 2008). The development of mouse mammary gland starts at 
puberty when the embryonic epithelial placode transforms into a branched network 
of collecting ducts and tubes, which consist of two distinct types of cell lineages: 
the inner layer of luminal lineage (including ductal and alveolar luminal cells) and 
the outer layer of basal lineage (the myoepithelial cells) (Muschler and Streuli 
2010). During pregnancy, increased progesterone and prolactin levels result in 
greater branching and formation of mature lobuloalveolar units that contain 
terminally differentiated cells for milk production (Hennighausen, Robinson et al. 
1997). The milk is released by contraction of ductal and lobular myoepithelial cells 
(Haaksma, Schwartz et al. 2011).  Following lactation, the mammary gland returns 
to a virgin-like state through involution, with the death of epithelial cells and 
extensive tissue remodeling (Richert, Schwertfeger et al. 2000, Watson and 
Khaled 2008, Inman, Robertson et al. 2015). 
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1.5.2 RUNX1 and mammary gland development 
    Runx1 has a spatial/temporal expression pattern in the mammary gland, as it is 
differentially expressed during physiological stages of mammary gland 
development. The highest levels are observed in virgin and early-pregnant glands 
and decrease in late pregnancy and during lactation (McDonald, Ferrari et al. 2014, 
van Bragt, Hu et al. 2014, Rooney, Riggio et al. 2017). Compared with cells of the 
luminal lineage, Runx1 is expressed at higher levels in basal progenitor cells 
(McDonald, Ferrari et al. 2014, van Bragt, Hu et al. 2014). As Runx1 expression is 
lost from differentiated alveolar luminal cells, it has been speculated that a 
reduction in RUNX1 expression is necessary for milk production and secretion (van 
Bragt, Hu et al. 2014).  Besides the expression pattern, the role of Runx1 in 
regulation of mammary development and its role in normal mammary gland are 
still understudied.  In normal-like basal MCF10A cells, RUNX1 is essential for 3D 
growth in Matrigel (Wang, Brugge et al. 2011). Furthermore, Runx1 is required for 
mammary stem cells to exit the bipotent state and differentiate into mature lobules 
and ducts (Sokol, Sanduja et al. 2015). In vivo, deletion of Runx1 specifically in the 
mouse mammary gland reduces the proportion of luminal cells. In particular, loss 
of Runx1 results in a deficit in mature estrogen receptor (ER) positive luminal cells 
(van Bragt, Hu et al. 2014).  The mechanism(s) of Runx1 regulation of mammary 
gland development is still unclear. It has been suggested that Runx1 decides the 
fate of the ER-positive luminal subpopulation and directs ductal differentiation by 
repressing the alveolar transcription factor Elf5 (van Bragt, Hu et al. 2014). There 
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are relatively few studies devoted to determining the role of Runx1 in the basal 
lineage of myoepithelial cells, even though Runx1 is expressed at a higher level in 
this subpopulation compared with luminal cells (van Bragt, Hu et al. 2014). 
Interestingly, Runx1 conditional knockout mice have defects in myoepithelial cell 
contraction and milk ejection, and most of the pups die within 24 hours after birth 
with no observed milk spots (van Bragt, Hu et al. 2014).   It is interesting to note 
that smooth muscle contraction is among the top down-regulated pathways in 
embryonic stem cells with RUNX1 depletion (VanOudenhove, Medina et al. 2016). 
These data reveal a potential role for RUNX1 in maintaining the normal phenotype 
of basal myoepithelial cells.  
 
1.5.3 RUNX1 and breast cancer  
In recent years, growing evidence has indicated that RUNX1 suppresses tumor 
growth in breast cancer. RUNX1 was initially identified as a potential transcription 
factor to suppress tumor growth in breast cancer, as it was down regulated among 
a 17-gene signature associated with metastasis in adenocarcinoma including 
breast cancer (Ramaswamy, Ross et al. 2003). The expression of RUNX1 was 
later shown to decrease when comparing normal mammary tissue to breast cancer, 
with a greater decrease in higher-grade tumors (Kadota, Yang et al. 2010). 
Sequencing of breast cancer patient samples then identified that 6% of all breast 
invasive cancers and 10% of invasive lobular breast cancers have an alteration in 
the RUNX1 gene (Ciriello, Gatza et al. 2015, Rooney, Riggio et al. 2017). Both 
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whole genome and whole exome sequencing have identified point mutations and 
deletions of RUNX1 in luminal and basal breast cancers (Banerji, Cibulskis et al. 
2012, Ellis, Ding et al. 2012, Network 2012). In these studies, RUNX1 is a 
frequently mutated gene along with other well-known tumor suppressor and 
oncogene genes including PTEN, CDH1, TP53, PIK3CA, which have been 
intensively investigated in breast cancer (Bertheau, Lehmann-Che et al. , 
Kechagioglou, Papi et al. 2014, Mukohara 2015, Maeirah Afzal and Ezharul Hoque 
2016). These RUNX1 mutations, including point mutations, frame-shift mutations, 
and deletions, were assumed to be loss-of-function mutations. The majority of 
these mutations are located at the interface between the Runt domain and DNA, 
suggesting that the RUNX1 mutants cannot bind properly to target genes (Fig.1.2). 
Notably, mutations were also identified in the RUNX1 binding partner CBF-b 
(Network 2012). Thus, it is possible that loss of RUNX1 function by disrupting 
RUNX1-DNA binding or the interaction between RUNX1 and CBF-b may promote 
tumorigenesis in mammary gland.  Recently, there are two studies that 
independently identified RUNX1 loss-of-function mutation as the driver for the 
existence of other mutations in breast cancer, thus strongly suggesting that 
RUNX1 loss promotes breast cancer progression (Pereira, Chin et al. 2016, Kas, 
de Ruiter et al. 2017).   
In summary, by sequencing the tumors from breast cancer patients, RUNX1 
mutations that associate with initiation and progression of the disease have been 
identified in multiple subtypes of breast cancer. In a tissue microarray study, 
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RUNX1 intensity was decreased in breast cancer tumors compared with normal 
mammary tissues (Browne, Taipaleenmäki et al. 2015). However, the molecular 
mechanisms underlying RUNX1 suppressed tumor growth remain unclear and 
require further investigation in cell lines, mouse models, and human patient 
samples.   
    Multiple studies using cell lines and mouse models have been carried out to 
identify RUNX1 function in breast cancer. In normal mammary epithelial cells, loss 
of RUNX1 in a 3D Matrigel assay resulted in hyper-proliferation and abnormal 
morphogenesis, which requires normal FOXO1 function (Wang, Brugge et al. 
2011). In another study, conditional knockout of Runx1 in mammary epithelial cells 
reduced the proportion of ER+ luminal cells, but did not result in mammary tumors 
(van Bragt, Hu et al. 2014).  However, loss of TP53 or Rb1 rescued this phenotype 
and resulted a hyper-proliferation of Runx1-deficient ER+ luminal cells. Cells 
harboring a double mutation may eventually develop into breast cancer (van Bragt, 
Hu et al. 2014).  Further exploration using double-knockout mice (Runx1/TP53 or 
Runx1/RB1) will be required to determine whether these mice develop abnormal 
mammary hyperplasias or tumors. Recent work from the Frenkel lab has 
demonstrated that loss of RUNX1 in Luminal A breast cancer cells facilitates 
estrogen-induced WNT signaling by suppressing the scaffold protein AXIN1 
(Chimge, Little et al. 2016). Therefore, along with genetic data, growing evidence 
in cell lines and mouse models establishes the concept that RUNX1 reduces 
aggressive phenotype in breast cancer, especially in the luminal subtype. 
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    In contrast, a few studies indicate that RUNX1 may function as an oncogene in 
breast cancer. In particular, triple-negative breast cancer was correlated with high 
RUNX1 expression and poor prognostic outcome (Ferrari, Mohammed et al. 2014). 
RUNX1 inhibition in the triple-negative MDA-MB-231 late stage breast cancer cell 
line, showed a less aggressive phenotype with decreased proliferation, migration 
and invasion in vitro (Recouvreux, Grasso et al. 2016). Furthermore, in the MMTV-
PyMT mouse model, RUNX1 expression is positively correlated with advanced 
disease (Browne, Taipaleenmäki et al. 2015).  The discrepancy could be due to 
heterogeneity in breast cancer, as breast cancer encompasses a diverse group of 
subtypes. These subtypes have different cellular origins (luminal versus basal) and 
molecular alterations (e.g., hormonal status including ER, PR, and HER2) (Eroles, 
Bosch et al. 2012).  In the luminal subtype of breast cancer, it has been well 
accepted that RUNX1 reduces tumor aggressive phenotypes. On the other hand, 
in the basal-like subtype, RUNX1 may have a dual function depending on the stage 
of breast cancer. In normal mammary myoepithelial cells, loss of RUNX1 disrupts 
the normal function of that cell layer’s ability to contract and eject milk (van Bragt, 
Hu et al. 2014). However, in late-stage triple-negative breast cancer, RUNX1 is 
linked to fast proliferation and a more aggressive phenotype (Recouvreux, Grasso 
et al. 2016). The molecular signatures of normal basal cells/early stage basal 
cancer and late stage basal cells are significantly different. Due to the distinct 
cellular context and gene expression patterns, RUNX1 may form complexes with 
different co-activator or co-repressor proteins. This differential binding of co-
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regulatory factors may convert its activity from being a gene against tumor growth 
to an oncogene by differentially regulating the same subset of genes. Alternatively, 
these RUNX1 complexes may be targeted to entirely new subsets of genes. 
         In conclusion, knowledge regarding the function of RUNX1 in breast cancer 
is still far from complete, and the potential dual role as promoting or suppressing 
tumor growth highlights its extreme context dependency. It is still a challenge to 
integrate the genomic data obtained from patients with molecular data from cell 
lines and animal models. A better understanding of RUNX1 function in different 
stages of breast cancer will potentially translate into targeted therapies that could 
greatly benefit prevention and screening. 
  
1.6 Epithelial Mesenchymal Transition in Breast Cancer   
1.6.1 Overview of EMT 
The concept of epithelial-mesenchymal transition (EMT) was first described almost 
50 years ago in 1968 by Elizabeth Hay (Hay 1968). EMT is an evolutionally 
conserved morphogenetic program during which epithelial or epithelial-like cells 
undergo a series of biochemical changes allowing them to acquire a mesenchymal 
phenotype (Thiery 2002). During the EMT process, polarized epithelial cells with 
tight junctions acquire mesenchymal properties, such as enhanced migration, 
invasiveness, and elevated resistance to apoptosis. EMT is precisely regulated by 
the interplay of signaling pathways, transcription factors and miRNAs. Several 
transcription factors, for example, the Zeb, Snail and Twist families, are activated 
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by a variety of signaling pathways, including TGF-b, NOTCH and WNT (Nieto 2002, 
Yang, Mani et al. 2004, Liu, El-Naggar et al. 2008, Lamouille, Xu et al. 2014). In 
turn, these transcription factors initiate the EMT program by silencing E-cadherin 
expression at the cell surface. The loss of E-cadherin is a fundamental hallmark of 
EMT (Kalluri and Weinberg 2009). Furthermore, mesenchymal-like cells 
commonly express Vimentin, which is a cytoskeletal protein necessary for 
migration (Kalluri and Weinberg 2009). Recent findings suggest that EMT is not an 
all-or-none process from purely epithelial to purely mesenchymal phenotypes, but 
rather is a multi-stage process, with one or multiple intermediate stages. These 
intermediate phenotypes have been referred to as partial EMT (Shibue and 
Weinberg 2017).  The details on partial EMT and its role in metastasis and cancer 
stem cells will be discussed in detail in section 1.7.2. 
    There are three different types of EMT, which carry out very different functions. 
1. EMT that is required for the formation of mesodermal and neural tube tissue 
during embryogenesis; 2. EMT associated with tissue regeneration and organ 
fibrosis; 3. EMT that contributes to the pathogenesis of cancer metastasis (Kalluri 
and Weinberg 2009, Thiery, Acloque et al. 2009, Kovacic, Mercader et al. 2012).  
I will discuss the role of EMT in development and cancer in the next two sections.  
 
1.6.2 Epithelial mesenchymal transition in development 
EMT drives essential aspects of embryonic development. During gastrulation, 
complete EMT occurs to generate fully committed mesenchymal cell types forming 
	 40	
the early mesoderm or endoderm (Viebahn, Lane et al. 1995, Thiery, Acloque et 
al. 2009). In contrast, partial and reversible EMT occurs during morphogenesis of 
certain epithelial tissues such as the mammary gland (Nakaya and Sheng 2013).   
    During puberty, mammary epithelial stem/progenitor cells that reside in the 
terminal end buds of the breast start to elongate and migrate, thereby driving 
branching morphogenesis (Micalizzi, Farabaugh et al. 2010). These epithelial cells 
transiently acquire mesenchymal features, including loss of apical-basal polarity 
(Ewald, Brenot et al. 2008, Ewald, Huebner et al. 2012), and elevated expression 
of the EMT transcription factors Snai1 and Twist (Kouros-Mehr and Werb 2006, 
Foubert, De Craene et al. 2010).  The cells in the terminal end buds are regulated 
by a number of extracellular factors known to induce EMT, including epidermal 
growth factor (EGF) and hepatocyte growth factor (HGF). For instance, in the 
mouse mammary gland, overexpression of HGF causes hyperplastic branching 
morphogenesis, while inhibition of HGF signaling blocks budding of side branches 
(Rosário and Birchmeier 2003).  Branching morphogenesis is a highly plastic 
process with an incomplete EMT program, as both the epithelial and mesenchymal 
lineages are essential for normal mammary gland function. Recently two 
transcription factors, Elf5 and Ovol2, have been shown to be the gatekeepers of 
mammary epithelial differentiation by inhibiting EMT at terminal end buds 
(Chakrabarti, Hwang et al. 2012, Watanabe, Villarreal-Ponce et al. 2014).  Elf5 is 
the master regulator for transforming luminal progenitor cells into alveolar cells 
during pregnancy and lactation (Oakes, Naylor et al. 2008, Choi, Chakrabarti et al. 
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2009). Therefore, a partial EMT state, gaining partial mesenchymal features with 
maintenance of some epithelial characteristics, is critical during mammary gland 
development.   
 
1.6.3 Epithelial mesenchymal transition in cancer 
Almost 80% of human cancer deaths derive from epithelial tissues including 
tumors of the breast, lung, pancreas, prostate, colon, ovary, kidney and liver	(Ye 
and Weinberg 2015).  Hyperplasia or early stage tumors arising in these tissues 
continue to express the epithelial marker E-cadherin, whereas cells from highly 
aggressive primary tumors exhibit mesenchymal features including motility and 
invasiveness (Choi, Lee et al. 2013, Cheng, Chang et al. 2014). Cancer cells have 
the capability to utilize the EMT process to initiate invasion and metastasis (Chaffer, 
San Juan et al. 2016).   
    In breast cancer, an EMT signature is enriched in basal-like and Claudin low 
subtypes compared with Luminal A/B subtypes	(Prat, Parker et al. 2010). Since 
tumor progression is positively associated with acquisition of mesenchymal 
features, this may be an explanation for why basal and Claudin low breast cancers 
are more aggressive. Depletion of activators of EMT, such as Twist, Snail and Zeb 
in human and mouse breast cancer cell lines, greatly inhibit metastasis after 
mammary fat pad or tail vein injection (Yang, Mani et al. 2004, Guo, Keckesova et 
al. 2012, Zhang, Corsa et al. 2013, Roy, Gonugunta et al. 2014, Tran, Luitel et al. 
2014). For instance, depleting Snail in MMTV-PyMT mice completely abolished 95% 
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of lung metastasis (Tran, Luitel et al. 2014). Consistently, activating EMT in human 
breast cancer cells can enhance metastatic dissemination (Tran, Luitel et al. 2014). 
Therefore, EMT has been defined as a critical component of the metastatic 
process.  
    Although EMT processes are well documented in many in vitro cancer cell 
models and even in vivo animal experiments, the existence of EMT during tumor 
progression and its relevance in metastasis have remained matters of controversy. 
One of the key concerns is the lack of convincing histological evidence of EMT in 
clinical samples (Thiery, Acloque et al. 2009).	 Two recent reports raise the 
question of whether EMT is dispensable for invasion and metastasis in mouse 
models of breast and pancreatic cancer	 (Fischer, Durrans et al. 2015, Zheng, 
Carstens et al. 2015). Fisher et al. used a spontaneous breast to lung metastasis 
mouse model and labeled fibroblast-specific protein 1 (Fsp1) as a marker for EMT. 
They observed that many Fsp1 negative cells metastasize to lung, indicating that 
EMT is not necessary for metastasis	 (Fischer, Durrans et al. 2015). In another 
study, Zheng et al. knocked out either Snail or Twist in a spontaneous pancreatic 
ductal adenocarcinoma (KPC model) and observed no difference in metastasis by 
tracing a-smooth muscle actin as a mesenchymal marker	(Zheng, Carstens et al. 
2015). However, there is some debate regarding whether Fsp1 or a-smooth 
muscle actin are proper EMT markers, as they are rarely induced upon activation 
of EMT (Aiello, Brabletz et al. 2017, Ye, Brabletz et al. 2017). Furthermore, using 
the same KPC mouse model, depleting Zeb1 suppresses stemness, invasion and 
	 43	
metastasis, indicating that EMT is necessary for metastasis in vivo	 (Krebs, 
Mitschke et al. 2017).   
    Although these two studies suggest that EMT is dispensable for metastasis, 
both uncovered that EMT is key to chemoresistance	(Fischer, Durrans et al. 2015, 
Zheng, Carstens et al. 2015). Several other studies also demonstrated that 
induction of EMT confers resistance to chemotherapy and radiotherapy	(Creighton, 
Li et al. 2009, Oliveras-Ferraros, Corominas-Faja et al. 2012, Chen, Gibbons et al. 
2014).  The underlying molecular mechanisms of EMT-induced chemoresistance 
remain unsolved.  One hypothesis is that the EMT activator Twist can bind to the 
promoter and activate the expression of the ABC transporter, which is responsible 
for efflux of drugs out of the cell (Saxena, Stephens et al. 2011).   In the past 
decade, studies have highlighted a link between EMT and cancer stem cells, which 
be discussed in detail in section 1.7.  
 
1.6.4 Runx and EMT 
The Runx proteins are important players in the determination of cell fate during 
development, which often overlaps with the occurrence of EMT. During 
embryogenesis, transient RUNX1 expression in early mesendodermal 
differentiation of human embryonic stem cells promotes EMT through TGF-b 
signaling (VanOudenhove, Medina et al. 2016). During mammary branching 
morphogenesis, the level of Runx2 is increased and accompanied by the up-
regulation of EMT activators such as Snail2 (Kouros-Mehr and Werb 2006, 
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McDonald, Ferrari et al. 2014). Overexpressing RUNX2 in mammary epithelial 
cells activated differentiation and induced EMT (Chimge, Baniwal et al. 2011, 
Owens, Rogers et al. 2014).  On the other hand, depleting Runx2 in mouse 
mammary glands disrupted ductal outgrowth at puberty and progenitor cell 
differentiation during pregnancy (Owens, Rogers et al. 2014, Ferrari, Riggio et al. 
2015).  All these data suggest that Runx2 is a positive regulator of EMT in 
mammary gland development.   
    Increasing evidence has suggested that deregulation of Runx expression and 
function is linked to the aberrant induction of EMT in cancer.  Parallel to its 
involvement in EMT during development, RUNX2 has been implicated in the 
aberrant activation of EMT and metastasis in breast and prostate cancer.  In breast 
cancer cells, RUNX2 is necessary for the induction of Snail expression	(Chimge, 
Baniwal et al. 2011), while in prostate cancer, RUNX2 also positively regulates 
EMT drivers such as Snail2, SMAD3, and Sox9 (Baniwal, Khalid et al. 2010, Little, 
Noushmehr et al. 2012, Little, Baniwal et al. 2014) .    
     Until now, there has been no direct evidence showing whether RUNX1 
regulates EMT in the mammary gland or breast cancer. However, it was shown 
that RUNX1 binds to the promoter of E-cadherin and positively regulates its 
promoter activity (Liu, Lee et al. 2005).  Runx1 also represses ELF5 expression, 
which is a key driver of alveolar luminal cell differentiation	(van Bragt, Hu et al. 
2014). Therefore, RUNX1 may be important in maintaining homeostasis and 
preventing EMT in the mammary gland.  
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1.7 Breast Cancer Stem cells  
1.7.1 Intra-tumor heterogeneity 
Breast cancer is a heterogeneous disease, which often displays intra-tumor and 
inter-tumor heterogeneity as the result of genetic and non-genetic alterations 
(Polyak 2007) . Inter-tumor heterogeneity has been proposed to reflect the different 
cells-of-origin that become transformed into the tumor cells (Burrell, McGranahan 
et al. 2013). In breast cancer, inter-tumor heterogeneity often leads to the 
classification of different tumor subtypes as discussed in Section 1.1.3. 
    It also has been noticed for a long time that tumors contain sub-clones that differ 
in karyotype and chemoresistance (Shapiro, Yung et al. 1981, Yung, Shapiro et al. 
1982) . Using deep-sequencing expression profiling of various regions in the same 
tumor, it has been found that within a single tumor, there are multiple clones with 
distinct genetic and epigenetic profiles, as well as somatic mutations (Anderson, 
Lutz et al. 2010, Gerlinger, Rowan et al. 2012). This phenomenon has been 
described as intra-tumor heterogeneity (Marjanovic, Weinberg et al. 2013, 
Prasetyanti and Medema 2017). Intra-tumor heterogeneity is not limited to the 
differences in malignant cancer cells. More importantly, a tumor is a complex 
structure containing different clones of tumor cells as well as other cell types, such 
as infiltrating immune cells, stromal cells and endothelial cells (Lu, Weaver et al. 
2012, Junttila and de Sauvage 2013).   
    Both intrinsic and extrinsic factors influence the intra-tumor heterogeneity. The 
intrinsic factors exist at both genetic and epigenetic levels (Prasetyanti and 
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Medema 2017).  Cancer cells usually inherit or acquire aberrations in their genome, 
such as point mutation, translocation, deletion and amplification (Vogelstein, 
Papadopoulos et al. 2013). Those mutations reflect a degree of genome instability, 
which is a hallmark of cancer (Hanahan and Weinberg 2011).  Among those 
mutations, some defined as driver mutations, induce activation of oncogenic 
pathways and suppression of tumor suppressors (Stratton, Campbell et al. 2009). 
Intensive efforts have been carried out to find these driver mutations in cancer 
patients. Recently, a list of 40 mutation driver genes has been identified in breast 
cancer patients (Pereira, Chin et al. 2016). Interestingly, RUNX1 is in that list, 
suggesting its role for maintaining genome stability (Pereira, Chin et al. 2016).  
Epigenetic heterogeneity is also often observed in tumors (Dawson and 
Kouzarides 2012). Drugs that target epigenetic enzymes, which rearrange 
chromatin structure and function, are being developed rapidly and undergoing 
clinical trials (Simó-Riudalbas and Esteller 2015, de Lera and Ganesan 2016).  
    The different environments surrounding tumors also influence the intra-tumor 
heterogeneity (McGranahan and Swanton 2017). Tumor cells that survive within 
the hypoxic region due to poor vascularization commonly maintain a mesenchymal 
phenotype, and have high hypoxia-inducible factor (HIF) expression, which inhibits 
cell differentiation (Terry, Buart et al. 2017). Besides the local environment of the 
tumor cells, tumors are constantly under selection pressure, which is a result of 
the dynamic tumor microenvironment, applied therapy, and attacks from the 
immune system (Colak and Medema 2014) (McGranahan and Swanton 2017).  
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These pressures act as the extrinsic factors for intra-tumor heterogeneity.  For 
instance, therapy acts as a selection mechanism that shapes the evolution of 
tumor cells (McGranahan and Swanton 2017)(Kreso and Dick 2014).  In breast 
cancer, treating luminal breast cancer with aromatase inhibitor induces the 
remodeling of the clonal population by the acquisition of new mutations or the 
enrichment of existing mutations (Miller, Gindin et al. 2016).  
    Therefore, the combination of genetic/epigenetic alterations and 
microenvironment components can generate intra-tumor heterogeneity and 
support tumor progression by conferring a competitive advantage on subsets of 
cancer cells (Prasetyanti and Medema 2017). The origin of intra-tumor 
heterogeneity could be explained by the cancer stem cell (CSC) theory, which will 
be discussed in section 1.7.2. 
 
1.7.2 Cancer stem cells 
Cancer stem cells (CSCs) are defined by their ability to form new tumors, self-
renew, and differentiate into non-stem like cancer cells (Shibue and Weinberg 
2017). Also, when injected into immunocompromised mice, CSCs have the ability 
to generate tumors with high efficiency	(Alison, Lim et al. 2011). Thus, CSCs have 
been implicated both in initiating and sustaining primary tumor growth and in 
driving the seeding and establishment of metastases at distal sites (Al-Hajj, Wicha 
et al. 2003, Abraham, Fritz et al. 2005, Sheridan, Kishimoto et al. 2006, Ginestier, 
Hur et al. 2007, Liu, Wang et al. 2007). Cancer stem cells were first isolated from 
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AML leukemia based on the expression of cell-surface markers (Lapidot, Sirard et 
al. 1994), and later in solid tumors such as breast	(Al-Hajj, Wicha et al. 2003), brain	
(Singh, Hawkins et al. 2004), colon	 (O’Brien, Pollett et al. 2006, Ricci-Vitiani, 
Lombardi et al. 2006) and pancreatic cancer (Hermann, Huber et al. 2007). 
The Wicha group first isolated breast cancer stem cells (BCSCs) in 2003 using 
cell surface markers for CD24low/CD44high Lineage negative (Al-Hajj, Wicha et al. 
2003). They showed that within this population, as few as 200 cells were able to 
initiate tumor formation in immunocompromised mice (Al-Hajj, Wicha et al. 2003). 
Now it is clear that BCSCs exist in two distinct development states and can 
reversibly transition between them due to their property of cell plasticity (Liu, Cong 
et al. 2014). The first state is the mesenchymal-like state in which BCSCs express 
the CD24-CD44+ cell surface marker profile. They are mainly quiescent with low 
proliferation. The location of this population is commonly at the tumor-invasive 
edge adjacent to the tumor stroma. The second population is the epithelial-like 
state, and they express the de-toxifying enzyme, aldehyde dehydrogenase (ALDH). 
These BCSCs are highly proliferative, and localized at the center of the tumor. 
BCSCs containing both of the CSC markers (CD24- CD44+ and ALDH+) show the 
greatest tumor-initiating capacity (Liu, Cong et al. 2014).    
Breast cancer stem cells have been associated with metastasis.  Gene 
expression profiles of BCSCs featured an invasive gene signature with increased 
metastastic potential (Liu, Wang et al. 2007). It was also shown that disseminated 
bone marrow cancer cells from breast cancer patients have the CD44+/CD24-/low 
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cancer stem cell phenotype (Balic, Lin et al. 2006).  In a mouse xenograft model, 
human breast cancer cells metastasized to the lung express high levels of the stem 
cell marker CD44, strongly suggesting the metastatic role of BCSCs (Liu, Patel et 
al. 2010). It has been proposed that BCSCs may enter the circulation and become 
the circulating tumor cells (CTCs) to metastasize to distal organs and serve as the 
seeds of metastatic lesions (Batlle and Clevers 2017).  Some CTCs have high 
expression levels of BCSC markers (Baccelli, Schneeweiss et al. 2013).  Moreover, 
from liquid biopsy samples of luminal breast cancer patients, the CTCs with BCSC 
signature are enriched upon disease progression, while the CTCs with bulk tumor 
signature are not changing (Baccelli, Schneeweiss et al. 2013).  
 
1.7.3 EMT and plasticity and cancer stem cells 
It has been postulated for decades that EMT is related to the generation of CSCs.  
In 2008, Mani et al. from the Weinberg group first demonstrated that a 
CD44high/CD24low population was generated from the bulk population upon EMT 
induced by either TGF-β or transcription factors (Mani, Guo et al. 2008). This sub 
population exhibits a gene expression profile similar to mammary stem cells and 
is able to initiate tumors quite efficiently in mouse (Mani, Guo et al. 2008). Later, 
multiple studies confirmed the link between EMT and breast (Thiery, Acloque et al. 
2009, Scheel, Eaton et al. 2011, Chaffer, Marjanovic et al. 2013). Mechanistically, 
a number of pathways and transcription factors that are known to induce EMT, 
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including Notch, hedgehog, WNT, TGF-b and NFkb, are also capable of regulating 
cancer stem cells (Scheel and Weinberg 2012).  
    Little is known regarding RUNX1 regulation of CSC in breast cancer or in other 
solid tumors.  Based on the evidence that RUNX1 regulates mammary stem cell 
differentiation and its role during mammary morphogenesis, it seems worth 
investigating whether RUNX1 inhibits/activates the cancer stem cell phenotype in 
breast cancer.  
 
1.8 Rationale for the dissertation 
Given the crucial role of RUNX1 in tissue development, especially in the mammary 
gland, and the fact that RUNX1 is often mutated in breast tumors, we hypothesized 
that RUNX1 functions to reduce tumor aggressive phenotype in breast cancer.   
    In Chapter II, I initiated the project by comparing the RUNX1 levels in a panel of 
normal mammary epithelial cells (MCF10A) and human breast cancer (MCF7) 
cells and found that the level of RUNX1 is decreased in breast cancer cell lines.  
By using a breast cancer progression model (MCF10 series), I also observed that 
RUNX1 expression is lost during breast cancer progression. From this observation, 
further experiments were performed to establish the concept that RUNX1 reduces 
tumor aggressive phenotypes in both normal and breast cancer cells and loss of 
RUNX1 is accompanied by disease progression. Since the mechanism(s) 
underlying the function of RUNX1 in breast cancer was unclear, in this dissertation 
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I explored the functional role of RUNX1 in mammary epithelial and breast cancer 
cells.  
When I joined the Stein-Lian lab, RUNX1 molecular mechanisms were focused 
in hematopoiesis and leukemia. The first report of RUNX1 mutations in breast 
cancer patients generated my and the lab’s enthusiasm for understanding the role 
of RUNX1 in mammary epithelial and breast cancer cells.  The aim of the first part 
of this dissertation was to investigate the consequences of loss of RUNX1 in both 
normal mammary epithelial and breast cancer cells at cellular levels.  There are 
several lines of evidence that suggest RUNX1 may be involved in EMT (Liu, Lee 
et al. 2005, van Bragt, Hu et al. 2014). Therefore, in Chapter II, I focused on testing 
whether RUNX1 depletion is associated with the activation of EMT in breast cancer; 
and identify the mechanisms on how RUNX1 represses EMT.   
In Chapter II, our studies found RUNX1 is a repressor of EMT and thus 
preserves the epithelial phenotype in normal mammary epithelial cells.  The next 
goal was to gain a better understanding of how RUNX1 regulates EMT, and to 
identify novel genes and pathways that are regulated by RUNX1. To achieve this 
goal, we performed gene expression profiling and genome-wide RUNX1 binding 
analysis (RNA-seq, ChIP-seq) in MCF10A cells (with or without RUNX1 depletion).  
These studies discovered novel genes and pathways indicating RUNX1 is a 
master transcription factor in mammary lineage. 
        Many recent studies have linked EMT phenotypes to cancer stem cells 
(Shibue and Weinberg 2017).  Breast cancer cells that undergo EMT or partial 
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EMT exhibit cancer stem cell properties with more aggressive metastatic potential 
(Grigore, Jolly et al. 2016). It was intriguing that results achieved in Chapter II 
suggested RUNX1 could repress the breast cancer stem cell phenotype. Therefore, 
the involvement of RUNX1 in breast cancer stem cells was investigated in Chapter 
IV through a combination of in vitro (tumorsphere assay, matrigel invasion and 
migration assays) and in vivo (mammary fat pad injection, tibia injection) studies.  
Overall, the goals of this dissertation are to determine the role of RUNX1 in 
normal mammary epithelial cells and to understand how the loss of RUNX1 
contributes to breast cancer progression. The novel findings obtained in this 
dissertation provide a better understanding of Runx biology, as well as 
mechanisms of tumor initiation and progression, and open many future directions 
for developing therapeutic interventions.     
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Chapter II RUNX1 stabilizes the mammary epithelial cell phenotype and 
prevents epithelial to mesenchymal transition 
 
 
 
A large portion of this chapter comes from the published work: 
Deli Hong, Terri L. Messier, Coralee E. Tye, Jason R. Dobson, Andrew J. Fritz, 
Kenneth R. Sikora, Gillian Browne, Janet L. Stein, Jane B. Lian, Gary S. Stein   
    Runx1 stabilizes the mammary epithelial cell phenotype and prevents epithelial 
to mesenchymal transition.  Oncotarget. 2017; 8:17610-17627 
 
Contribution: Deli Hong, Jane B. Lian, Janet L. Stein and Gary. S. Stein. 
conceived and designed the experiments, and analyzed data. Deli Hong 
performed the majority of the experiments. Terri L. Messier helped with the 
experiment in Fig. 2.4.  Jason R. Dobson, Gillian Browne and Deli Hong 
performed tissue microarray. Coralee E. Tye and Kenneth R. Sikora build the 
RNA-seq library and normalized the RNA-seq count. Andrew J. Fritz performed 
ChIP-seq qPCR. Deli Hong created all the figures. Deli Hong, Jane B. Lian, Janet 
L. Stein and Gary S. Stein wrote the manuscript. 
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2.1 ABSTRACT 
RUNX1 is a well characterized transcription factor essential for hematopoietic 
differentiation and RUNX1 mutations are the cause of leukemias. RUNX1 is highly 
expressed in normal epithelium of most glands and recently has been associated 
with solid tumors. Notably, the function of RUNX1 in mammary gland and how it is 
involved in initiation and progression of breast cancer is still unclear.  Here we 
demonstrate the consequences of RUNX1 loss in normal mammary epithelial and 
breast cancer cells. We first observed that RUNX1 is decreased in tumorigenic and 
metastatic breast cancer cells. We also observed loss of RUNX1 expression upon 
induction of epithelial-mesenchymal transition (EMT) in MCF10A (normal-like) 
cells. Furthermore, depletion of RUNX1 in MCF10A cells resulted in striking 
changes in cell shape, leading to mesenchymal cell morphology. The epithelial 
phenotype could be restored in breast cancer cells by re-expressing RUNX1. 
Analyses of breast tumors and patient data revealed that low RUNX1 expression 
is associated with poor prognosis and decreased survival. We addressed 
mechanisms for the function of RUNX1 in maintaining the epithelial phenotype and 
find RUNX1 directly regulates E-cadherin; and serves as a downstream 
transcription factor mediating TGF-β signaling.  We also observed through global 
gene expression profiling of growth factor depleted cells that induction of EMT and 
loss of RUNX1 is associated with activation of TGF-β and WNT pathways. Thus, 
these findings have identified a novel function for RUNX1 in sustaining normal 
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epithelial morphology and preventing EMT and suggest RUNX1 levels could be a 
prognostic indicator of tumor progression. 
 
2.2 INTRODUCTION 
 Evidence is rapidly accruing for the oncogenic and tumor suppressor functions 
of the Runx family of transcription factors, RUNX1, RUNX2 and RUNX3, which are 
essential for normal lineage-specific development (Ito 2004, Blyth, Cameron et al. 
2005). In late stage cancer, including breast, prostate and thyroid, abnormal 
expression of RUNX2 drives metastasis to bone (Pratap, Lian et al. 2006, Pratap, 
Wixted et al. 2008, Pratap, Imbalzano et al. 2009). Inhibition of RUNX2 in 
metastatic breast and prostate cancer cells drastically reduces tumor growth and 
metastasis in vivo (Pratap, Imbalzano et al. 2009, Akech, Wixted et al. 2010), 
revealing Runx2 function as an oncogene. It has been well documented that 
translocations of RUNX1, the essential hematopoiesis factor, with ETO, TEL 
(ETV6) (Bhojwani, Pei et al. 2012) or other genes cause a wide range of leukemias 
(Zhang and Rowley 2006). However, little is known of RUNX1 oncogenic or tumor 
suppressor activities in solid tumors. An early microarray profiling study comparing 
adenocarcinoma metastasis with primary adenocarcinoma tumors identified 
RUNX1 as one of 17 genes signature that associate with metastasis (Ramaswamy, 
Ross et al. 2003). Recent genetic studies have identified loss-of-function somatic 
mutations or deletion of RUNX1 in breast cancer patients (Banerji, Cibulskis et al. 
2012, Network 2012). These data are consistent with evidence that RUNX1 is 
reduced in metastasis-prone solid tumors (Ramaswamy, Ross et al. 2003). There 
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is a requirement for understanding RUNX1-mediated regulatory mechanism(s) in 
breast cancer. 
 Breast cancer remains the leading cause of cancer related death in women 
worldwide (Jemal, Bray et al. 2011).  Among the different subtypes of breast 
cancer, both the basal-like and Her2-enriched subtypes are the most clinically 
challenging; they have the worst survival rates and are often associated with 
metastasis (Martin-Castillo, Oliveras-Ferraros et al. 2013). It has been speculated 
that this aggressive phenotype of basal like breast cancer is linked with the 
Epithelial to Mesenchymal Transition (EMT), which is a key biological process in 
cancer progression and is involved in the conversion of early stage tumors into 
invasive malignancies (Bill and Christofori 2015). Oncogenic EMT occurs when 
primary tumor cells undergo a switch from an epithelial phenotype, which lacks 
motility and exhibits extensive cell-to-cell contact, to a mesenchymal phenotype 
having high cellular motility, lower cellular interactions, and a non-polarized cell 
organization (Zavadil and Böttinger 2005). Several studies, using breast cancer 
cell lines and clinical samples, have demonstrated that increased expression of 
mesenchymal markers including Vimentin, Fibronectin and N-cadherin, as well as 
reduced expression of epithelial markers including E-cadherin are observed in 
basal subtype breast cancer (Ramaswamy, Ross et al. 2003, Zhang and Rowley 
2006, Banerji, Cibulskis et al. 2012, Network 2012). The specific mechanisms that 
preserve the structural and functional properties of the epithelial cells of the 
glandular tissues and protect normal epithelial cells from transitioning to 
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malignancy in basal-like breast cancer are compelling and unresolved questions. 
We therefore have focused our studies on the functional activities of RUNX1 in 
basal subtype breast cancer cells.  
 In this chapter, I hypothesize that RUNX1 maintains the normal epithelial 
phenotype and that loss of RUNX1 promotes EMT. Our results demonstrate that 
depletion of RUNX1 in mammary epithelial cells disrupts/alters cellular morphology 
and suppresses E-cadherin expression. We find that RUNX1 level decreases 
during both TGF-β-induced and growth factor starvation-induced EMT, supporting 
a crucial role for RUNX1 in preventing EMT. Furthermore, our analysis of breast 
tumors and survival data supports the above finding that loss of RUNX1 promotes 
tumor progression. Thus, these studies demonstrate that RUNX1 functions to 
preserve epithelial phenotype in mammary epithelial cells and reveal that RUNX1 
has potential to reduce tumor growth in breast cancer.  
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2.3 MATERIALS AND METHODS 
2.3.1 Cell lines and cultures 
 Human breast cancer cell lines MCF10A, MCF7, MDA-MB-231 and T47D cells 
were purchased from ATCC. MCF10AT1 and MCF10CA1a cells are a gift from 
Jeff Nickerson’s lab. 
 MCF10A cells were grown in DMEM: F12 (Hyclone: SH30271, Thermo Fisher 
Scientific, Waltham, MA, USA) with 5% (v/v) horse serum (Gibco: 16050, Thermo 
Fisher Scientific, Waltham, MA, USA) + 10 μg/ml human insulin (Sigma Aldrich, St. 
Louis, MO: I-1882) + 20 ng/ml recombinant hEGF (Peprotech, Rocky Hill, NJ, USA: 
AF-100-15) + 100 ng/ml cholera toxin (Sigma Aldrich: C-8052) + 0.5 μg/ml 
hydrocortisone (Sigma Aldrich: H-0888) 50 IU/ml penicillin/50 μg/ml streptomycin 
and 2 mM glutamine (Life Technologies, Carlsbad, CA, USA: 15140-122 and 
25030-081, respectively). TGF-β induced EMT in MCF10A cells was initiated by 
addition of 10 ng/ml TGFβ1 (R&D Systems, Minneapolis, MN, USA) to the medium. 
Growth factors starvation induced EMT in MCF10A cells was performed as 
previously described (Santner, Dawson et al. 2001). Briefly, MCF10A cells were 
plated in completed medial and at day 2, the medium was switched to DMEM: F12, 
with 5% (v/v) horse serum and 50 IU/ml penicillin/50 μg/ml streptomycin without 
added growth factors. The cells were maintained in this medium for up to 14 days 
until the morphological change was observed. 
 MCF10AT1 cells were grown in the same medium as MCF10A cells. 
MCF10CA1a cells were grown in DMEM: F12 with 5% (v/v) horse serum with 50 
	 59	
IU/ml penicillin/50 μg/ml streptomycin and 2 mM glutamine. MCF7 cells were 
maintained in Dulbecco modified Eagle medium (DMEM) high glucose (Fisher 
Scientific: Thermo Fisher Scientific, Waltham, MA, USA: MT-10-017-CM) 
supplemented with 10% (v/v) FBS (Atlanta Biologicals, Flowery Branch, GA, USA: 
S11550), 50 IU/ml penicillin/50 μg/ml streptomycin. T47D cells were maintained in 
RPMI 1640 with phenol red (Fisher Scientific: MT-10-040-CM) supplemented with 
10% (v/v) FBS and 50 IU/ml penicillin/50 μg/ml streptomycin. MDA-MB-231 cells 
were cultured in alpha minimal essential medium (α-MEM) (Life Technologies: 
A10490-01) containing 10% (v/v) FBS and 50 IU/ml penicillin/50 μg/ml 
streptomycin. MCF10CA1a cells were transfected using FuGENE-6 (Roche, 
Indianapolis, IN, USA) according to the instructions of the manufacturer. 
 
2.3.2 Lentiviral plasmid preparation and viral vector production 
 Lentivirus-based RNAi transfer plasmids with pGIPZ shRunx1 (clone 
V2LHS_150257 and V3LHS_367631, GE Dharmacon) and pGIPZ non-silencing 
(Cat No. RHS4346, GE Dharmacon) were purchased from Thermo Scientific. To 
generate lentivirus vectors, 293T cells in 10 cm culture dishes were co-transfected 
with 10 μg of pGIPZ shRunx1 or pGIPZ non-silencing, with 5 μg of psPAX2, and 5 
μg of pMD2.G using lipofectamine 2000 reagent (Life Technologies). Viruses were 
harvested every 48 h post-transfection. After filtration through a 0.45 μm-pore-size 
filter, viruses were concentrated by using LentiX concentrator (Clontech, Mountain 
View, CA, USA). 
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2.3.3 Gene delivery by transfection and infection 
 For shRNA-mediated knockdown of RUNX1 expression, MCF10A or MCF7 
cells were plated in six-well plates (1x105 cells per well) and infected 24 h later 
with lentivirus expressing shRunx1 or nonspecific shRNA. Briefly, cells were 
treated with 0.5 ml of lentivirus and 1.5 ml complete fresh DMEM-F12 per well with 
a final concentration of 4 μg/ml polybrene. Plates were centrifuged upon addition 
of the virus at 1460 × g at 37°C for 30 min. Infection efficiency was monitored by 
GFP co-expression at 2 days post infection. Cells were selected with 2 μg/ml 
puromycin (Sigma Aldrich P7255-100MG) for at least two additional days. After 
removal of the floating cells, the remaining attached cells were passed and 
analyzed. 
 
2.3.4 Western blotting 
 Cells were lysed in RIPA buffer and 2X SDS sample buffer supplemented with 
cOmplete, EDTA-free protease inhibitors (Roche Diagnostics) and MG132 (EMD 
Millipore San Diego, CA, USA). Lysates were fractionated in an 8.5% acrylamide 
gel and subjected to immunoblotting. The gels are transferred to PVDF 
membranes (EMD Millipore) using a wet transfer apparatus (Bio-Rad Laboratories, 
Hercules, CA, USA). Membranes were blocked using 5% Blotting Grade Blocker 
Non-Fat Dry Milk (Bio-Rad Laboratories) and incubated overnight at 4°C with the 
following primary antibodies: a rabbit polyclonal RUNX1 (Cell Signaling 
Technology, Danvers, MA, USA: #4334, 1:1000); a mouse monoclonal to E-
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cadherin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA: sc21791, 1:1000); 
a mouse monoclonal Vimentin (Santa-Cruz Biotechnology sc-6260, 1:1000); a 
mouse monoclonal to β-Actin (Cell Signaling Technology #3700, 1:1000); a rabbit 
polyclonal LaminB1 (Abcam, Cambridge, UK: 16048, 1:2000); a rabbit polyclonal 
N-cadherin (Santa Cruz Biotechnology sc-7939, 1:2000). Secondary antibodies 
conjugated to HRP (Santa Cruz Biotechnology) were used for immunodetection, 
along with the Clarity Western ECL Substrate (Bio-Rad Laboratories) on a 
Chemidoc XRS+ imaging system (Bio-Rad Laboratories). 
 
2.3.5 Immunofluorescence staining microscopy 
 Cells grown on coverslips were fixed with using 3.7% formaldehyde in 
phosphate buffered saline (PBS) for 10 min. Cells were then permeabilized in 0.1% 
Triton X-100 in PBS, and washed in 0.5% Bovine Serum Albumin in PBS. 
Detection was performed using a rabbit polyclonal RUNX1 antibody (Cell Signaling 
Technology #4336), a mouse monoclonal Vimentin (Santa Cruz Biotechnology sc-
6260), a rabbit polyclonal N-cadherin (Santa Cruz Biotechnology sc-7939) and a 
mouse monoclonal to E-cadherin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, 
USA). Staining was performed using fluorescent secondary antibodies; for rabbit 
polyclonal antibodies a goat anti-rabbit IgG (H+L) secondary antibody, Alexa 
Fluor® 488 conjugate (Life Technologies A-11008), was used and for mouse 
monoclonal a F(ab')2-goat anti-mouse IgG (H+L) secondary antibody, Alexa 
Fluor® 488 conjugate was used (Life Technologies A-11001). 
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2.3.6 Quantitative PCR 
 RNA was isolated with Trizol (Life Technologies) and cleaned by DNase 
digestion (Zymo Research, Irvine, CA, USA). RNA was reversed transcribed using 
SuperScript II and random hexamers (Life Technologies). cDNA was then 
subjected to quantitative PCR using SYBR Green technology (Applied Biosystems, 
Foster City, CA, USA). Sequences of primers used in the paper. RUNX1 Forward: 
AACCCTCAGCCTCAGAGTCA, RUNX1 Reverse: 
CAATGGATCCCAGGTATTGG; E-cadherin Forward: 
GGAAGTCAGTTCAGAGCATC, E-cadherin Reverse:  
AGGCCTTTTGACTGTAATCACACC; N-cadherin Forward: 
TGTTTGACTATGAAGGCAGTGG, N-cadherin Reverse: 
TCAGTCATCACCTCCACCAT; Vimentin Forward: 
AGGAAATGGCTCGTCACCTTCGTGAATA, Vimentin Reverse: 
GGAGTGTCGGTTGTTAAGAACTAGAGCT; GAPDH Forward: 
TGTGGTCATGAGTCCTTCCA, GAPDH Reverse: 
ATGTTCGTCATGGGTGTGAA; HPRT Forward: TGCTGACCTGCTGGATTACA, 
HPRT Reverse: TCCCCTGTTGACTGGTCATT; b-Actin Forward: 
AGCACAGAGCCTCGCCTTT, β-Actin Reverse: CGGCGATATCATCATCCAT. 
 
2.3.7 Tissue microarray 
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 Formalin-fixed paraffin-embedded (FFPE) human breast cancer samples were 
obtained from the UMMS tissue bank and FFPE human breast cancer tissue 
microarrays (TMA) from US BioMax (Rockville, MD, USA). TMAs (BR1503a & 
BR10010) were obtained from US BioMax. Sample information pertaining to Type, 
Grade, Stage, TNM, were provided by US BioMax. BR1503a is a primary breast 
tissue array of 150 samples of 75 patient cases: three cases of adjacent normal 
breast tissue, three cases of breast fibroadenoma, two cases of breast 
cystosarcoma phyllodes, seven cases of breast intraductal carcinoma, and 60 
cases of breast invasive ductal carcinoma. Duplicate cores per case. BR10010 is 
a breast carcinoma and matched metastatic carcinoma array of 100 samples of 50 
patient cases: 46 cases of invasive ductal carcinoma, one case of micropapillary 
carcinoma, two cases of invasive lobular carcinoma, and one case of 
neuroendocrine carcinoma. Duplicate cores per case. RUNX1 staining was done 
as previously described (Liu, Lengner et al. 2011) using RUNX1 Rabbit Polyclonal 
4334 from Cell Signaling Technology. Each tissue section was imaged and 
independent researchers blindly scored the sections based on the metric in Fig. 
2.12 A. 
 
2.3.8 Analysis of RUNX1 expression in various cancers using public data 
sets 
 RUNX1 expression was analyzed in various breast cancer subtype types using 
the TCGA database (www.cbioportal.org) (Network 2012). The PROGgene 
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database (www.compbio.iupui.edu/proggene) was used to identify the data sets 
for survival analysis and re-analyzed the public GEO data sets 
(www.ncbi.nlm.nih.gov/gds) (GSE3494-U133A). 
 
 
2.3.9 RNA-Seq, ontology, and pathway analysis 
 RNA was isolated using DirectZol RNA mini prep kit (Zymo Research), 
quantified by Qubit HS RNA assay (Thermo Fisher Scientific) and assayed for RNA 
integrity by Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Total RNA 
was depleted of ribosomal RNA, reverse transcribed and strand-specific adapters 
added following manufacturer’s protocol (TruSeq Stranded Total RNA Library Prep 
kit with Ribo-Zero Gold, Illumina, San Diego, CA, USA) with the exception that the 
final cDNA libraries were amplified using the Real-time Library Amplification Kit 
(Kapa Biosystems, Wilmington, MA, USA) to prevent over-amplification of libraries. 
Generated cDNA libraries were assayed for quality then sequenced as single-end 
100 bp reads (IlluminaHiSeq1000, UVM Advanced Genome Technologies Core). 
Sequence files (fastq) were mapped to the most recent assemblies of the human 
genome (hg38) using TopHat2 (Kim, Pertea et al. 2013). Expression counts were 
determined by HTSeq (Anders, Pyl et al. 2015) with recent gene annotations 
(Gencode v22) (Harrow, Frankish et al. 2012). Differential expression was 
analyzed by DESeq2 (Love, Huber et al. 2014). Correlation between replicates and 
differential gene expression between time points was assessed by principal 
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component analysis (PCA). RNA-Seq data have been deposited in the GEO under 
accession codes GSE85857. In addition, mRNA expression data was uploaded to 
IPA (www.ingenuity.com) and analyzed using default parameters. The expression 
heat map was generated using GENE-E (Broad Institute, MA, USA 
www.broadinstitute.org/cancer/software/GENE-E/). Fifty-eight EMT genes were 
selected by using the list from (Taube, Herschkowitz et al. 2010, Minafra, BravatÀ 
et al. 2014). 
2.3.10 ChIP-qPCR 
 RUNX1 ChIP-qPCR was performed essentially as described(O’Geen, Frietze 
et al. 2010) . Briefly, 200,000 MCF10A cells were cross-linked, lysed and sonicated 
to obtain DNA fragments mostly in the 200-1000-bp range. Immunoprecipitation 
was performed at 4°C overnight with anti-RUNX1 antibody (4334, Cell Signaling 
Technology) at a 1:15 antibody to chromatin ratio. Primers used in ChIP-qPCR are 
listed below: CDH1 Forward: CCCAACCTGACCACAGGAAT, CDH1 Reverse: 
GCTGCATGCGTAACAACACA; TGFB2 Forward: AGTCCTCCTCCCCCTAATGT, 
TGFB2 Reverse: CAGGGTATAGGCCACGACTG; TGFBR3 Forward: 
TCTTTGTAGCCTGCTGGGTT, TGFBR3 Reverse: 
CCCCCATCCTTACAAGTGGTT; ZNF333 (negative control 1) Forward: 
TGAAGACACATCTGCGAACC, ZNF333 Reverse: 
TCGCGCACTCATACAGTTTC; ZNF180 (negative control 2) Forward: 
TGATGCACAATAAGTCGAGCA, ZNF180 Reverse: 
TGCAGTCAATGTGGGAAGTC. 
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2.3.11 Statistical analysis 
 The results were reported as Mean ± S.E.M. unless otherwise indicated, and 
Student’s t-Tests were used to calculate statistical significance. 
 
The following datasets were generated: 
- RNA-sequences: 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE85857, publicly 
available at NCBI Gene Expression Omnibus (accession no. GSE 85857) 
 
2.4 RESULTS 
2.4.1 RUNX1 expression is decreased in breast cancer 
 RUNX1 involvement in breast cancer was first tested using a panel of normal 
and breast cancer cell lines representing different breast cancer subtypes (Fig. 
2.1). The selected cell lines included non-metastatic luminal MCF7 and T47D 
breast cancer cells and basal-like breast cancer MDA-MB-231 cells. Compared to 
the high level of RUNX1 in normal-like basal MCF10A control cells, RUNX1 mRNA 
(Fig. 2.1A) and protein (Fig. 2.1B) were significantly decreased in all breast cancer 
cell lines tested, but less so in the triple-negative MDA-MB-231 cells. 
We next evaluated RUNX1 mRNA and protein expression in the MCF10 
progression series of MCF10A normal-like mammary epithelial cells, tumorigenic 
MCF10AT1 and MCF10CA1a cells (Santner, Dawson et al. 2001). RUNX1 mRNA 
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(Fig. 2.1C) and protein (Fig. 2.1D) expression were strikingly decreased in both 
MCF10AT1 and MCF10CA1a cells compared with MCF10A cells. In both non-
metastatic cancer cell types, loss of RUNX1 expression paralleled decreases of 
the epithelial marker E-cadherin, while the mesenchymal marker Vimentin was 
highly expressed only in the MCF10CA1a cells. These changes in EMT markers 
are consistent with the mesenchymal phenotype of the two cancer cell lines. Thus, 
decreased RUNX1 with tumor progression correlates with EMT. Together our 
findings indicate an important role for RUNX1 in normal breast epithelial cells and 
provide evidence for the emerging concept that RUNX1 may function to suppress 
tumor growth in breast cancer (Chuang, Ito et al. 2013). 
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 Figure 2.1. Decreased RUNX1 expression is related to breast cancer 
progression in cell models. (A) RUNX1 RNA expression by RT-qPCR 
for a panel of breast cancer cell lines compared to MCF10A cells show 
that RUNX1 protein is decreased in breast cancer cells. (B) Western blot 
of cell lysate for the same panel of cell lines shown in A. (C) RUNX1 RNA 
expression by RT-qPCR of normal mammary-like MCF10A cells, 
MCF10A-derived tumorigenic cell line MCF10AT1, and metastatic 
MCF10CA1a cells shows RUNX1 is decreased in the cancer cells. (D) 
Western blot comparison in the MCF10 series. All the experiments are 
performed 3 times (N=3). 
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2.4.2 TGF-β induced EMT decreases RUNX1 expression in MCF10A cells 
 The above results show that RUNX1 levels are decreased in breast cancer 
cells and that decreased RUNX1 is accompanied with EMT in the MCF10 series. 
To mechanistically address if decreased RUNX1 and EMT are coupled in breast 
cancer, we used a well-known method to induce EMT in mammary cells, by adding 
TGF-β to MCF10A cells (Xu, Lamouille et al. 2009). TGFB1-Smad signaling is the 
most frequently described inducer of EMT, and RUNX1 is known to be a 
downstream target of TGF-β signaling. Furthermore, it is well documented that 
RUNX1 forms an interaction complex with SMADs (Ito and Miyazono 2003), 
thereby regulating genes responsive to TGF-β. Taken together, we hypothesized 
that RUNX1 expression would be repressed upon treating with TGF-β.  
 MCF10A cells were incubated with 10 ng/ml TGFβ1 for 6 days, and we 
observed that the original cobblestone-like epithelial morphology with tight cell-cell 
contact was lost, and cells gained an elongated fibroblast-like morphology (Fig. 
2.2A). When the levels of epithelial and mesenchymal markers were examined by 
western blotting and immunofluorescence microscopy, the TGFβ1-treated cells 
exhibited a 50% down-regulation of the epithelial marker E-cadherin, while 
expression of the mesenchymal markers Vimentin and N-cadherin was induced 
(Fig. 2.2B, C). Significantly, in this TGF-β-induced EMT model, we observed the 
down-regulation of RUNX1 at both the protein and mRNA levels (Fig. 2.2B). 
Although the immunofluorescence results showed that not all cells acquired the 
mesenchymal phenotype (Fig. 2.2C), indicating that only a subset of the cells 
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underwent EMT, we still find that RUNX1 is decreased during EMT. As further 
evidence that loss of RUNX1 occurs concomitantly with EMT, co-
immunofluorescence reveals that the subset of cells undergoing EMT (Vimentin-
positive cells), had lower or no RUNX1 expression (Fig. 2.2D). These results 
support the idea that RUNX1 may function as a suppressor of the EMT.  
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2.4.3 RUNX1 reverses the TGF-β-induced EMT phenotype 
 To further prove a functional role for RUNX1 in preventing EMT and maintaining 
the epithelial phenotype, we examined whether overexpressing RUNX1 could 
reverse the EMT phenotype after TGF-β induction. 
 A plasmid containing HA-tagged RUNX1 was transfected into TGF-β-treated 
MCF10A cells. We observed that the cells with RUNX1 overexpression changed 
Figure 2.2. RUNX1 decreases during TGFβ-induced EMT. MCF10A 
cells treated with 10 ng/ml TGFβ for 6 days. (A) MCF10A cells treated 
with TGFβ show morphological changes toward an EMT-like state. (B) 
Western blot analyses show changes in EMT markers and RUNX1 
expression during EMT. Left lower panel: RT-qPCR of RNA from 
MCF10A cells shows decreased RUNX1 expression in TGFβ treated 
cells. Student’s t test * p value <0.05 for TGFβ-treated cells compared to 
control cells. Where error bars are shown these represent the standard 
error of the mean (SEM) from three independent experiments. (C) 
Immunostaining shows increased Vimentin and N-cadherin expression 
in the cytoskeleton during TGFβ-induced EMT. (D) Immunostaining 
shows the cells with Vimentin (Green) expression have less or no 
RUNX1 (Red) expression.  All the experiments are performed 3 times 
(N=3). 
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their morphology from mesenchymal-like back to epithelial-like (Fig. 2.3A). 
Overexpressing RUNX1 in these cells also increased E-cadherin and repressed 
Vimentin expression, suggesting that cells re-acquired an epithelial phenotype and 
that the TGF-β-induced EMT was blocked (Fig. 2.3B). This result demonstrated 
that the repression of RUNX1 is a necessary step during TGF-β induced EMT.  
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2.4.4 Decreased expression of RUNX1 during TGF-β independent EMT in 
MCF10A cells 
 We considered the possibility that RUNX1 may function in an exogenous TGF-
β-independent manner to repress EMT. We used a cell model of EMT induction 
Figure 2.3. RUNX1 reverses TGFβ induced EMT. (A) Images of 
MCF10A cells treated with TGF-β show morphological changes toward 
an mesenchymal state. Overexpressing RUNX1 in TGF-β-treated cells 
returned cell morphology to an epithelial-like state. (B) RT-qPCR of RNA 
from MCF10A cells show changes in gene expression by overexpressing 
RUNX1 in TGFβ-treated cells, which activates E-cadherin and represses 
Vimentin expression. Student’s t test * p value <0.05 for HA-RUNX1 
overexpression in MFC10A cells compared to EV control cells. Error bars 
represent the standard error of the mean (SEM) from three independent 
experiments. All the experiments are performed 3 times (N=3). 
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that is independent of treatment with exogenous TGF-β. It has been previously 
shown that withdrawal from MCF10A medium of specific factors required for 
optimal cell growth (insulin, EGF, Hydrocortisone and Cholera Toxin), changed cell 
morphology from cobblestone to spindle like (Yusuf and Frenkel 2010). Here we 
demonstrate that this morphological change (Fig. 2.4A) resembles an EMT 
process. Western blotting and qRT-PCR results show that the epithelial marker E-
cadherin was down regulated, while mesenchymal markers N-cadherin and 
Vimentin were upregulated (Fig. 2.4B and C). Importantly RUNX1 protein is not 
detected in growth factor-depleted cells by western blot and immunofluorescence 
microscopy (Fig. 2.4B and D, top panel). Compared with TGF-β-induced EMT (Fig. 
2.2C), in this exogenous TGFB independent model, all cells acquired the 
mesenchymal phenotype and lost epithelial markers and RUNX1 expression (Fig. 
2.4D). These results reveal that modifying growth medium is a more powerful 
method for inducing EMT in MCF10A cells. Based on the loss of RUNX1 during 
both exogenous TGF-β-dependent and -independent EMT, we conclude that 
RUNX1 is a key factor in repressing the EMT and maintaining epithelial 
morphology in normal-like mammary epithelial cells. 
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2.4.5 Gene expression profiling of growth factor-depleted MCF10A cells 
reveals the spectrum of EMT markers 
 To further understand the mechanisms of growth factor depletion-induced EMT, 
we carried out unbiased genome-wide expression profiling by RNA-Seq, 
comparing cells grown in normal and growth factor depleted conditions. Among 
Figure 2.4. Decreased RUNX1 during TGF-β-independent EMT. (A) 
Images of MCF10A cells grown in medium without growth factors 
(Insulin, EGF, Hydrocortisone and Cholera toxin) for 7 days show 
morphological changes from cobblestone to spindle-like. (B) Western 
blot analyses of cell lysates from MCF10A cells treated with or without 
growth factors show changes in EMT markers and RUNX1 expression 
during EMT. (C) RNA expression of the EMT markers E-cadherin, N-
cadherin and Fibronectin was quantified using RT-qPCR in MCF10A 
cells in the presence or absence of growth factors. Student’s t test 
* p value <0.05, ** p value <0.01 for growth factors depleted MCF10A 
cells compared to cells with growth factors. Error bars represent the 
standard error of the mean (SEM) from three independent experiments. 
(D) Immunostaining of E-cadherin, Vimentin, N-Cadherin and RUNX1 
reveals changes in organization of cell–cell adhesion, cytoskeleton and 
decreased RUNX1. All the experiments are performed 3 times (N=3). 
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the 1880 differentially expressed mRNAs that have a 2-fold cut off, 457 genes were 
up- and 1423 were down-regulated. Gene ontology analysis identified functional 
categories and associated pathways (Fig. 2.5). Among the top 5 canonical 
pathways that were affected, regulation of the EMT pathway was the most 
significant with 20 genes altered in the network (Fig. 2.5A and C). This observation 
further confirmed that this novel method of removing growth factors in MCF10A 
induces EMT. Other relevant pathways include cancer metastasis signaling and 
integrin-like kinase (ILK) signaling (Fig. 2.5A). Together these most significant 
signaling pathways are indicative of the MCF10A cells acquiring a more cancer 
related phenotype. 
 In addition to pathway analysis, we selected 58 epithelial and mesenchymal 
genes by using two database sources (described in Materials and Methods) and 
examined the expression patterns based on relative reads from our RNA-Seq 
profiling. The heat map constructed from these data (Fig. 2.5B) compares 
expression of EMT genes under two different growth conditions—normal and 
growth factor-depleted. Well-established epithelial genes such as DSP, Claudins 
and KRT family (Tomaskovic-Crook, Thompson et al. 2009) were down-regulated. 
We observed consistent up-regulation of common mesenchymal genes (CDH2, 
FN1 and VIM) as well as genes related to signaling pathways such as BMP/TGFB 
and WNT when growth factors were removed. We also noted that both TGFβ2 and 
Runx2 are among the up-regulated genes (Fig. 2.5B). Moreover, we found that 
expression of 43 genes in the Runx2 interaction network were altered (Fig. 2.5C), 
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consistent with up-regulation of Runx2 protein level upon growth factor depletion 
(Fig. 2.6) and its role in promoting invasion and metastasis to bone (Pratap, Lian 
et al. 2006). 
To study how loss of RUNX1 is involved in this EMT process, we also examined 
the RUNX1 interaction network and found that 20 genes (Fig. 2.5C) were altered 
upon growth factor depletion. Further pathway analysis with the 1880 differentially 
expressed genes revealed that decreased RUNX1 and the altered RUNX1 
interaction network are associated with activation of TGFβ and WNT pathways 
(Fig. 2.5D), which are known to relate to RUNX1 function (Chimge, Little et al. 
2016). The stimulated TGFβ and WNT pathways further activate the downstream 
well-studied EMT-inducing transcription factors Snail and Twist (Fig. 2.5D) 
(Tomaskovic-Crook, Thompson et al. 2009). These studies provide evidence that 
depletion of RUNX1 contributes to initiation of EMT in the normal-like MCF10A 
mammary epithelial cells. These results also indicate that Runx2 plays an 
important role during growth factor starvation-induced EMT and elucidate 
mechanisms by which RUNX1 and Runx2 are involved in EMT. Together, these 
RNA-Seq data confirm that the growth factor starvation method is a unique cell 
treatment to induce EMT in MCF10A cells without exogenous addition of TGFβ. 
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Figure 2.5. RNA-Seq reveals MCF10A cells undergo EMT upon 
growth factor removal. (A) Top canonical pathways with the most 
significant p values identified by using Ingenuity Pathway Analysis 
(QIAGEN, Hilden, Germany). (B) Relative expression heat map of 58 
EMT related genes confirming MCF10A cells undergo EMT. (C) 
Differentially expressed genes (2-fold cut off) in the EMT regulation 
pathway (p val 1.66E-06), RUNX1 interaction network (p val 2.56E-02) 
and Runx2 interaction network (p val 3.73E-09). (D) Model of RUNX1 
function in growth factor depletion induced EMT. Illustration shows the 
consequences of up and down regulated genes when RUNX1 is 
decreased upon growth factor depletion. The listed genes and pathways 
are promoting EMT by loss of RUNX1 function. Blue indicates down 
regulated genes. Red indicates up regulated genes or pathways. 
Ingenuity Pathway Analysis (QIAGEN) was used in panel A, C and D; 
GENE-E (Broad Institute, Cambridge, MA, USA) was used in panel B. 
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2.4.6 Directly Depleting RUNX1 in MCF10A cells results in loss of epithelial 
morphology and activation of EMT   
 We have shown by multiple lines of evidence that down-regulation of RUNX1 
is a key step during breast cancer EMT. However, we still could not distinguish 
whether decreased RUNX1 expression drives the activation of EMT or is an 
outcome of EMT. To address that question and understand whether RUNX1 can 
function directly to maintain normal epithelial morphology, we inhibited 
endogenous RUNX1 expression in MCF10A cells using lentivirus that contained 
short-hairpin RNA targeting RUNX1 (shRunx1) (Fig. 2.7). We generated two 
different MCF10A shRunx1 cell lines using two different shRNA sequences (shR1-
1, shR1-2). Compared to the parental and control (non-silencing) cells, we 
observed that RUNX1-depleted MCF10A cells showed an obvious shift in 
morphology from cobblestone-like cells to more spindle-shaped cells (Fig. 2.7A). 
Figure 2.6. Increased Runx2 during growth factor depleted induced 
EMT. Western blot analyses of cell lysates from MCF10A cells treated 
with or without growth factors showing changes in Runx2 activation 
during EMT. The experiments is performed 3 times (N=3). 
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Western blot and Q-PCR analysis demonstrated endogenous RUNX1 was down 
regulated at both the protein and mRNA levels (Fig. 2.7B and C). Because the 
shRunx1 cells exhibited a morphological change consistent with loss of the 
epithelial phenotype, E-cadherin expression was examined. RUNX1 knockdown 
cells showed a significant decrease of E-cadherin, as well as up-regulation of the 
mesenchymal genes Vimentin and N-cadherin (Fig. 2.7C).  
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    Taken together, these results indicate that depletion of RUNX1 directly initiates 
EMT in MCF10A cells, and establishes for the first time that RUNX1 is required to 
maintain the normal mammary epithelial phenotype. The mechanism for these 
biological activities involves RUNX1 binding to EMT-related target genes. 
Figure 2.7. Depleting RUNX1 in MCF10A cells promotes a 
mesenchymal-like phenotype. (A) MCF10A cells treated with shRunx1 
show morphological changes toward an EMT- like state. (B) Western blot 
analyses of lysates from MCF10A cells treated with shRunx1 show 
decreased protein expression of RUNX1 and E-cadherin. (C) RT-qPCR 
analyses of RNA from MCF10A cells treated with shRunx1 show 
decreased gene expression of E-cadherin and activation of 
mesenchymal marks of N-cadherin and Vimentin. Student’s t test 
* p value <0.05, ** p value <0.01 for MCF10A shRunx1 cells compared 
to the MCF10A ns cells. Error bars represent the standard error of the 
mean (SEM) from three independent experiments. (D) ChIP-qPCR 
confirmation of RUNX1 occupancy at CDH1, TGFB2 and TGFBR1. 
ZNF188 (NC1) and ZNF333 (NC2) were used as the negative control as 
RUNX1 are predicted not to bind these genes. Data obtained with 
antibodies against RUNX1 are normalized to input control. All the 
experiments are performed 3 times (N=3). 
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    Previously it has been shown that both E-cadherin (Liu, Lee et al. 2005) and 
genes in TGFB family (Hanai, Chen et al. 1999) have RUNX1 binding sites. Thus, 
to further support a direct role for RUNX1 regulation of E-cadherin and TGF-β 
signaling in MCF10A cells, a RUNX1 ChIP-qPCR was performed (Fig. 2.7D). 
Significant enrichment of RUNX1 binding on E-cadherin (CDH1), TGFB2 and 
TGFBR3 genes were observed. The positions of the amplicons on tested genes 
are shown in Figure 2.8. These results indicate that RUNX1 may directly bind to 
the E-cadherin gene and regulate its expression. Our findings also provide an 
additional line of evidence for a key function of RUNX1 in blocking TGF-β signaling 
and maintaining epithelial morphology. Further the binding of RUNX1 to the E-
cadherin gene is also associated with the H3K4ac activating histone mark (Messier, 
Gordon et al. 2016). We searched for putative RUNX1 binding sites and found 5 
consensus motif sequences that are coincident with H3K4ac peaks present in 
MCF10A cells but not in metastatic MDA-MB-231 cells Figure 2.9.  
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Figure 2.8. Schematic diagram of ChIP qPCR primers and 
amplicons over the tested gene for ChIP-qPCR. 
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2.4.7 Depleting RUNX1 in MCF7 breast cancer cells promotes EMT 
 The loss of epithelial morphology in normal-like mammary cells by knockdown 
of RUNX1 (Fig. 2.7) raises a compelling question regarding the role of RUNX1 in 
Figure 2.9. RUNX1 consensus sequences in CDH1 are coincident 
with H3K4Ac peaks in MCF10A cells. ChIP analysis showing 
significant binding of H3K4Ac (GSE69377) to a region in CDH1 genes 
with multiple RUNX1 binding motifs in MCF10A cells but not in MDA-
MB-231 cells. 
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breast cancer cells. Therefore, we tested whether this regulation also occurs in 
epithelial-like MCF7 breast cancer cells. Two shRunx1 (shR1-1, shR1-2) stable 
knockdown in the MCF7 cell line were generated. Endogenous RUNX1 was down-
regulated at both the protein and mRNA levels for both short-hairpin RNAs (Fig. 
2.10A and B). In these RUNX1-depleted MCF7 cells, western blot and qRT-PCR 
analyses revealed a significant decrease of E-cadherin expression at both the 
protein and mRNA levels and an up-regulation of the mesenchymal genes 
Vimentin and N-cadherin at the mRNA level (Fig. 2.10C). Based on these results, 
we conclude that RUNX1 is preventing EMT in both normal mammary cells 
(MCF10A) and early breast cancer cells (MCF7), consistent with its function in 
maintaining an epithelial phenotype.  
 
2.4.8 Overexpressing RUNX1 in mesenchymal like breast cancer cells drives 
mesenchymal to epithelial transition (MET) 
 To further establish a definitive role for RUNX1 function in preserving the 
epithelial phenotype, we carried out a “rescue” study to examine the consequences 
of restoring RUNX1 expression in mesenchymal like breast cancer cells (Fig. 
2.10D and E). RUNX1 was ectopically expressed in tumorigenic MCF10AT1 cells, 
which resulted in increased E-cadherin expression and decreased Vimentin 
expression (Fig. 2.10D and E). Notably, the E-cadherin level is only increased at 
the mRNA level but not the protein level under transient transfection conditions 
(data not shown). This key finding shows that overexpression of RUNX1 in 
	 90	
mesenchymal cancer cells drives the cells back to the epithelial stage. These 
observations provide direct evidence that RUNX1 prevents EMT. 
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Figure 2.10. RUNX1 controls EMT-MET in non-metastatic breast 
cancer cells. Two breast cancer cell lines MCF7 (epithelial-like) (A-C) 
and MCF10AT1 (mesenchymal-like) (D, E) were examined for RUNX1 
knockdown or ectopic expression, respectively. (A) Western blot 
analyses of lysates from MCF7 cells with RUNX1 depletion show 
decreased protein expression of RUNX1 and E-cadherin. (B) RT-qPCR 
of RNA from MCF7 cells treated with shRunx1 shows decreased gene 
expression of RUNX1. (C) RT-qPCR shows decreased gene expression 
of E-cadherin and increased gene expression of N-cadherin and 
Vimentin in RUNX1 depleted MCF7 cells. Student’s t test * p value 
<0.05, ** p value <0.01 for MCF7 shRunx1 cells compared to the 
MCF7ns cells. Error bars represent the standard error of the mean (SEM) 
from three independent experiments. (D) RT-qPCR of RNA from 
MCF10AT1 cells overexpressing RUNX1 show increased gene 
expression of E-cadherin and decreased gene expression of Vimentin. 
Student’s t test * p value <0.05 for MCF10AT1 RUNX1 overexpression 
cells compared to the MCF10AT1 EV cells. Error bars represent the 
standard error of the mean (SEM) from three independent experiments. 
(E) Western blot analyses of lysates from MCF10AT1 cells treated with 
RUNX1 overexpression show increased protein expression of RUNX1 
and decreased expression of Vimentin. All the experiments are 
performed 3 times (N=3). 
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2.4.9 RUNX1 expression in breast tumors correlates with metastasis, tumor 
subtype and survival 
 We next evaluated RUNX1 expression in breast cancer patient tissues. With a 
highly specific RUNX1 antibody, we applied immunohistochemistry to determine 
the expression pattern of RUNX1 in different types of breast cancer using a Tissue 
Microarray (TMA) of 185 tumors and 6 control normal adjacent tissue sections. 
The results identified that RUNX1 expression is associated with breast cancer 
stages and subtypes. We observed RUNX1 expression at high levels in all normal 
and benign mammary epithelial tissues (Fig. 2.11A). RUNX1 is also expressed in 
breast cancer samples including ductal carcinoma in situ and invasive ductal 
carcinoma (Fig. 2.11A). However, breast cancer cells metastatic to the lymph node 
showed significantly less RUNX1 expression compared with the primary tumor site 
(Fig. 2.11A and B). Quantification of RUNX1 levels at primary sites and lymph 
metastatic sites in 50 patients showed that RUNX1 is significantly lower (p=0.005 
using two tailed t test) in lymph samples (Fig. 2.11C). We also observed slightly 
higher RUNX1 levels in grade 1 compared with grade 2 tumors (Fig. 2.12) 
 We further investigated the relationship of RUNX1 expression to clinical 
outcomes through mining of The Cancer Genome Atlas (TCGA) database. RUNX1 
was found to be under-expressed in several breast cancer subtypes, including 
Luminal B, Her2-enriched and basal-like breast cancers, which all have a poor 
prognosis (Fig. 2.11D). Luminal A subtype, which is generally associated with a 
good prognosis, showed RUNX1 levels equivalent to normal-like breast tissue. 
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However, 5% of samples in this subtype have RUNX1 somatic mutations (Network 
2012), with the majority located in the RUNX1 DNA-binding domain, which can 
compromise RUNX1 transcriptional activity. We conclude from these data that 
RUNX1 expression is subtype-dependent and correlates with prognosis. 
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 RUNX1 expression levels were also compared with patient survival rates using 
a data set (GSE3494-U133A) in the Gene Expression Omnibus database (Fig. 
2.11E). Our analyses show that patients with low RUNX1 levels in their tumors 
exhibit poor survival relative to patients with high RUNX1 expression.  
 Taken together our data demonstrate that RUNX1 sustains the epithelial 
phenotype and preserving the epithelial integrity in normal epithelial cells. Loss of 
Figure 2.11. RUNX1 expression in breast tumors correlates with 
metastasis, tumor subtype and survival. (A) Representative tissue 
microarray images of RUNX1 in normal adjacent tissue (NAT), 
fibroadenoma, invasive ductal carcinoma, and tumor metastasis to 
lymph. (B) Representative of TMAs (n=50) showing two patients’ primary 
tumor and their lymph metastasis with RUNX1 positive cells (brown 
stain). Two tailed t test ** p<0.005 between primary tumor and lymph 
metastatic sites. (C) Distribution of RUNX1 staining scores for 50 patients 
with primary breast tumor and lymph metastasis. Using a semi-
quantitative scoring system, three researchers blindly scored TMAs. (D) 
RUNX1 mRNA is decreased in breast cancer subtypes. (E) Kaplan-Meier 
analysis showed higher overall survival in patients with higher RUNX1 
mRNA expression (GSE3494-U133A). Gehan-Breslow-Wilcoxon test 
with p value<0.0001 compared with high RUNX1 expression patients and 
low RUNX1 expression patients. 
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RUNX1 is not only accompanied with EMT (Fig. 2.2-2.5) but can also initiate the 
EMT transformation (Figs. 2.7 and 2.10). Therefore, loss of RUNX1 normal 
activities in tumor tissues may serve as an indicator of poor prognosis for breast 
cancer patients as revealed in several clinical studies (Fig. 2.11). We conclude 
from these clinical data that as tumors advance from early stage to a more 
aggressive phenotype, loss of RUNX1 may promote tumor progression.    
Figure 2.12. RUNX1 tissue microarray show that RUNX1 is 
associated with early stage tumor. (A) Representative tissue 
microarray images of RUNX1 in invasive ductal carcinoma represent 
each scoring. (B) RUNX1 in scoring in each category including normal 
adjacent tissue (NAT), fibroadenoma, invasive ductal carcinoma, and 
tumor metastasis to lymph. (C) RUNX1 scoring in grade 1 and grade 2 
tumors 
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2.5 DISCUSSION for Chapter II 
 Our study has established a crucial role for RUNX1 in maintaining the normal 
epithelial phenotype. This finding is supported by our demonstration that RUNX1 
is decreased during EMT and that loss of endogenous RUNX1 initiates and 
promotes EMT which is also accompanied by changes in the morphology of 
mammary epithelial cells. Using two independent methods to induce EMT, either 
by adding TGF-β or removing required growth factors which increases/activates 
TGF-β expression, we observed significantly decreased RUNX1 expression. 
Further, RUNX1 re-expression rescues the epithelial phenotype following TGF-β 
treatment, which assures maintenance of normal epithelial cell morphology and 
prevents EMT. By inhibition of RUNX1 in MCF10A (normal) and MCF7 (epithelial-
like breast cancer) cells, together with re-expression in MCF10AT1 (malignant 
cells with low RUNX1 levels), we provide direct evidence that loss of RUNX1 
directly contributes to the initiation of EMT in breast cancer, while the presence of 
RUNX1 restores the epithelial phenotype. Together these findings have revealed, 
for the first time, that the expression of RUNX1 has a critical function in preserving 
epithelial morphology in mammary epithelial cells and preventing EMT; thus, 
RUNX1 can be considered as a transcription factor preventing tumor initiation in 
normal epithelial cells.    
 Here we focused our study on normal mammary epithelial and epithelial-like 
breast cancer cells, and discovered a key function for RUNX1 in preventing EMT. 
We examined the mechanisms by which RUNX1 regulates EMT in cancer 
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progression. First, we show RUNX1 is a positive regulator of the epithelial marker 
E-cadherin. Upon loss of RUNX1, the expression level of E-cadherin is strikingly 
decreased. We also showed that RUNX1 directly binds to a consensus motif in the 
E-cadherin gene using ChIP-qPCR. Second, we demonstrate RUNX1 operates 
downstream of the TGF-β pathway and functions as a suppressor of TGF-β 
regulation. RUNX1 is well established to mediate TGF-β-BMP signaling by forming 
co-regulatory complexes with SMADs (Zaidi, Sullivan et al. 2002, Ito and Miyazono 
2003). Our RNA-Seq analysis of growth factor-depleted cells suggests that loss of 
RUNX1 is coupled with activation of the TGF-β pathway. This was confirmed 
experimentally by showing that RUNX1 is decreased upon TGF-β treatment and 
RUNX1 reverses TGF-β induced EMT. Supporting these molecular mechanisms, 
RUNX1 has known properties that establish cell phenotypes, including the 
hematopoietic lineage (Tober, Yzaguirre et al. 2013), and regulating quiescent hair 
follicle bulge stem cells to differentiate to early progenitor hair germ cells (Lee, 
Sada et al. 2014). Very recently RUNX1 was shown to be transiently upregulated 
early in hESC differentiation to mesendodermal lineages via RUNX1-TGFB2 
signaling and that loss of RUNX1 impaired epithelial differentiation 
(VanOudenhove, Medina et al. 2016). Thus, our studies, which have now identified 
a cellular function for RUNX1 in normal mammary cells, is consistent with these 
other normal tissues to support their cell type specific phenotype. We have further 
studied the consequence of disturbing normal RUNX1 function in breast cancer 
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cells and provided evidence that RUNX1 loss of function has a significant effect on 
cancer-related mechanisms. 
 Repression, overexpression, and/or deregulated functioning of RUNX1 have 
been shown to cause cancers (Ito, Bae et al. 2015). TGF-β is a well-known EMT 
inducer and has a dual role in breast cancer progression (David, Huang et al. 2016). 
In normal epithelial cells and early stage breast cancer, TGF-β acts as a tumor 
suppressor, yet at later stages of tumor progression can promote cancer cell 
migration, invasion and metastasis (Padua and Massague 2009). Our results have 
provided evidence that TGF-β is an upstream regulator of RUNX1. Because 
RUNX1 is downstream of TGF-β, RUNX1 may also have different functions 
depending on the specific cellular context (Browne, Taipaleenmäki et al. 2015). 
For example, while RUNX1 has been shown to function as a tumor suppressor in 
prostate cancer (Takayama, Suzuki et al. 2015), it acts as an oncogene in ovarian 
cancer (Keita, Bachvarova et al. 2013) and in a mouse model of breast cancer 
(Browne, Taipaleenmäki et al. 2015). Our identification of TGF-β as a RUNX1 
upstream regulator provides insight into the compromised mechanisms of RUNX1 
function that are associated with breast cancer. 
 RUNX1 is also subject to the hormonal status of cells. Treating ER+ breast 
cancer cells with 17β-estradiol promotes EMT (Huang, Fernandez et al. 2007) and 
also decreases RUNX1 expression (Vivacqua, De Marco et al. 2015). In turn, 
depletion of RUNX1 represses the expression of estrogen receptor α (van Bragt, 
Hu et al. 2014), suggesting a negative feedback loop in progression of ER+ breast 
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cancer. Our data show MCF7 ER+ breast cancer cells can be induced into EMT 
by RUNX1 depletion. One study using computational analysis revealed that 
RUNX1 is highly correlated with mammary stem cell differentiation (Sokol, Sanduja 
et al. 2015). Other studies showed that RUNX1 is important for mammary gland 
maturation, and its interaction with ERα is necessary for luminal development and 
may prevent breast cancer progression (van Bragt, Hu et al. 2014, Sokol, Sanduja 
et al. 2015). It also has been shown that RUNX1 represses WNT pathways, which 
allows ER to be expressed in luminal breast cancer cells (Chimge, Little et al. 2016). 
All these pieces of evidence raise the hypothesis that RUNX1 could reduce 
aggressiveness in ER-positive breast cancer; here we clearly demonstrate RUNX1 
has a direct role to prevent EMT in MCF7 ER+ breast cancer cells. 
 In addition to RUNX1-mediated mechanisms downstream of TGF-β (feedback 
loop) and upstream hormonal regulation of RUNX1, miRNAs are also a likely 
mechanism contributing to the down regulation of RUNX1 during EMT. MicroRNAs 
are known to promote/inhibit EMT (e.g., miR-200 family, miR-27 and miR-30) 
(Zaravinos 2015). Our analysis using TargetScan7.0 indicates that most of these 
miRNAs also target the RUNX1 3’UTR. It has been shown that miR27a (Tang, Yu 
et al. 2014), miR144 (Vivacqua, De Marco et al. 2015) and miR387 (Browne, 
Dragon et al. 2016), which are upregulated during breast cancer progression, are 
directly down-regulating RUNX1. The convergence of these multiple pathways that 
inhibit RUNX1 expression leads us to conclude that loss of RUNX1 is an important 
mechanistic step in breast cancer initiation and/or progression. 
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 Examination of TCGA and other public datasets identified loss of RUNX1 
correlates with poor prognosis (Fig. 2.12C) and poor survival (Fig. 2.12D). It has 
been shown in breast tumors that the majority of EMT markers are expressed in 
basal layer cells (Sarrio, Rodriguez-Pinilla et al. 2008). Also reported is that basal 
subtypes of breast cancer are more aggressive and metastatic compared to the 
luminal subtypes (Kennecke, Yerushalmi et al. 2010). TCGA data show that 
RUNX1 is expressed at the lowest level in patients with basal-like breast cancer. 
These findings are consistent with our identification of a RUNX1 function in 
preserving the epithelial phenotype in normal-like basal cells (MCF10A). Loss of 
RUNX1 expression may cause the basal cells to lose their epithelial morphology, 
phenotype integrity and become more susceptible to initiation of EMT. This 
explains why our functional studies focused on the role of RUNX1 in basal-like 
mammary epithelial cells (MCF10A). 
 Intact RUNX1 function is also important for Luminal A breast cancer. Genetic 
studies show RUNX1 is mutated in 5% of Luminal A subtype breast cancer patients 
(Banerji, Cibulskis et al. 2012, Network 2012). A recent study suggested that in 
MCF7 cells, disruption of RUNX1 function might contribute to development of 
ER+ luminal breast cancer in the context of either TP53 or RB1 loss (van Bragt, Hu 
et al. 2014). Significantly, we demonstrated that loss of RUNX1 in luminal like 
breast cancer cells (MCF7) can promote EMT (Fig. 2.10). Taken together, these 
biochemical and clinical data support the emerging concept that RUNX1 reduces 
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tumor aggressiveness and that loss of RUNX1 is associated with the progression 
of breast cancer. 
    Our studies demonstrate a clear reduction of endogenous RUNX1 in two cell 
models (MCF7 and MCF10AT1) of breast cancer. This finding is consistent with 
human TMA data that showed the strongest RUNX1 staining (66% strong or 
moderate levels) in normal cases, compared with 29% and 35% in DCIS and IDC 
samples, respectively (Sarrio, Rodriguez-Pinilla et al. 2008, Kennecke, Yerushalmi 
et al. 2010). However, this human data is in contrast to findings in the MMTV-PyMT 
mouse model of breast cancer (Browne, Taipaleenmäki et al. 2015), where Browne 
et al. reported that RUNX1 steadily increased during tumor growth. Thus, the 
decreased RUNX1 in human samples with increased disease progression 
indicates RUNX1 has distinct functional activities that differ between mouse and 
human breast tumors.   
 In conclusion, we identified RUNX1 as a key transcription factor in basal 
epithelial breast cells through its ability to maintain normal epithelial morphology. 
Our studies offer RUNX1 as a novel bio-therapeutic molecule for breast cancer 
intervention. 
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Chapter III RUNX1 Genome-wide Regulation of Normal Mammary Epithelial 
Cells: Novel Functions for Mitosis and Genome Stability 
 
A large portion of this chapter comes from the manuscript: 
Deli Hong, Andrew J. Fritz, Coralee E. Tye, Natalie A. Page, Joseph R. Boyd 
Janet L. Stein, Jane B. Lian, Gary S. Stein   
RUNX1 Global Binding and Gene Regulation in Mammary Epithelial Cells 
Revealed Novel Runx1 Mediated Cellular Activities 
 
Contribution: Deli Hong, Jane B. Lian, Janet L. Stein and Gary. S. Stein. 
conceived and designed the experiments, and analyzed data.  Deli Hong 
performed the majority of the experiments. Andrew J. Fritz built the ChIP-seq 
library. Coralee E. Tye and Natalie A. Page built the RNA-seq library.  Andrew J. 
Fritz, Coralee E. Tye and Joseph R. Boyd analyzed the RNA-seq and ChIP-seq 
results. Deli Hong created all the figures. Deli Hong, Jane B. Lian, Janet L. Stein 
and Gary S. Stein wrote the manuscript. 
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3.1 Introduction: 
    RUNX1 belongs to the Runx family of transcription factor that have been known 
for their function in balancing proliferation and differentiation during development 
(Ito, Bae et al. 2015). In particular, RUNX1 is essential for hematopoiesis, as 
Runx1-null mice die between embryonic day (E) 12.5 and E13.5 due to the lack of 
definitive hematopoiesis (Okuda, van Deursen et al. 1996, Wang, Stacy et al. 
1996). The role of RUNX1 in definitive hematopoiesis is to differentiate the 
hemogenic endothelium cells into hematopoietic stem cells through the endothelial 
to hematopoietic transition (Yzaguirre, de Bruijn et al. 2017). Disrupting normal 
RUNX1 function in hematopoietic cells promotes leukemogenesis (Sood, 
Kamikubo et al. 2017). For example, RUNX1 mutations, including translocations 
and point mutations, are frequently found in a variety of human hematological 
malignancies. These mutations function as oncogenes to promote 
leukemogenesis (Sood, Kamikubo et al. 2017).  
      In recent years, it has been revealed that the role of RUNX1 is not confined to 
the hematopoietic lineage. Multiple lines of evidence have emerged demonstrating 
that RUNX1 plays a key role in epithelial glands and in solid tumors, especially in 
breast cancer (Scheitz and Tumbar 2013, Riggio and Blyth 2017). Next generation 
sequencing studies on breast cancer tumor samples have consistently identified 
RUNX1 point mutations and deletions in human breast cancers, especially in 
luminal subtypes (Banerji, Cibulskis et al. 2012, Ellis, Ding et al. 2012, Network 
2012, Ciriello, Gatza et al. 2015). Moreover, in several studies, RUNX1 mutations 
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are characterized as cancer driver mutations, which directly contribute to tumor 
progression (Pereira, Chin et al. 2016, Kas, de Ruiter et al. 2017).  In one such 
study, insertional mutagenesis screening identified that RUNX1 truncation is 
involved in invasive lobular cancer development (Kas, de Ruiter et al. 2017).   
    Since RUNX1 mutations have been identified as driver mutations (Pereira, Chin 
et al. 2016), several studies have examined the function of RUNX1 in breast 
cancer cells (van Bragt, Hu et al. 2014, Barutcu, Hong et al. 2016, Chimge, Little 
et al. 2016). These studies have generally found that RUNX1 has a role to reduce 
aggressive phenotype in luminal subtypes of breast cancer. In ER-positive MCF7 
breast cancer cells, RUNX1 contributes to local chromatin interactions, and loss of 
RUNX1 leads to the deregulation of genes associated with chromatin structure and 
the activation of an epithelial to mesenchymal transition (Barutcu, Hong et al. 2016, 
Chimge, Little et al. 2016). Mechanistically, loss of RUNX1 activates WNT 
signaling by preventing the inhibition of AXIN1 (van Bragt, Hu et al. 2014, Chimge, 
Little et al. 2016) . Conversely, in MDA-MB-231 triple-negative breast cancer 
(TNBC) cells, RUNX1 has been shown to have tumor-promoting activity by 
supporting migration and invasion (Recouvreux, Grasso et al. 2016).   
    Compared with breast cancer, our understanding of RUNX1 function in normal 
mammary gland remains inadequate. RUNX1 levels fluctuate during physiological 
stages of mammary gland development, and in mice the highest level of RUNX1 
is observed in virgin and early-pregnant glands (van Bragt, Hu et al. 2014). In the 
mammary gland, RUNX1 is expressed primarily in the basal layer compared with 
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the luminal layer (van Bragt, Hu et al. 2014, Rooney, Riggio et al. 2017). 
Furthermore, depleting RUNX1 in mammary stem cells (MSC) leads to a reduction 
in luminal MSC and an increase in the basal MSC population (van Bragt, Hu et al. 
2014). This spatial/temporal expression pattern suggests that RUNX1 is precisely 
regulated and that its normal function is necessary for mammary gland 
development and morphogenesis. Previously, our group has demonstrated that 
RUNX1 stabilizes mammary epithelial cells by repressing the epithelial to 
mesenchymal transition (EMT) (Hong, Messier et al. 2017). Loss of RUNX1 
induces the initiation of EMT and changes the morphology of the cells. While 
limited evidence suggests that RUNX1 regulates proliferation and differentiation in 
mammary epithelial cells (Wang, Brugge et al. 2011, Sokol, Sanduja et al. 2015, 
Hong, Messier et al. 2017), the precise function(s) of RUNX1 in these cells is (are) 
unclear.  
To better elucidate the function of RUNX1 and the consequences of its loss of 
expression in mammary epithelial cells, in this chapter, I characterized the gene 
expression profile of the MCF10A cells with and without RUNX1 expression by 
RNA-seq analysis. In addition, to gain insight into RUNX1-mediated gene 
regulation, I determined RUNX1 genomic occupancy by performing RUNX1 ChIP-
seq analysis in MCF10A cells. I observed that loss of RUNX1 significantly alters 
the gene expression pattern and many aspects of cellular activities. ChIP-seq 
analysis reveals that RUNX1 binding is enriched at promoter regions and miRNA 
genes.  RUNX1 binds to a broad spectrum of up- and down-regulated genes, 
	 106	
suggesting that RUNX1 utilizes different mechanisms to regulate gene expression 
in normal mammary epithelial cells. I provided evidence that RUNX1 knockdown 
deregulates mitosis and induces genome instability in mammary epithelial cells.  
As a result, in this chapter, I provide additional insight into the underlying RUNX1 
regulatory mechanisms and the consequences of RUNX1 perturbation in 
mammary epithelial cells.  
 
3.2.  Materials and Methods: 
3.2.1 Generation of MCF10A stable cell lines and cell culture 
Human breast cancer cell lines MCF10A cells were purchased from ATCC. 
MCF10A cells were grown in DMEM: F12 (Hyclone: SH30271, Thermo Fisher 
Scientific, Waltham, MA, USA) with 5% (v/v) horse serum (Gibco: 16050, Thermo 
Fisher Scientific, Waltham, MA, USA) + 10 μg/ml human insulin (Sigma Aldrich, St. 
Louis, MO: I-1882) + 20 ng/ml recombinant hEGF (Peprotech, Rocky Hill, NJ, USA: 
AF-100-15) + 100 ng/ml cholera toxin (Sigma Aldrich: C-8052) + 0.5 μg/ml 
hydrocortisone (Sigma Aldrich: H-0888) 50 IU/ml penicillin/50 μg/ml streptomycin 
and 2 mM glutamine (Life Technologies, Carlsbad, CA, USA: 15140-122 and 
25030-081, respectively).  
Lentivirus generation and infection have been previous described in (Hong, 
Messier et al. 2017). Lentivirus-based RNAi transfer plasmids with pGIPZ shRunx1 
(clone V2LHS_150257 and V3LHS_367631, GE Dharmacon), pGIPZ EV control 
(Cat No. RHS4351, GE Dharmacon) and pGIPZ non-silencing (Cat No. RHS4346, 
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GE Dharmacon) were purchased from Thermo Scientific. To generate lentivirus 
vectors, 293T cells in 10 cm culture dishes were co-transfected with 10 μg of 
pGIPZ shRunx1 or pGIPZ non-silencing, with 5 μg of psPAX2, and 5 μg of pMD2.G 
using lipofectamine 2000 reagent (Life Technologies). Viruses were harvested 
every 48 hr post-transfection. After filtration through a 0.45 μm-pore-size filter, 
viruses were concentrated by using LentiX concentrator (Clontech, Mountain View, 
CA, USA). For shRNA-mediated knockdown of RUNX1 expression, MCF10A cells 
were plated in six-well plates (1×105 cells per well) and infected 24 hr later with 
lentivirus expressing shRunx1 or nonspecific shRNA. Briefly, cells were treated 
with 0.5 ml of lentivirus and 1.5 ml complete fresh DMEM-F12 per well with a final 
concentration of 4 μg/ml polybrene. Plates were centrifuged upon addition of the 
virus at 1460 × g at 37°C for 30 min. Infection efficiency was monitored by GFP 
co-expression at 2 days post infection. Cells were selected with 2μg/ml puromycin 
(Sigma Aldrich P7255-100MG) for at least two additional days. After removal of 
non-viable cells, the remaining attached cells were passed and analyzed. 
3.2.2 RNA-seq and analysis 
RNA was isolated using DirectZol RNA mini prep kit (Zymo Research), quantified 
by Qubit HS RNA assay (Thermo Fisher Scientific) and assayed for RNA integrity 
by Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Total RNA was 
depleted of ribosomal RNA, reverse transcribed and strand-specific adapters 
added following manufacturer's protocol (TruSeq Stranded Total RNA Library Prep 
kit with Ribo-Zero Gold, Illumina, San Diego, CA, USA) with the exception that the 
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final cDNA libraries were amplified using the Real-time Library Amplification Kit 
(Kapa Biosystems, Wilmington, MA, USA) to prevent over-amplification of libraries. 
Generated cDNA libraries were assayed for quality then sequenced as single-end 
100 bp reads (IlluminaHiSeq1000, UVM Advanced Genome Technologies Core). 
Sequence files (fastq) were mapped to the most recent human genome (hg38) 
assembly using TopHat2. Expression counts were determined by HTSeq with 
recent gene annotations (Gencode v22). Differential expression was analyzed by 
DESeq2. Correlation between replicates and differential gene expression between 
time points was assessed by principal component analysis (PCA). In addition, 
mRNA expression data was uploaded to IPA (www.ingenuity.com) and analyzed 
using default parameters. 
3.2.3 ChIP-seq and analysis 
ChIP-seq was performed as previously described (O’Geen, Frietze et al. 2010). 
We performed independent replicates for MCF10A using 10ul of antibody against 
RUNX1 (Cell Signaling Technologies, 4334BF, 1ug/ul) and 150ug of chromatin for 
each sample. Adapters were cut (cutadapt v1.11) and low-quality reads trimmed 
(Galaxy FASTQ Quality Trimmer 1.0.0; window 10, step 1, minimum quality 20). 
Reads were mapped to the human genome (hg38 canonical) using STAR version 
2.4 (Dobin, Davis et al. 2013) with splicing disabled (–alignIntronMax 1) (Dobin, 
Davis et al. 2013). Enriched regions (narrowPeak calls) for each replicate were 
generated using MACS2 (Feng, Liu et al. 2012)  and replicates were then 
evaluated using deepTools (Ramírez, Ryan et al. 2016) to correlate alignments 
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and IDR (Li, Brown et al. 2011) to evaluate peak call reproducibility. After pooling 
replicates, MACS2 (Zhang, Liu et al. 2008) was used to call narrowPeak at high 
stringency (P-value <10e-5), these peaks were further filtered according to IDR 
cutoffs.  FE wiggle tracks were generated using MACS2’s bdgcmp and UCSC’s 
bedGraphToBigwig utility. HOMER motif analysis was used to determine motifs 
within 200bp of the peak summits. ChIPBETA (Binding and Expression Target 
Analysis) was used to predict targets that are activated or repressed by RUNX1 
(Wang, Sun et al. 2013). Gene expression heatmap was generated by web-based 
tool Morpheus (https://software.broadinstitute.org/morpheus/). Venn diagrams 
were generated by BioVenn (Hulsen, de Vlieg et al. 2008).   
3.2.4 Western blotting  
Cells were lysed in RIPA buffer and 5X SDS sample buffer supplemented with 
cOmplete, EDTA-free protease inhibitors (Roche Diagnostics) and MG132 (EMD 
Millipore San Diego, CA, USA). Lysates were fractionated in an 8.5% acrylamide 
gel and subjected to immunoblotting. The gels are transferred to PVDF 
membranes (EMD Millipore) using a wet transfer apparatus (Bio-Rad Laboratories, 
Hercules, CA, USA). Membranes were blocked using 5% Blotting Grade Blocker 
Non-Fat Dry Milk (Bio-Rad Laboratories) and incubated overnight at 4°C with the 
following primary antibodies: a rabbit polyclonal RUNX1 (Cell Signaling 
Technology, Danvers, MA, USA:#4334, 1:1000); a mouse monoclonal to E-
cadherin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA: sc21791, 1:1000); 
a mouse monoclonal CDK1 (Santa-Cruz Biotechnology sc-54, 1:1000); a mouse 
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monoclonal to β-Actin (Cell Signaling Technology #3700, 1:1000), a rabbit 
polyclonal Tyr15-p-CDK1(Abcam: 47594, 1:1000); a rabbit polyclonal Cyclin 
B1(Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA: sc752, 1:1000); a rabbit 
polyclonal Cyclin A (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA: H432, 
1:1000); a mouse monoclonal Cyclin E (BD Bioscience, 554183 1:1000), a rabbit 
polyclonal Bub1 (Cell Signaling Technology, Danvers, MA, USA:#4116s, 1:1000); ), 
a rabbit polyclonal Wee1 (Cell Signaling Technology, Danvers, MA, USA:#4936S, 
1:1000); a rabbit polyclonal Cdc25B  (Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA, USA: SC326, 1:1000); a rabbit polyclonal Cdc25C (Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA, USA: SC327, 1:1000);. Secondary antibodies conjugated to 
HRP (Santa Cruz Biotechnology) were used for immunodetection, along with the 
Clarity Western ECL Substrate (Bio-Rad Laboratories) on a Chemidoc XRS+ 
imaging system (Bio-Rad Laboratories). 
3.2.5 Immunofluorescence staining microscopy 
Cells were fixed with using 3.7% formaldehyde in phosphate buffered saline (PBS) 
for 10 min. Cells were then permeabilized in 0.1% Triton X-100 in PBS, and 
washed in 0.5% Bovine Serum Albumin in PBS. Detection was performed using a 
mouse monoclonal gH2AX antibody (Millipore JBW301). Staining was performed 
using fluorescent secondary antibodies; for rabbit polyclonal antibodies a goat anti-
rabbit IgG (H+L) secondary antibody, Alexa Fluor® 594 conjugate (Life 
Technologies A-11062), was used for 1:5000 dilution and 1 hour at 37 °C. Cell 
were also stained with DAPI (Sigma-Aldrich: D9542-10MG) for DNA content. 
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3.2.6 Flow cytometry analysis 
Cells analyzed by flow cytometry were fixed for 10 minutes in ice cold 70% ethanol 
for 30 mins before being stained for 30 minutes with an antibody against H3S28P 
(Alexa fluor 647-conjugated, BD Biosciences, 558609). Cells were then 
suspended in 2% FBS in PBS and stained with Propidium iodide (PI) (BD 
Pharminge 550825) for 15 minutes to determine DNA content. Flow cytometric 
analysis was performed using the LSRII instrument (BD Biosciences). FlowJo 
(Ashland, OR, http://www.flowjo.com/) version 10 was used to display DNA 
histograms and to determine the percent of cells positive for H3S28P, a marker of 
mitosis,  within the cycling cell populations. 
 
3.3 Results: 
3.3.1. RUNX1 knockdown in normal-like mammary epithelial cells results in 
aberrant gene regulation  
To investigate the role of RUNX1 in normal mammary epithelial cells, we used 
previously described normal-like mammary epithelial MCF10A cells stably 
expressing either control (non-silencing shRNA control (NS), empty vector control 
(EV)), or two different shRNAs against RUNX1 (shRunx1-1 and shRunx1-2) (Hong, 
Messier et al. 2017). I confirmed the down-regulation of RUNX1 at the protein level 
by Western blot analysis (Fig 3.1A), and then performed RNA-seq analysis using 
above cell lines and validated the quality of the RNA-seq results by principal 
component analysis (Figure 3.1B).  Two of the control cell lines (NS and EV) form 
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a cluster, which is more similar to the parental MCF10A cells than the cluster 
formed by two RUNX1 knockdown cell lines (shRunx1-1 and shRunx1-2).  
Heatmap of gene expression shows the results of three replicates within each 
condition. (Figure 3.1C) The reproducibility suggests the quality of these RNA-seq 
libraries will enable identification of genes differentially expressed upon RUNX1 
depletion.  
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 Notably, from the initial assessment of RNA-seq data, we found several 
mesenchymal markers including N-cadherin (CDH2), Fibronectin 1 (FN1) and 
Matrix metallopeptidase 13 (MMP13) significantly up- regulated upon depletion of 
RUNX1 (Figure 3.2). These findings are consistent with our previous reports that 
loss of RUNX1 initiates EMT in MCF10A cells (Chapter II). We next delineated the 
differentially expressed genes between the two control cell lines (NS, EV) and two 
shRunx1 (shRunx1-1, shRunx1-2) in MCF10A cells. Differentially expressed 
genes were defined as those with at least a 2-fold change within all 4 groups (EV 
vs shRunx1-1; EV vs shRunx1-2; NS vs shRunx1-1; NS vs shRunx1-2) (Fig. 3.3A, 
B). Overall, we identified 1209 up- and 660 down- regulated genes upon RUNX1 
depletion in MCF10A cells (Fig. 3.3A, B).   
     
Figure 3.1 RNA-seq in RUNX1 depleted MCF10A cells. (A) Western 
blot analyses of lysates from MCF10A cells treated with shRunx1 show 
decreased protein expression of RUNX1. The experiment is performed 3 
times (N=3). (B) Sample-to-sample distances. Heatmap showing the 
Euclidean distances between the samples as calculated from the 
regularized log transformation. (C) Heatmap showing the transcripts per 
million (TPM) expression values of the differentially expressed gene 
replicates. Samples were calculated from the regularized log 
transformation. 
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Figure 3.2 The expression of mesenchymal genes is increased in 
RUNX1 depleted MCF10A cells.  RNA-seq analysis of MCF10A cells 
treated with shRunx1 shows increased gene expression of CDH2, FN1 
and MMP13. Student's t test * p value <0.05, ** p value <0.01, *** p value 
<0.001, **** p value <0.0001 for MCF10A shRunx1 cells compared to the 
MCF10A NS cells. Error bars represent the standard error of the mean 
(SEM) for the three biological samples. 
 
	 116	
 
Figure 3.3   Defining differentially expressed genes in RUNX1 
knockdown in MCF10A cells showing in Venn diagram. (A) Left: 
Genes that are upregulated (> 2-fold; p<0.05) in shRunx1-1 and 
shRunx1-2 cells compared to EV control.  Middle: Venn diagram showing 
genes that are upregulated (> 2-fold; p<0.05) in shRunx1-1 and 
shRunx1-2 cells compared to NS control. Right: upregulated genes 
identified between EV control and NS control. (B) Left: Genes that are 
downregulated (> 2-fold; p<0.05) in shRunx1-1 and shRunx1-2 cells 
compared to EV control.  Middle: Venn diagram showing genes that are 
downregulated (> 2-fold; p<0.05) in shRunx1-1 and shRunx1-2 cells 
compared to NS control. Right: downregulated genes identified between 
EV control and NS control.  
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    To elucidate the cellular consequence of RUNX1 depletion in MCF10A cells, we 
performed Ingenuity Pathway Analysis (IPA) to identify pathways altered upon 
RUNX1 loss (Fig. 3.4). Several pathways involved in growth factor signaling-such 
as FGF signaling, HGF signaling and PDGF signaling-are activated upon the loss 
of RUNX1, suggesting RUNX1 is necessary for normal cell growth in MCF10A cells 
(Fig. 3.4A).  Activation of other pathways-such as NF-kB signaling, Lymphotoxin b 
Receptor signaling and FcgRIIB signaling in B-lymphocytes, implies that RUNX1 
is involved in cellular inflammation and immune response. It has been 
demonstrated that downregulation of RUNX1 activates the NF-kB pathway in both 
myeloid tumor and gastric cancer cells (Nakagawa, Shimabe et al. 2011, Wu, 
Zhang et al. 2017). The top up-regulated pathways in this analysis suggest the 
involvement of RUNX1 of inflammation in mammary tissue. We also found that 
multiple pathways linked to cell cycle regulation, including cyclins and Cell Cycle 
Regulation, Cell Cycle Regulation by BTG (B-cell translocation gene 2) and Mitotic 
Roles of Polo-like Kinase, are decreased in RUNX1-depleted cells (Fig. 3.4B). 
Moreover, many pathways related to breast cancer progression, for instance 
Hereditary Breast Cancer Signaling, Her-2 Signaling in Breast Cancer, and Breast 
Cancer Regulation by Stathmin1, are drastically altered upon loss of RUNX1, 
providing evidence that RUNX1 is involved in breast cancer biology (Fig 3.4C). 
Taken together, these results suggest that RUNX1 acts as a master 
transcriptional regulator in mammary epithelial cells, controlling the expression of 
nearly 1,900 genes. Loss of RUNX1 disturbs many aspects of cellular activities, 
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including cell cycle and cell growth, response to inflammation and immune stress 
and breast cancer progression.  
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3.3.2. RUNX1 ChIP-seq analysis identifies enriched binding at promoters     
To determine whether the differences in gene expression in RUNX1 depleted cells 
are directly related to RUNX1 binding, we performed RUNX1 ChIP-Seq in the 
parental MCF10A cells and identified 11969 reproducible peaks of RUNX1 binding.  
Next, we investigated the distribution of RUNX1 binding sites across eight different 
categories of genomic elements including promoter, exon, intron, intergenic, 
5’UTR, 3’UTR, TSS and pseudo gene regions by mapping RUNX1 sites to the 
annotated genes.  The annotation of these RUNX1 binding sites revealed that 
majority of the RUNX1 bindings are within intergenic regions (46%) and introns 
Figure 3.4 IPA canonical pathway analyses from each tier of core 
analysis. (A) Pathways upregulated in response toRUNX1 knockdown 
in MCF10A cells.  (B) Down-regulated pathways in RUNX1 knockdown 
in MCF10A cells.  (C) Top pathways based on p values, which are highly 
altered upon RUNX1 depletion in MCF10A cells.  The X axis represents 
negative log p values based on the probability that molecules in the 
uploaded dataset were included in the predefined IPA canonical 
pathways by true association as opposed to inclusion of molecules based 
on chance alone. Only the top 15 pathways in each category with the 
largest negative log p values are shown.   
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(42%), and only 8% of the peaks are located within promoter regions (Fig 3.5 A).  
However, after normalizing the peaks based on the frequency of those elements 
in the genome, we observed that RUNX1 peaks are specifically enriched in 
promoter and 5’UTR regions of protein coding genes, as well as miRNA genes (Fig 
3.5 B, C).  The binding of RUNX1 within promoters and 5’UTRs is consistent with 
the role of RUNX1 as a transcription factor, which validate further the quality of our 
ChIP-seq analysis. Notably, we also observed significant binding of RUNX1 to 
miRNA genes suggesting that RUNX1 is involved in miRNA biogenesis in 
mammary epithelial cells.  
    We next performed de novo motif analysis on these RUNX1 ChIP-seq peaks 
(Fig. 3.5D). The most significantly enriched motif was the RUNX1 motif itself (Fig. 
3.5D), validating the quality of the RUNX1-ChIP-seq data. Moreover, we identified 
additional binding motifs close to the RUNX1 binding site including AP1, TEAD4 
and STAT5 which are known to form transcription complexes with RUNX1 (Fig. 
3.5D) (Ogawa, Satake et al. 2008, Pencovich, Jaschek et al. 2011, Li, Wang et al. 
2016, Obier, Cauchy et al. 2016).  Additional several functional motifs that were 
not previously associated with RUNX1, such as ZFP410, BCL6B, NFIA and 
TFAP2B, are also present in the analysis suggesting that they might be part of 
RUNX1-mediated gene regulation (Fig. 3.5D).  Overall, our motif analysis indicates 
a complex regulatory network for RUNX1 that includes interactions with other 
transcription factors.   
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Figure 3.5 RUNX1 ChIP-seq in parental MCF10A cells. (A) Pie chart 
showing the distribution of RUNX1 ChIP-seq peak annotation.  (B). The 
enrichment of RUNX1 ChIP-seq peak annotation. (C) Normalized 
RUNX1 ChIP-seq signal intensity plot for all human UCSC genes ± 2 kb. 
(D) HOMER de novo motif analysis of the RUNX1 peaks. The motifs are 
ordered by significance from top to bottom. 
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3.3.3.  RUNX1 binds to up- or down-regulated genes  
Next, we asked whether RUNX1 binding was associated with differentially 
expressed genes. To address this question, we analyzed the RUNX1 peak 
frequency at the differentially expressed genes; although we determined that 
approximately 90% of the differentially expressed genes harbor RUNX1 binding 
within 100 kb of their TSS, only 20% of these genes have RUNX1 binding at their 
promoters (0-1kb to TSS) (Fig. 3.6A). These data indicate RUNX1 employs 
multiple mechanisms to regulate gene expression, either directly binding to the 
promoter region or binding to the distal regulatory loci. We further analyzed RUNX1 
regulatory mechanism by using ChIP-Binding and Expression Target Analysis 
(ChIP-BETA analysis), which predicts whether RUNX1 has activating or repressive 
function. ChIP-BETA analysis showed that down-regulated genes are directly 
associated with RUNX1 depletion (Fig. 3.6B). These data suggest that the primary 
function of RUNX1 is to activate gene expression and RUNX1 represses gene 
expression mainly in an indirect manner.  
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  Motif analysis on differentially expressed genes also illustrates distinctive motif 
patterns among up- and down-regulated genes, even though RUNX1 binding is 
detected in a similar percent of targets (Fig. 3.6C, D).  For down-regulated genes, 
Figure 3.6 RUNX1 regulates up- and down- regulated genes in a 
different pattern.  (A) Bar graph showing RUNX1 peak binding within 
± 100 kb of transcriptional start site (TSS), or > 100 kb of the gene bodies 
of up- and down-regulated genes or non-differentially expressed genes.   
(B) ChIP-BETA activating/repressive function prediction of the RNA-seq 
and RUNX1 ChIP-seq data set identified from the RUNX1 knockdown 
compared with NS control. The red and the purple lines represent 
upregulated and downregulated genes, respectively. The dashed line 
indicates the non-differentially expressed genes as background. Genes 
are cumulated by rank on the basis of their regulatory potential score 
from high to low. P-values represent significance comparing up- or down-
regulated group distributions with the non-differentially expressed group 
by the Kolmogorov-Smirnov test. (C) HOMER de novo motif analysis of 
the RUNX1 peaks in down-regulated genes. The peaks are ordered by 
significance from top to bottom. (D) HOMER de novo motif analysis of 
the RUNX1 peaks in up-regulated genes. The peaks are ordered by 
significance from top to bottom. 
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the top motif is Runx itself, suggesting direct binding (Fig. 3.6C).  However, for up-
regulated genes, the Runx motif is not the most significant motif; these results 
suggest RUNX1 represses genes in an indirect manner (Fig. 3.6D). Moreover, 
besides the Runx motif, no other motif is shared between up- and down-regulated 
genes, indicating that RUNX1 may utilize distinct mechanisms to activate or 
repress gene expression (Fig. 3.6C, D). We also performed the motif analysis at 
the promoter regions of the genes, which expression are not changed upon loss 
of RUNX1.  The results showed that Runx motif is still the most significant motif at 
the promoter (Fig. 3.7). This specific binding suggests RUNX1 has the potential to 
regulate those genes in other cellular contexts.  
 Overall, the RUNX1 binding pattern and motif analysis are consistent with the 
engagement of RUNX1 in both transcriptional activation and repression. 
Furthermore, it is the first time showing that RUNX1 may utilize different 
mechanisms to control target gene activation and repression. 
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Figure 3.7 HOMER de novo motif analysis of the RUNX1 peaks in 
un-differentially expresses genes. The peaks are ordered by 
significance from top to bottom.  
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3.3.4. Loss of RUNX1 affects cell cycle-related genes  
From pathway analysis, we discovered that many pathways related to cell cycle 
regulation were altered upon loss of RUNX1 (Fig.3.4). Therefore, we hypothesized 
that loss of RUNX1 dysregulates the expression of cell cycle genes and thus 
influences the overall cell cycle.  To test this hypothesis, we first generated an 
expression heatmap for the cell cycle related genes using normalized counts from 
the RNA-seq data (Fig 3.8A).  From the heatmap, we observed that there are no 
consistent patterns associated with G1 phase-related genes or G2 phase-related 
genes (Fig 3.8A).  However, the expression of genes linked to S phase and DNA 
replication is severely down-regulated upon loss of RUNX1 (Fig 3.8A). Decreased 
expression of S phase genes is consistent with previous reports that RUNX1 is 
necessary for acceleration of the G1/S transition and that RUNX1 promotes 
proliferation in mesenchymal stem cells (Bernardin-Fried, Kummalue et al. 2004, 
Kim, Barron et al. 2014).  We also observed that genes related to mitosis, such as 
Cyclin B1 and Cyclin-dependent kinase 1 (CDK1), are down-regulated in RUNX1 
knockdown cells (Fig 3.8A).  The key event that initiates mitotic entry is the 
activation of the Cyclin B1-CDK1 complex by increasing Cyclin B1 expression and 
of inactivate p-CDK1(Thr14/Tyr15) by dephosphorylation (Malumbres and 
Barbacid 2009).  To validate the RNA-seq data, we performed western blot 
analysis on proliferating cells to determine the protein levels of these cell cycle 
genes and the phosphorylation state of CDK1 in RUNX1 knockdown MCF10A cells 
(Fig 3.8B).  We observed that the level of Cyclin A is increased while Cyclin E 
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remains unchanged upon loss of RUNX1. Consistent with RNA-seq data, the level 
of Cyclin B1 is decreased with RUNX1 knockdown.  Although total CDK1 protein 
level does not decrease as dramatically as was observed in the RNA-seq data, the 
level of phospho-CDK1 (Tyr 15), which is the inactive form of CDK1, accumulates 
in RUNX1-depleted cells (Fig 3.8B).   With the lower level of Cyclin B and the 
increased level of pTyr15-CDK1, we hypothesized that RUNX1 is necessary for 
G2/M transition and mitotic entry in MCF10A cells.  However, cell cycle profiling 
showed that RUNX1 knockdown has no significant impact on overall cell cycle (Fig. 
3.8C upper and middle). We observed only very mild and not significant increase 
in the G2 population in two shRunx1 cell lines compared with NS control cells (Fig. 
3.8C bottom).  
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3.3.5. Loss of RUNX1 decreases the proportion of mitotic cells.  
Although we did not observe a significant change in overall cell cycle in RUNX1-
depleted MCF10A cells, we explored the explanation for the decreased level of 
Cyclin B1 and the accumulation of Tyr15-p-CDK1.  Therefore, we tested whether 
loss of RUNX1 specifically affects mitosis and performed flow cytometry analysis 
on the MCF10A cells labeled with the mitotic-specific marker H3S28P. We 
observed an over 40% decrease in the mitotic population, suggesting RUNX1 is 
required for mitosis (Fig.3.9A).  
Figure 3.8 RUNX1 alters the expression of cell cycle genes.  (A) Heat map 
of relative expression from RNA-seq data of cell cycle-related genes in 
MCF10A control (EV, NS) and shRunx1 (shRunx1-1, shRunx1-2) cells.   (B) 
Western blot analyses of whole cell lysates from MCF10A cells with RUNX1 
depletion show decreased protein expression of RUNX1 and alteration of 
protein expression of cell cycle related genes. Tyr15 pCDK1: Phospho-CDk1 
(Tyr15). The experiment is performed 3 times (N=3). (C) Top: Histogram plots 
of cell cycle profiles of control and RUNX1-depleted MCF10A cells were 
obtained by FACS analysis of propidium iodide (PI)-stained cells.  Middle: The 
cell cycle distribution plotted as a bar chart. Columns, mean; Error bars, SEM, 
from three independent experiments.   Bottom:  Percentage of cells in G2 
phase were plotted. Student's t test * p value <0.05.  
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 Interestingly, from RNA-seq data, the RNA levels of several components of the 
mitotic checkpoint complex (MCC), including Bub1, Bub1b and MAD2L1, are 
significantly decreased upon loss of RUNX1 (Fig 3.9B, C, Fig 3.10A).  Moreover, 
ChIP-seq data also reveal that RUNX1 binds to their promoters, indicating a direct 
regulation by RUNX1(Fig 3.9D, Fig 3.10B). Previously it has been reported that in 
leukemia cells, a RUNX1 mutant abrogates mitotic checkpoints by targeting the 
MCC component MAD2L1 (Krapf, Kaindl et al. 2010).  Here, we show that the 
native form of RUNX1 is a direct activator of several MCC components, including 
BuB1, BuB1b and MAD2L1, highlighting the importance of RUNX1 during mitosis. 
Further exploration will be required to elucidate the precise function of RUNX1 
during mitosis.  
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Figure 3.9 Loss of RUNX1 reduces the mitotic population.  (A) 
Representative flow cytometric analysis of control and RUNX1 depleted 
MCF10A cells with H3S28P versus DNA content (PI staining). The 
percentage of mitotic cells is indicated above the rectangles. The cells 
below the rectangles are the non-mitotic cells. Right: Bar graph of mitotic 
population in each condition. Error bars represent the standard error of 
the mean (SEM) from three biological samples. Student's t test * p value 
<0.05. (B) Western blot analyses of whole cell lysates from MCF10A cells 
with RUNX1 depletion show decreased protein expression of Bub1. The 
experiment is performed 3 times (N=3). (C) RNA-seq analyses from 
MCF10A cells treated with shRunx1 show increased gene expression of 
Bub1. Error bars represent the standard error of the mean (SEM) from 
three biological samples. Student's t test **** p value <0.0001. (D) ChIP-
seq genome browser view of RUNX1 binding near the transcription start 
site (TSS) of Bub1 gene.  
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Figure 3.10 RUNX1 is a direct regulator of Bub1b, MAD2L1 and APC. 
(A) RNA-seq analyses from MCF10A cells treated with shRunx1 show 
decreased gene expression of Bub1b and MAD2L1, and increased gene 
expression of APC. Student's t test ** p value <0.01, *** p value <0.001, 
for MCF10A shRunx1 cells compared to the MCF10A NS cells. Error 
bars represent the standard error of the mean (SEM) from three 
biological samples.  (B) ChIP-seq genome browser views of RUNX1 
binding at the transcription start site (TSS) of Bub1b, MAD2L1 and APC 
gene.  
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3.3.6.  Loss of RUNX1 decreases genomic stability  
It has been demonstrated that loss of Bub1 and the mitotic checkpoint complex is 
associated with genome instability (Baker, Jin et al. 2009).  Upon loss of RUNX1, 
we observed activation of genes that sense DNA damage, such as ATM and 
Rad50, and the decreased expression of DNA repair-related genes, such as 
PARP1 and members of Fanconi anemia proteins (Fig. 3.11A). Therefore, we 
hypothesized that loss of RUNX1 induces genome instability in MCF10A cells.  To 
test this hypothesis, we stained the cells with the DNA damage marker gH2AX, 
and observed no differences between RUNX1-depleted cells and control cells (Fig. 
3.11B left).  However, when comparing the DNA damage response after treating 
cells for 4 hrs with 5µg/ml bleomycin, which induces double-strand breaks, RUNX1 
knockdown cells displayed a pronounced delay of DNA repair after 24 hrs of 
induced DNA damage (Fig. 3.11B middle and right).  
    Therefore, the alteration of the genes associated with DNA damage (Fig. 3.11A) 
and repair and the delay of the DNA repair process (Fig.3.11B) demonstrate that 
RUNX1 knockdown cells exhibit the feature of genomic instability. We propose that 
the enhanced propensity of RUNX1 depleted cells to acquire chromosomal 
abnormalities may increase the potential of developing a cancer phenotype. These 
findings indicate that loss of RUNX1 is accompanied with genome instability, which 
is consistent its role to preserve the normal phenotype in mammary epithelial cells.  
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3.4. Discussion:  
The transcription factor RUNX1 is well known for its function in hematopoiesis and 
its involvement in leukemogenesis (de Bruijn and Dzierzak 2017, Sood, Kamikubo 
et al. 2017). In the past few years, using deep-sequencing technology, RUNX1 has 
been identified as one of the frequently mutated genes in breast cancer patients 
along with other well-studied tumor suppressors such as P53, PTEN and RB1 
(Banerji, Cibulskis et al. 2012, Ellis, Ding et al. 2012, Network 2012, Ciriello, Gatza 
et al. 2015). Although multiple lines of evidence support the concept that impaired 
RUNX1 function in normal mammary epithelial cells promotes breast cancer 
initiation and progression, the mechanism(s) of RUNX1-mediated gene expression 
Figure 3.11 Loss of RUNX1 slows DNA repair. (A) RNA-seq analyses 
of RNA from MCF10A cells with shRunx1 show increased gene 
expression of DNA damage sensing genes such as ATM and Rad50, and 
decreased gene expression of DNA repair genes such as FANCA and 
PARP1. Student's t test ** p value <0.01, *** p value <0.001, **** p value 
<0.0001 for MCF10A shRunx1 cells compared to the MCF10A NS cells. 
Error bars represent the standard error of the mean (SEM) from three 
biological samples.  (B) Representative images of γH2AX foci in 
untreated cells, the cells treated for 4hr with 5µg/ml bleomycin, and the 
cells stained 24h after bleomycin treatment.  Blue: DAPI staining; Red: 
γH2AX. All the experiments are performed 2 times (N=2). 
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in this cell lineage remain(s) unknown. In this chapter, we delineated the molecular 
consequences of RUNX1 loss in MCF10A cells and examined RUNX1 cellular 
functions. We also examined how loss of RUNX1 contributes to the onset and 
progression of breast cancer.    
    We investigated RUNX1-mediated genome-wide transcriptional regulation in 
normal-like mammary epithelial MCF10A cells. Loss of RUNX1 expression in 
MCF10A cells alters the expression of approximately 2,000 genes and the pathway 
analysis on these differentially expressed genes revealed that RUNX1 is involved 
in multiple aspects of cellular activities. For instance, RUNX1 is involved in cell 
proliferation by activating cell cycle-related pathways. RUNX1 is also involved in 
cellular stress response by repressing several pathways related to immune or 
inflammation response.  Combining RUNX1 ChIP-seq data in MCF10A cells and 
RNA-seq data in RUNX1 depleted cells, we observed that RUNX1 employs 
multiple mechanisms to regulation its target genes. We further demonstrated that 
loss of RUNX1 alters mitosis in mammary epithelial cells. Depleting RUNX1 
resulted in a reduced mitotic cell population and decreased expression of several 
components of the mitotic checkpoint complex. Moreover, loss of RUNX1 
increased genome instability as DNA repair is slowed in RUNX1-depleted cells. 
Overall, our results highlight the importance of RUNX1 in mammary epithelial cells.  
Loss of RUNX1 alters the expression of many genes and various aspects of 
cellular function and thus affect normal cell growth and may lead to genome 
instability.  
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     Previously, it has been well documented that RUNX1 regulates its target gene 
expression by binding to a well-defined Runx consensus sequence located within 
promoter or enhancer elements (Meyers, Downing et al. 1993, Otto, Lübbert et al. 
2003).  Now, additional lines of evidence suggest that RUNX1 regulates gene 
expression in a more complex manner, which encompasses multiple regulatory 
layers involving interaction with other co-factors or transcription factors, distal 
regulatory elements and epigenetic factors (Elagib, Racke et al. 2003, Reed-
Inderbitzin, Moreno-Miralles et al. 2006, Huang, Yu et al. 2009, Bowers, Calero-
Nieto et al. 2010, Phillips, Taberlay et al. 2017). For instance, in leukemia cells, 
RUNX1 regulates the expression of two integrins in different manners (Phillips, 
Taberlay et al. 2017). It regulates ITGA6 gene by directly binding to the consensus 
motif in its promoter (Phillips, Taberlay et al. 2017).  In contrast, RUNX1 regulates 
ITGB4 gene expression in a more complex manner, as it activates the ITGB4 
promoter without binding to the RUNX1 consensus motif (Phillips, Taberlay et al. 
2017).  Therefore, RUNX1 can utilize different mechanisms to regulate gene 
expression. Consistently, from our RUNX1 binding site analysis using ChIP-seq, 
we observed that RUNX1 might employ different mechanisms for up or down-
regulated genes. ChIP-BETA analysis revealed that the primary function of RUNX1 
is to directly activate gene expression. The exact mechanism(s) explaining 
RUNX1-mediated fine-tuning of transcription control remains to be determined. We 
propose that RUNX1, based on cellular content, either directly binds to target gene 
promoters to support competency for transcription regulation or RUNX1 scaffolds 
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with the other co-activator(s)/repressor(s) at distal loci.  Further studies will be 
critical to elucidate these roles and specify the altered protein-protein interactions 
that affect RUNX1 function in different cellular contexts.   
    From RUNX1-ChIP-seq results, we observed that RUNX1 binding is enriched 
at miRNA and other non-coding RNA genes in MCF10A cells (Fig. 3.5 B). RUNX1 
is well known as a hub of miRNA biogenesis in both normal hematopoiesis and in 
leukemic cells (Rossetti and Sacchi 2013). RUNX1 expression is not only 
controlled by hematopoietic transcription factors such as GATA2, ETS and RUNX1 
itself (Nottingham, Jarratt et al. 2007, Pimanda, Donaldson et al. 2007), but also 
by an increasing number of miRNAs (Rossetti and Sacchi 2013).  Using 
bioinformatics tools such as TargetScan, more than 60 conserved miRNAs with 
potential binding to the RUNX1 3’UTR have been predicted (Rossetti and Sacchi 
2013). Many of them, such as miR-17, miR-20a and miR-27, have been validated 
experimentally (Fontana, Pelosi et al. 2007, Ben-Ami, Pencovich et al. 2009). 
RUNX1 also controls miRNA gene expression by binding to the Runx consensus 
sequences in miRNA regulatory regions. From RUNX1-ChIP-seq data in 
hematopoietic cells, RUNX1 physically binds over 200 miRNA genes including the 
above-mentioned miR-17 and miR-27 (Ptasinska, Assi et al. 2012, Wu, Seay et al. 
2012).  In fact, the feed-back regulatory loops between RUNX1 and miRNAs are 
essential for hematopoietic differentiation and proliferation (Mi, Li et al. 2010).  The 
enrichment of RUNX1 on miRNA genes in MCF10A cells suggests that RUNX1 
may also regulate the expression of miRNAs in mammary epithelial and breast 
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cancer cells. Currently, in those mammary lineages, studies have only focused on 
identifying the miRNAs targeting RUNX1 stability, such as miR-378 and miR-144 
(Vivacqua, De Marco et al. 2015, Browne, Dragon et al. 2016). Therefore, further 
exploration of the overlap between miRNA expression arrays in RUNX1-depleted 
cells and RUNX1 ChIP-seq data from this chapter will be useful in identifying 
miRNAs regulated by RUNX1.   
For a long time, RUNX1 was postulated to control cell cycle because of its 
function in regulating cell proliferation. Studies have demonstrated that RUNX1 
contains three serine residues (S48, S303, and S424) that match the cyclin-
dependent kinase (CDK) consensus on target proteins (Biggs, Peterson et al. 
2006). Multiple CDKs such as CDK1, CDK4 and CDK6 phosphorylate RUNX1 both 
in vitro and in vivo (Biggs, Peterson et al. 2006). This phosphorylation is necessary 
for RUNX1 degradation during mitosis by the Anaphase-promoting complex (APC) 
(Biggs, Peterson et al. 2006). Later on, it was shown that RUNX1 accelerates the 
G1/S transition in hematopoietic cells and knockdown of RUNX1 reduces S phase 
cells (Bernardin-Fried, Kummalue et al. 2004, Kim, Barron et al. 2014).  Therefore, 
it is not surprising that S-phase and DNA replication-related genes are down-
regulated upon RUNX1 depletion in MCF10A cells (Fig.3.8A). However, the 
involvement of RUNX1 in mitosis is not well known. Very recently, Nyam-Osor 
Chimge et al. showed that in MCF7 breast cancer cells, loss of RUNX1 represses 
Cyclin B1 expression and accumulates cells in G2 phase, indicating a G2/M arrest 
(Chimge, Little et al. 2016). In this chapter, by labeling the cells with the mitotic 
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specific marker, H3S28P, we detected that the mitotic cell population is reduced 
by RUNX1 knockdown in MCF10A cells. This raises the compelling question of the 
mechanism(s) of mitotic reduction in RUNX1 depleted cells. Additionally, what 
triggers the degradation of Cyclin B1 and the accumulation of p-CDK1(Thr14, 
Tyr15) in RUNX1 depleted MCF10A cells (Fig.3.8B)?  During the cell cycle, CDK1 
is phosphorylated and inactivated by Wee1 and MYT1 at Thr-14 and Tyr-15, and 
the phosphoryl group in phosphorylated-CDK1 is removed by the Cdc25 
phosphatases (Pines 1999, Malumbres and Barbacid 2009).  From RNA-seq data, 
we did observe that two members of CDC25 family, CDC25B and CDC25C, are 
significantly down-regulated upon RUNX1 depletion, while Wee1 and MYT1 
expression are not changed (Fig. 3.12).  Moreover, RUNX1 directly binds to the 
transcription start site of Wee1, CDC25B and CDC25C. These data suggest that 
RUNX1 is a direct positive regulator of CDC25B and CDC25C, and without RUNX1, 
the inactive form of p-CDK1 may not be efficiently activated by CDC25B and 
CDC25C, and thus block the cell from entering mitosis. However, our western blot 
analyses on MCF10A cells are not consistent with our RNA-seq data, which shows 
a decreased level of CDC25B but increased expression of CDC25C. It is unclear 
whether the decreased CDC25B is sufficient to keep CDK1 in its inactive form.  
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Another possibility for RUNX1-mediated progression through mitosis is by 
improper regulation of mitosis related genes. In Figure 3.9 and Figure 3.10, we 
showed that RUNX1 is a positive regulator of Bub1, Bub1b and MAD2L1, which 
are components of the mitotic checkpoint complex (Lara-Gonzalez, Westhorpe et 
al. 2012). When RUNX1 is depleted, expression levels of members of the mitotic 
checkpoint complex are severely inhibited (Fig. 3.9-3.10).  It also has been shown 
that the mitotic checkpoint complex is an inhibitor of the anaphase-promoting 
Figure 3.12 RUNX1 is a direct regulator of Bub1b, MAD2L1 and APC. 
(A) RNA-seq analyses of RNA from MCF10A cells treated with shRunx1 
show only slightly altered gene expression of Wee1 and MYT1, and 
decreased gene expression of CDC25B and CDC25C. Student's t test ** 
p value <0.01, *** p value <0.001, for MCF10A shRunx1 cells compared 
to the MCF10A NS cells. Error bars represent the standard error of the 
mean (SEM) from three biological samples.  (B) ChIP-seq genome 
browser views of RUNX1 binding at the transcription start site (TSS) of 
Wee1, CDC25B and CDC25C but not MYT1. (C) Western blot analyses 
of whole cell lysates from MCF10A cells with RUNX1 depletion show 
protein expression of Wee1, CDC25B and CDC25C. The experiments 
are performed 3 times (N=3). 
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complex (APC) (Lischetti and Nilsson 2015). APC is a multi-subunit E3 ubiquitin 
ligase, which is inactive prior to entry into mitosis (Lischetti and Nilsson 2015). 
During mitosis, APC is activated through interaction with Cdh1(FZR1), and 
facilitates mitotic exit by ubiquitinating and degrading cell-cycle regulators such as 
cyclin B1 and Securin (Lischetti and Nilsson 2015, Zhou, He et al. 2016). 
Interestingly, RUNX1 is also a target of APC and is degraded during mitosis (Biggs, 
Peterson et al. 2006). The activity of APC is subject to multiple layers of regulation 
throughout the cell cycle (Lischetti and Nilsson 2015).  Our data show that RUNX1 
is a direct negative regulator of APC, as RUNX1 binds to the APC promoter region 
and loss of RUNX1 activates the expression of APC (Fig. 3.10A, B). Therefore, it 
is possible that RUNX1 is an essential repressor of APC, and a feedback 
regulatory mechanism between RUNX1 and APC is necessary for keeping APC 
activity specifically in mitosis. During normal cell cycle, RUNX1 negatively 
regulates APC expression before entering mitosis.  In mitosis, RUNX1 is degraded 
by APC, which further activates APC expression to promote Cyclin B1 degradation 
and mitotic exit (Fig. 3.13).  When RUNX1 expression is disrupted, APC is 
aberrantly activated and leads to constitutive degradation of Cyclin B1 in the cell 
cycle and thus blocks cells from entering mitosis (Fig. 3.13).  
Alternatively, the decreased mitotic population in RUNX1 depleted cells may be 
due to premature mitotic exit.  Depleted or mutated components in the mitotic 
checkpoint complex, such as Bub1, have been shown to lead to inappropriate 
chromosome segregation and premature mitotic exit which leads to aneuploidy 
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and genome instability (Goto, Mishra et al. 2011).  It is possible that loss of RUNX1 
will increase the incidence of spindle checkpoint defects and premature mitotic exit, 
resulting in a reduced population of mitotic cells.   
Despite the inconclusive mechanism(s) on how RUNX1 is involved in cell cycle, 
especially in mitosis, in this chapter we demonstrated that RUNX1 is a major 
transcription factor which regulates expression of key genes and is involved in 
various aspects of cellular activity. Further experiments based on our RUNX1 
ChIP-seq and RNA-seq data from RUNX1 depleted cells will aide in elucidating 
the function of RUNX1 in mammary epithelial cells.  These future investigations 
will provide an improved understanding of how dysregulated RUNX1 leads to 
breast cancer initiation and progression.  
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Figure 3.13 Possible mechanisms of RUNX1-controlled mitotic 
entry.  
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Chapter IV RUNX1 suppresses breast cancer stemness and tumor growth   
 
 
A large portion of this chapter comes from the manuscript: 
Runx1 exhibits anti-tumor activity and inhibits stemness in breast cancer 
cells 
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4.1 Abstract:  
 Breast cancer remains the most common malignant disease in women worldwide. 
Despite advances in detection and therapies, studies are still needed for further 
understanding mechanisms underlying this cancer. Cancer stem cells (CSC) play 
an important role in tumor formation, growth, drug-resistance and recurrence. Here, 
we demonstrate for the first time that the transcription factor RUNX1, well known 
as essential for hematopoietic differentiation, represses the breast cancer stem 
cell (BCSC) phenotype and suppresses tumor growth in vivo. The present studies 
show that BCSCs sorted from pre-malignant breast cancer cells exhibit decreased 
RUNX1 levels, while overexpression of RUNX1 suppresses tumorsphere 
formation and reduces the BCSC population. RUNX1 ectopic expression in breast 
cancer cell lines reduces migration, invasion and in vivo tumor growth (57%) in 
mouse mammary fat pad. Mechanistically, RUNX1 functions to suppress breast 
cancer tumor growth through repression of cancer stem cell activity and direct 
inhibition of Zeb1 expression. Consistent with these cellular and biochemical 
results are the clinical findings that the highest RUNX1 levels occur in normal 
mammary epithelial cells in patient specimens and that low RUNX1 expression in 
tumor is associated with poor patient survival. Our key finding that RUNX1 
represses stemness in several breast cancer cell lines points to the importance of 
RUNX1 in other solid tumors and suggests RUNX1 may regulate cancer stem cells. 
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4.2 Introduction: 
Breast tumors are heterogeneous, as they are comprised of several types of 
cells, including transformed cancer cells, supportive cells, tumor-infiltrating cells 
and cancer stem cells (CSC). The CSC is acknowledged to be a significant 
component of growing tumors (Ming, Michael et al. 2015, Chaffer, San Juan et 
al. 2016). As the name implies, CSC can self-renew and reconstitute the cellular 
hierarchy within tumors (Visvader and Lindeman 2008, Meacham and Morrison 
2013). Moreover, these stem-like cells are highly chemo-resistant and 
metastatic (Abdullah and Chow 2013, Zhao 2016). Significantly, signaling 
pathways (TGF-β, WNT, Hedgehog and Notch) and transcription factors (Snail, 
Twist and Zeb) regulating stemness properties in CSC are involved in controlling 
an essential cellular process designated epithelial-mesenchymal transition (EMT) 
(Scheel and Weinberg 2012, Hadjimichael, Chanoumidou et al. 2015). The EMT 
process is linked to chemo-resistance and cancer metastasis (Singh and 
Settleman 2010, Pattabiraman and Weinberg 2014, Shibue and Weinberg 2017). 
One such example is Zeb1, a well-known EMT-activator that is also a key factor 
for cell plasticity and promotes stemness properties in breast and pancreatic 
cancers (Lehmann, Mossmann et al. 2016, Krebs, Mitschke et al. 2017). However 
there remains a compelling requirement to understand regulatory mechanisms 
that contribute to and sustain the stemness of the CSC population. Identifying 
regulator(s) that maintain or repress the cancer stem cell phenotype can provide 
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insights for novel therapeutic approaches. Recently, a list of 40 mutation-driver 
genes for which deregulation contributes directly to breast tumor progression 
has been identified (Pereira, Chin et al. 2016); among these is the transcription 
factor RUNX1, which has been shown to repress EMT. Here we address for the 
first time, the function of RUNX1 in regulating breast cancer stem cells.  
    The Runx family, including RUNX1, Runx2 and Runx3, are evolutionarily 
conserved transcription factors and function as critical lineage determinants of 
various tissues (Ito, Bae et al. 2015).  During normal development, it is well 
documented that RUNX1 plays a fundamental role in controlling the stem cell 
population in hematopoietic (Yokomizo, Ogawa et al. 2001, Jacob, Osato et al. 
2010, Wang, Krishnan et al. 2014), hair follicle (Hoi, Lee et al. 2010, Osorio, Lilja 
et al. 2011), gastric (Matsuo, Kimura et al. 2017) and oral epithelial stem cells 
(Scheitz, Lee et al. 2012). As a master transcriptional regulator, RUNX1 is a 
central player in fine-tuning the balance among cell differentiation, proliferation, 
and cell cycle control in stem cells during normal development (Wang, Jacob et 
al. 2010). In the mammary gland, it has recently been shown that RUNX1 is 
involved in luminal development (Sokol, Sanduja et al. 2015). These studies also 
showed that loss of RUNX1 in mammary epithelial cells blocked differentiation 
into ductal and lobular tissues. These findings suggest that RUNX1 is an 
essential regulator of normal mammary stem cells (Sokol, Sanduja et al. 
2015).  In addition to its essential function during normal development, disrupting 
	 151	
RUNX1 function(s) can cause cancer (Ito 2004, Ito, Bae et al. 2015).  RUNX1 is 
a frequent target of translocations and other mutations in hematopoietic 
malignancies.  For example, RUNX1 related chromosomal translocations 
including RUNX1-ETO (Hatlen, Wang et al. 2012), TEL-RUNX1 (Fischer, 
Schwieger et al. 2005) and RUNX1-EVI (Mitani, Ogawa et al. 1994) are 
associated with distinct leukemia subtypes.  
In breast cancer, RUNX1 has been shown to regulate the WNT pathway and 
key transcription factors including ERa and ELF5 (Ito, Bae et al. 2015)(van Bragt, 
Hu et al. 2014)(Chimge, Little et al. 2016)(Barutcu, Hong et al. 2016). Recent 
studies from our group have demonstrated that RUNX1 maintains the epithelial 
phenotype and represses EMT (Hong, Messier et al. 2017). RUNX1 expression 
is decreased during breast cell EMT, and loss of RUNX1 expression in normal-
like epithelial cells (MCF10A) and epithelial-like breast cancer cells (MCF7) 
initiates the EMT process. Complementary studies demonstrated that ectopic 
expression of RUNX1 reverts cells to the epithelial state. However, mechanisms 
underlying RUNX1 regulation of cancer stem cell properties and the 
consequences for tumor growth in vivo remain to be resolved.  
Based on evidence that RUNX1 regulates stem cell properties during normal 
development and that loss of RUNX1 activates partial EMT in breast cancer, we 
hypothesized that RUNX1 represses the cancer stem cell population and/or 
stemness properties in breast cancer. We investigated whether altering RUNX1 
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levels by overexpression and knockdown in breast cancer cells changes the 
stemness phenotype, aggressive properties and tumor progression in vivo.  Our 
findings have identified for the first time a significant function for RUNX1 in 
repressing the cancer stem cell population as well as tumorsphere formation, and 
demonstrated that RUNX1 represses breast cancer tumor growth in vivo.    
 
4.3 Materials and Methods 
4.3.1 Cell culture: 
MCF10AT1 and MCF10A cells were grown in DMEM: F12 (Hyclone: SH30271, 
Thermo Fisher Scientific, Waltham, MA) with 5% (v/v) horse serum (Gibco: 16050, 
Thermo Fisher Scientific, Waltham, MA, USA) + 10 μg/ml human insulin (Sigma 
Aldrich, St. Louis, MO: I-1882) + 20 ng/ml recombinant hEGF (Peprotech, Rocky 
Hill, NJ, USA: AF-100-15) + 100 ng/ml cholera toxin (Sigma Aldrich: C-8052) + 0.5 
μg/ml hydrocortisone (Sigma Aldrich: H-0888) 50 IU/ml penicillin/50 μg/ml 
streptomycin and 2 mM glutamine (Life Technologies, Carlsbad, CA, USA: 15140-
122 and 25030-081, respectively). MCF10CA1a cells were grown in DMEM: F with 
12, 5% (v/v) horse serum with 50 IU/ml penicillin/50 μg/ml streptomycin and 2 mM 
glutamine. MCF7 cells were maintained in Dulbecco modified Eagle medium 
(DMEM) high glucose (Fisher Scientific: Thermo Fisher Scientific, Waltham, MA, 
USA: MT-10-017-CM) supplemented with 10% (v/v) FBS (Atlanta Biologicals, 
Flowery Branch, GA, USA: S11550), 50 IU/ml penicillin/50 μg/ml streptomycin. 
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4.3.2 Lentiviral plasmid preparation and viral vector production 
RUNX1 cDNA was cloned into Lentivirus-based overexpression plasmids pLenti-
CMV-Blast-DEST (Addgene). To generate lentivirus vectors, 293T cells in 10 cm 
culture dishes were co-transfected with 10 μg of pGIPZ shRunx1 or pGIPZ non-
silencing, with 5 μg of psPAX2, and 5 μg of pMD2.G using lipofectamine 2000 
reagent (Life Technologies). Viruses were harvested every 48 h post-transfection. 
After filtration through a 0.45 μm-pore-size filter, viruses were concentrated by 
using LentiX concentrator (Clontech, Mountain View, CA, USA).  
4.3.3 Gene delivery by transfection and infection 
 For overexpression RUNX1, MCF10AT1 or MCF10CA1a cells were plated in 
six-well plates (1x105 cells per well) and infected 24 h later with lentivirus 
expressing RUNX1 overexpression or Empty Vector. Briefly, cells were treated 
with 0.5 ml of lentivirus and 1.5 ml complete fresh DMEM-F12 per well with a final 
concentration of 4 μg/ml polybrene. Plates were centrifuged upon addition of the 
virus at 1460 × g at 37°C for 30 min. Infection efficiency was monitored by GFP 
co-expression at 2 days post infection. Cells were selected with 2 μg/ml puromycin 
(Sigma Aldrich P7255-100MG) for at least two additional days. After removal of 
the floating cells, the remaining attached cells were passed and analyzed. 
ShRunx1 virus were generated and delivered as has been described previously 
(Hong, Messier et al. 2017). 
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4.3.4 Western blotting 
 Cells were lysed in RIPA buffer and 2X SDS sample buffer supplemented with 
cOmplete, EDTA-free protease inhibitors (Roche Diagnostics) and MG132 (EMD 
Millipore San Diego, CA, USA). Lysates were fractionated in an 8.5% acrylamide 
gel and subjected to immunoblotting. The gels are transferred to PVDF 
membranes (EMD Millipore) using a wet transfer apparatus (Bio-Rad Laboratories, 
Hercules, CA, USA). Membranes were blocked using 5% Blotting Grade Blocker 
Non-Fat Dry Milk (Bio-Rad Laboratories) and incubated overnight at 4°C with the 
following primary antibodies: a rabbit polyclonal RUNX1 (Cell Signaling 
Technology, Danvers, MA, USA: #4334, 1:1000); a mouse monoclonal to E-
cadherin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA: sc21791, 1:1000); 
a mouse monoclonal Vimentin (Santa-Cruz Biotechnology sc-6260, 1:1000); a 
mouse monoclonal to β-Actin (Cell Signaling Technology #3700, 1:1000); a rabbit 
polyclonal Twist1 (Santa Cruz Biotechnology sc-15393, 1:2000); a rabbit 
polyclonal Zeb1 (Sigma-Aldrich HPA027524-100UL, 1:1000). Secondary 
antibodies conjugated to HRP (Santa Cruz Biotechnology) were used for 
immunodetection, along with the Clarity Western ECL Substrate (Bio-Rad 
Laboratories) on a Chemidoc XRS+ imaging system (Bio-Rad Laboratories). 
4.3.5 Tumorsphere formation assay: 
Monolayer cells were enzymatically dissociated into single cells with 0.05% 
trypsin-EDTA. Cells were plated at 10,000 cells per well in a 24-well low-
attachment plate (Corning). Cells were grown for 7 days in DMEM/F12 
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supplemented with B27 (Invitrogen) in the presence of 10 ng/ml EGF and 10 ng/ml 
bFGF. Where indicated, the CDK4 inhibitor palbocilib (Sigma) was added at a final 
concentration of 100 nM. Tumorsphere-forming efficiency was calculated as the 
number of spheres divided by the number of singles cells seeded, expressed as a 
percentage. 
4.3.6 CD24/CD44 flow cytometry 
Flow cytometry for CD24 (PE-cy7, Biolegend 311120) and CD44 (APC, BD 
Pharmigen 559942) was performed using the best conditions for marker detection 
as previously described (Fillmore and Kuperwasser 2008)(Quan 2013). Cells were 
grown to sub-confluency and dissociated with Accutase. The Accutase was quickly 
neutralized with serum and 1x106 cells were washed with 1xPBS. These cells were 
then re-suspended in 475ul of 1%FBS/ 1xPBS, to which 25ul of CD44-APC and 
4ul of CD24-PE-cy7 were added and incubated at room temperature for 30 
minutes. Cells were then washed with PBS and strained (Falcon 352235) to obtain 
single cell suspensions. Isotype controls were used to gate for negative signal in 
each replicate of the experiment. 
4.3.7 Migration assays 
    For the scratch assays, cells were seeded in triplicate and when they reached 
95–100% confluence, were serum starved with 0.1% FBS-containing media for 12 
h. Subsequently, a scratch was made across the cell layer using a P-200 pipette 
tip, and cell migration was monitored by recording images at indicated time points 
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post-scratch. The area of the scratch was quantified using the MiToBo plug-in for 
ImageJ software and plotted as a percentage of total area.  
    For the transwell migration assay, cells were trypsinized and re-seeded in 
triplicate in migration chambers (BD Bioscience, Bedford, MA) in serum-free 
medium for 24 hours (MCF10AT1 cells) or 48 hours (MCF10CA1a cells) after cell 
seeding. Cells were allowed to migrate through 8 μm pores toward medium 
containing 5% Horse Serum. The experiment was performed and results quantified 
as previously described (Browne, Taipaleenmäki et al. 2015). 
4.3.8 Invasion Assay 
    For the invasion assay, cells were trypsinized and reseeded in triplicate in 
growth factor-reduced Matrigel invasion chambers (BD Bioscience, Bedford, MA) 
in serum-free medium for 24 hours (MCF10AT1 cells) or 48 hours (MCF10CA1a 
cells) after cell seeding.  Cells were allowed to migrate through 8 μm pores toward 
medium containing 5% Horse Serum. The experiment was performed and results 
quantified as previously described (Browne, Taipaleenmäki et al. 2015). 
4.3.9 Immunofluorescence staining microscopy 
 Cells grown on coverslips were fixed with using 3.7% formaldehyde in Phosphate 
Buffered Saline (PBS) for 10 min. Cells were then permeabilized in 0.1% Triton X-100 in 
PBS, and washed in 0.5% Bovine Serum Albumin in PBS. Detection was performed using 
a rabbit polyclonal RUNX1 antibody (Cell Signaling #4336), a mouse monoclonal CD24 
(Santa-Cruz sc-11406). Staining was performed using fluorescent secondary antibodies; 
for rabbit polyclonal antibodies a goat anti-rabbit IgG (H+L) secondary antibody, Alexa 
Fluor® 568 conjugate (Life Technologies A-11011), was used and for mouse monoclonal 
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a F(ab')2-goat anti-mouse IgG (H+L) secondary antibody, Alexa Fluor® 488 conjugate 
was used (Life Technologies A-11001). 
4.3.10 Animal studies 
Female SCID mice 7 weeks of age were used for mammary fat pad injection.  The 
mice were randomly divided into two groups (seven for each group). In all, 1X106 
MCF10CA1a cells suspended in 0.1 ml of saline were mixed with 0.1 ml of Matrigel 
(BD) and were injected under mammary fat pads. Bioluminescence images were 
acquired by using the IVIS Imaging System (Xenogen) 5 min after injection 150 
mg/kg of D-Luciferin (Gold BioTech, St. Louis, MO) in PBS.  All animals were 
housed in a pathogen-free environment and handled according to protocol number 
12-051 approved by the Institutional Animal Care and Use Committee at the 
University of Vermont. In conducting using animals, the investigators adhere to the 
laws of the United States and regulations of the Department of Agriculture. 
4.3.11 Analysis of RUNX1 expression and patient survival using public data 
sets 
The PROGgene database (www.compbio.iupui.edu/proggene) (Goswami and 
Nakshatri 2013) (Goswami and Nakshatri 2014) was used to identify the data sets 
for survival analysis and re-analyzed the public GEO data sets 
(www.ncbi.nlm.nih.gov/gds) (GSE37751 (Terunuma, Putluri et al. 2014), GSE7390 
(Desmedt, Piette et al. 2007), TCGA (Network 2012)). RUNX1 expression in 
different breast cancer stages was analyzed using the TCGA database 
(www.cbioportal.org). 
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4.3.12 Quantitative PCR 
 RNA was isolated with Trizol (Life Technologies) and cleaned by DNase 
digestion (Zymo Research, Irvine, CA, USA). RNA was reversed transcribed using 
SuperScript II and random hexamers (Life Technologies). cDNA was then 
subjected to quantitative PCR using SYBR Green technology (Applied Biosystems, 
Foster City, CA, USA).   
RUNX1 Forward: AACCCTCAGCCTCAGAGTCA,  
RUNX1 Reverse: CAATGGATCCCAGGTATTGG;  
FN1 Forward: CATGAAGGGGGTCAGTCCTA;  
FN1 Reverse: CTTCTCAGCTATGGGCTTGC;  
VEGF Forward: CCTTGCTGCTCTACCTCCAC;  
VEGF Reverse: CCATGAACTTCACCACTTCG;  
CXCR4 Forward: TACACCGAGGAAATGGGCTCA;  
CXCR4 Reverse: TTCTTCACGGAAACAGGGTTC;  
CXCL12 Forward: GTGGTCGTGCTGGTCCTC;  
CXCL12 Reverse: AGATGCTTGACGTTGGCTCT;  
MMP13 Forward: ATGAGCCAGAGTGTCGGTTC;  
MMP13 Reverse: GTTAGTAGCGACGAGCAGGAC;  
MMP9 Forward: ATAGACTACTACAGGCT;  
MMP9 Reverse: TAGCACGGATAGACCA;  
GAPDH Forward: TGTGGTCATGAGTCCTTCCA,  
GAPDH Reverse: ATGTTCGTCATGGGTGTGAA;  
HPRT Forward: TGCTGACCTGCTGGATTACA,  
HPRT Reverse: TCCCCTGTTGACTGGTCATT;  
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β-Actin Forward: AGCACAGAGCCTCGCCTTT,  
β-Actin Reverse: CGGCGATATCATCATCCAT. 
4.3.13 ChIP-qPCR 
    ChIP-qPCR was performed essentially as described (O’Geen, Frietze et al. 
2010). Briefly, 200,000 MCF10AT1 or MCF10CA1a cells were cross-linked, lysed 
and sonicated to obtain DNA fragments mostly in the 200-1000-bp range. 
Immunoprecipitation was performed at 4°C overnight with anti-RUNX1 antibody 
(4334, Cell Signaling Technology) at a 1:15 antibody to chromatin ratio.  Primers 
used in ChIP-qPCR are listed below:   
Zeb1 Forward: GTCGTAAAGCCGGGAGTGTC,  
Zeb1 Reverse: GCCATCCGCCATGATCCTC;  
ZNF333 (negative control 1) Forward: TGAAGACACATCTGCGAACC,  
ZNF333 Reverse: TCGCGCACTCATACAGTTTC;  
ZNF180 (negative control 2) Forward: TGATGCACAATAAGTCGAGCA,  
ZNF180 Reverse: TGCAGTCAATGTGGGAAGTC. 
4.3.14 Tissue microarray 
Tissue microarray data of RUNX1 in breast cancer patients were obtained from 
Human Protein Atlas (www.proteinatlas.org) (Uhlén, Fagerberg et al. 2015). 
4.3.15 Statistical analysis 
Each experiment was repeated at least three times. The differences in mean 
values among groups were evaluated and expressed as the mean ± SEM. A P-
value less than 0.05 was considered statistically significant (*P < 0.05, **P < 0.01, 
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***P < 0.001). Student's t-test was used to compare the expressions of cell surface 
markers, side population analysis, cell viability, relative mRNA levels, migrated 
cells and invaded cells.  
 
4.4 Results: 
4.4.1. Reduced RUNX1 expression is associated with decreased survival 
probability in breast cancer patients. 
    To investigate possible association between RUNX1 expression and breast 
cancer progression, we first examined RUNX1 expression in normal and breast 
cancer patients using the Human Protein Atlas. Within normal breast tissues, 
RUNX1 is highly expressed in the mammary gland (Fig. 4.1A).  However, in ductal 
carcinoma tissues, the level of RUNX1 is decreased in malignant regions (red 
circle) compared with normal glandular tissues (blue circle) in the same tumor 
specimen (Fig. 4.1B). In the majority of ductal carcinoma specimens (9 out 12 
samples) from the Human Protein Atlas, 75% of breast cancer tumors show low 
RUNX1 staining (Fig. 4.1C). We also analyzed TCGA data and found that RUNX1 
levels are progressively decreased across early stage breast cancer (Stage 1 vs 
Stage2; Stage 2 vs Stage 3) (Figure 4.2). These findings suggest that during breast 
cancer progression, the mammary gland loses its original structure and RUNX1 
levels are decreased. The data are consistent with our previous report that RUNX1 
is highly expressed in normal-like mammary epithelial MCF10A cells and reduced 
in a panel of breast cancer cell lines (Hong, Messier et al. 2017).  With the reduced 
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RUNX1 expression, mammary epithelial cells do not maintain their epithelial 
phenotype (Hong, Messier et al. 2017)  From these observations of low  RUNX1 
in  breast tumors and the concomitants loss of RUNX1 in  normal epithelial cells 
with loss of epithelial properties, we hypothesized that loss of RUNX1 is promoting 
a breast cancer phenotype. 
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    We therefore addressed whether there was a clinical relation of RUNX1 
expression in breast cancer patient tumors to survival. Using publically available 
mRNA expression datasets, we analyzed the correlation of mean expression levels 
of RUNX1 and survival rate in breast cancer patient tissue samples. Kaplan–Meier 
analysis of the expression of RUNX1 in three separate datasets of GSE37751- 
“Molecular Profiles of Human Breast Cancer and Their Association with Tumor 
Subtypes and Disease Prognosis” (36 high RUNX1 and 24 low RUNX1 patients), 
GSE7390-“Strong Time Dependence of the 76-Gene Prognostic Signature” (82 
high RUNX1 and 116 low RUNX1 patients) and TCGA data of breast cancer 
patients mRNAs (304 high RUNX1 and 290 low RUNX1 patients) indicated a 
statistically significant correlation (p < 0.01, p < 0.05, and p<0.01 respectively) 
Figure 4.1. Reduced RUNX1 expression is associated with 
decreased survival probability in breast cancer patients. 
(A) Representative tissue microarray images of RUNX1 in normal breast 
tissue. (B) and (C) Representative tissue microarray images of RUNX1 
in breast tumor tissues. (D) Kaplan-Meier analysis showed higher overall 
survival in patients with higher RUNX1 mRNA expression (GSE37751, 
GSE7390 and TCGA). Gehan-Breslow-Wilcoxon test with p value<0.01, 
p value<0.05, p value<0.01 respectively compared with high RUNX1 
expression patients and low RUNX1 expression patients in three data 
sets. 
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between high RUNX1 expression levels and longer patient survival time (Fig. 4.1D).  
These results suggested that reduction in RUNX1 expression is associated with 
low survival probability of breast cancer patients. Thus several in vitro studies 
combined with these clinical observations support a role for RUNX1 in repressing 
tumor growth.  
 
 
Figure 4.2.  RUNX1 mRNA is decreased during breast cancer 
progression.  TCGA data shows that RUNX1 mRNA is decreased in 
Stage 2 and Stage 3 tumors. 
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4.4.2. RUNX1 is decreased in tumors formed in mouse mammary fat pad 
To further establish if RUNX1 decreases during breast tumor growth in vivo, we 
utilized a mouse xenograft model to examine RUNX1 levels before and after tumor 
formation. MCF10CA1a cells, which are aggressive breast cancer cells, were 
injected into mammary fat pad of SCID mice and tumor growth was monitored 
weekly. Tumors formed within two weeks (Fig. 4.3A), and one month post-injection, 
mice were sacrificed and tumors were removed to analyze for RUNX1 and other 
factors at both protein and mRNA levels.  The parental MCF10CA1a cells had a 
3.3-fold higher RUNX1 protein level than the removed tumor (Fig. 4.3B, C). qRT-
PCR using human-specific primer sets confirmed that RUNX1 mRNA is also 
decreased specifically within the tumor (Fig. 4.3C). The epithelial marker E-
cadherin was decreased in tumor samples, while the mesenchymal marker 
Vimentin was increased (Fig. 4.3B). In addition to Vimentin, the mRNA levels of 
several human cancer-related genes such as VEGF, FN1, MMP13, MMP9, 
CXCR4, CXCL12 are also up regulated (Fig. 4.3B, D).  These findings indicate that 
the human breast cancer cells that formed a tumor in mouse mammary fat pads 
acquired a more aggressive phenotype and that RUNX1 expression is decreased 
during the period of tumor growth. Therefore, we have directly demonstrated that 
in this MCF10CA1a mouse xenograft model, RUNX1 expression is decreased 
during in vivo model of tumor progression.  
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Figure 4.3. RUNX1 is decreased in tumors formed in mouse 
mammary fat pad. (A) MCF10CA1a cells were injected into the 
mammary fat pad of SCID mice. Points represent mean tumor volume. 
(B) Western blot analyses show RUNX1 and E-cadherin levels are 
decreased and Vimentin level is increased in tumor samples compared 
to MCF10CA1a cells.  (C) Upper panel, Protein quantification show that 
RUNX1 is significant decreased in tumor samples compared to 
MCF10CA1a cells. Lower panel, RT-qPCR analyses of RNA from tumor 
samples show decreased RUNX1 expression of compared with 
MCF10CA1a cells. Student’s t test * p value <0.05, *** p value <0.001 
and. Error bars represent the standard error of the mean (SEM) from 
three independent experiments. (D) RT-qPCR analyses of RNA from 
tumor samples show activation of mesenchymal marks Vimentin and 
FN1 and other tumor growth related genes including MMP9, MMP13, 
VGF, CXCR4 and CXCL12 compared with MCF10CA1a cells. 
Student’s t test * p value <0.05, ** p value <0.01, *** p value <0.001 and 
**** p value <0.0001. Error bars represent the standard error of the mean 
(SEM) from three independent experiments. 
 
	 168	
4.4.3. RUNX1 reduces the aggressive phenotype of breast cancer cells in 
vitro. 
It has been suggested that RUNX1 reduces aggressive phenotypes in breast 
cancer (van Bragt, Hu et al. 2014, Chimge, Little et al. 2016, Hong, Messier et al. 
2017).  Based on these data and the results that RUNX1 level is decreased in the 
xenograft model (Fig. 4.3B), we further addressed whether ectopic expression of 
RUNX1 in malignant breast cancer cells reduces the aggressive phenotype. 
RUNX1 was overexpressed using a lentivirus delivery system (pLenti-CMV) in pre-
malignant MCF10AT1 and highly aggressive malignant MCF10Ca1a cells (Fig. 
4.4A). Upon overexpressing RUNX1, Vimentin expression is decreased in both cell 
lines (Fig. 4.4A). However, E-cadherin expression was not affected by RUNX1 
overexpression, suggesting that the cells have not fully transitioned back to 
normal-like stage.  
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Figure 4.4. RUNX1 reduces the aggressive phenotype of breast 
cancer cells in vitro. (A) Western blot analyses confirm RUNX1 
overexpression in MCF10CA1a (Upper) and MCF10AT1 (Lower) cells. 
Vimentin expression is repressed upon RUNX1 overexpression in both 
cell lines. (B) Representative phase contrast images (magnification 
100×) of MCF10AT1 and MCF10CA1a cells with EV control or RUNX1 
overexpression subjected to a scratch assay for times indicated. The 
area of the scratch was plotted as a percentage of total area for N = 3 
independent experiments carried out in duplicate. (C) Light microscopy 
images (mag. 12×) of stained cells from a representative (1 of N = 2) 
trans-well migration assay experiment MCF10AT1 and MCF10CA1a 
cells with EV control or RUNX1 overexpression (left); quantitation of 
migrated cells assessed by measurement of the absorbance of 
solubilized crystal violet stain retained by migrated cells (right). (D) Light 
microscopy images (mag. 12×) of stained cells from a representative (1 
of N = 2) trans-well matrigel invasion assay experiment with MCF10AT1 
and MCF10CA1a cells with EV control or RUNX1 overexpression to 
evaluate invasion (left); quantitation of invaded cells assessed by 
measurement of the absorbance of solubilized crystal violet stain 
retained by invaded cells (right). For all assays, three independent 
experiments were carried out in duplicates. All quantitative data are 
depicted as mean ± S.E. per group. *P < 0.05, **P < 0.01  
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Figure 4.5. RUNX1 overexpression does not change cell 
proliferation.  (A.) Growth curves for MCF10AT1 cells either express 
empty vector (black) or RUNx1 (blue). Line graph represents mean SEM 
from two experiments with a technical replicate each (N=4). No 
statistician difference was found (*, p<0.05). (B.) Growth curves for 
MCF10Ca1a cells either express empty vector (black) or RUNx1 (blue). 
Line graph represents mean SEM from two experiments with two 
technical replicates each (N=2). No statistician difference was found (*, 
p<0.05). 
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 Overexpressing RUNX1 in both MCF10AT1 and MCF10CCA1a cells does not 
change the proliferation (Fig.4.5 A, B). To evaluate the effect of RUNX1 in 
regulation of migration and invasion capacities of the breast cancer cells in vitro, 
we used the scratch migration and Transwell assays. Figure 4.4B shows 
representative images of the scratch assay, both at the time of the scratch and 
48 h (MCF10AT1) or 16 h (MCF10CA1a) later. RUNX1 overexpression decreases 
the ability of breast cancer cells to migrate. These results were confirmed using 
the trans-well migration assay (Fig. 4.4C). Invasion of both MCF10AT1 and 
MCF10CA1a cells was also significantly inhibited when RUNX1 was 
overexpressed (Fig. 4.4D).  We conclude from these studies that loss of RUNX1 
in MCF10A and cancer cells is detrimental in promoting EMT in vitro (Hong, 
Messier et al. 2017) and in  vivo (Fig 4.3B), while exogenous expression of RUNX1 
suppresses the migration and invasion of breast cancer cells in vitro.  
4.4.4. RUNX1 represses tumor growth in vivo 
Together our data above and the earlier studies demonstrate that RUNX1 has 
tumor suppresser activity in vitro. However, to date there are no studies showing 
that RUNX1 inhibits tumor growth in vivo.  We tested the ability of RUNX1 to alter 
tumor growth in vivo by using the metastatic MCF10CA1a breast cancer cells. 
MCF10CA1a/EV (control) and MCF10CA1a/ RUNX1- overexpression cells 
carrying a luciferase reporter (experiment) were injected into the mammary fat pad 
of SCID mice.  Eighteen days post-injection tumors appeared in the control mice, 
with an average volume of 63 mm3 (caliper measurement), while the experimental 
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group had barely palpable tumors (Fig. 4.6A). At the end point of this experiment 
(4 weeks), we sacrificed the mice, excised the tumors, and measured tumor 
volume and weight (Fig. 4.6B, C). Mice injected with MCF10CA1a/OE RUNX1 cells 
had a significantly reduced tumor size (57%) and weight (47%) compared with 
tumors from control mice. Figures 4.7A and 4.7B show the excised tumors and 
luminescence of tumors in all seven mice from each group.  MCF10CA1a cells 
with EV or OE RUNX1 were validated before injection into the SCID mice (Figure 
4.7C). Luminescent images of representative mice (Fig. 4.6D) confirm reduced 
tumor growth. Collectively, these data indicate that RUNX1 suppresses breast 
tumor growth in vivo. 
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Figure 4.6. RUNX1 represses tumor growth in vivo. (A) A total of 1 × 
106 MCF10CA1a cells with EV or RUNX1 overexpression were injected 
into mammary fat pad of SCID mice (n = 7 in each group). The points 
represent average tumor volume at each time point ± SD. P values were 
obtained by 2-tailed Student t test. *, P < 0.05; ***, P<0.001; ****, 
P<0.0001.  (B) Tumor size measured at day 28 (end point). P values 
were obtained by 2-tailed Student t test. *, P < 0.05. (C) Tumor weight at 
day 28 (end point). P values were obtained by 2-tailed Student t test. 
*, P < 0.05. (D) Representative luminescence images at 4 weeks after 
mammary fat pad injection.  
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Figure 4.7.  RUNX1 represses tumor growth in mammary fat pad. (A) 
Luminescence images at 4 weeks after mammary fat pad injection.  (B) 
Picture of excised tumors show that MCF10CA1a cells with RUNX1 
overexpression formed smaller tumors in mice mammary fat pad. (C) Western 
Blot for MCF10CA1a cells shows RUNX1 is overexpressed.  
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4.4.5.  RUNX1 level is decreased in breast cancer stem cells (BCSC). 
As breast cancer stem cells have been shown to be critical for tumor initiation and 
growth (Shibue and Weinberg 2017) and all of our data demonstrate a role for 
RUNX1 in decreasing tumorigenesis, we next investigated the potential role of 
RUNX1 in breast cancer stemness. We used fluorescence-activated cell sorting 
(FACS) to isolate BCSCs from pre-malignant MCF10AT1 cells based on 
expression of the cell-surface antigen markers CD44 and CD24. These two 
markers have been successfully used to identify putative CSCs in primary breast 
tumors or mammary cell lines (CD44high/CD24low).  We compared the BCSC cells 
with bulk cells (CD44high/CD24high) as gated in Figure 4.8. The 
CD44high/CD24low subpopulation from MCF10AT1 cells displayed lower levels of 
RUNX1 protein (33%) compared to the bulk cell population and the parental 
MCF10AT1 cells (Fig. 4.9A).  To examine whether CD24low cells have low RUNX1 
expression, we also performed immunofluorescence co-staining of RUNX1 and 
CD24 in MCF10AT1 cells. The cells with high CD24 expression also have high 
RUNX1 expression (Figure 4.10).  Moreover, the CD44high/CD24low population 
displays many CSC-like properties; they are endowed with higher expression of 
cancer stem cell markers Zeb1 and Twist1 (Fig. 4.9A) and greater long-term self-
renewal capacity as measured by tumorsphere formation assays (Fig. 4.9B). 
Collectively, these data provide evidence that cell populations with BCSC 
properties express lower levels of RUNX1 compared to the bulk and parental 
population, and suggest that RUNX1 influences BCSC properties. 
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Figure 4.8. Gate for MCF10AT1 sorting and MCF10CA1a cells have 
high BCSC population. A. Gating for BCSC and Bulk sub-population 
in MCF10AT1 cells. 
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Figure 4.9.  RUNX1 level is decreased in BCSC.  (A) Western blot 
analyses show RUNX1 is decreased and Zeb1, Twist1 and Vimentin 
level are increased in BCSC samples compared to Parental and Bulk 
MCF10AT1 cells.  Right, protein quantification shows that RUNX1 is 
significant decreased in BCSC. (B) Tumorsphere formation efficiency for 
BCSC populations is significantly higher than bulk population. **P < 0.01. 
(C) RUNX1 overexpression in MCF10CA1a cells reduces tumorsphere 
formation efficiency. *P < 0.05. Right, represent picture of tumorsphere. 
(D) RUNX1 overexpression in MCF10AT1 cells reduces tumorsphere 
formation efficiency. *P < 0.05 Right, represent picture of tumorsphere. 
(E) Western blot analyses of lysates from MCF10AT1 cells treated with 
shRunx1 show decreased protein expression of RUNX1 and E-cadherin 
and increased protein expression of Vimentin. (F) RUNX1 knockdown in 
MCF10AT1 cells activates tumorsphere formation efficiency. *P < 0.05. 
Right, represents picture of tumorsphere. All the experiments are 
performed 3 times (N=3). 
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Figure 4.10. CD24high Cells have high RUNX1 expression in 
MCF10AT1 cells. Immunostaining shows the cells with CD24 (Green) 
expression have high RUNX1 (Red) expression. All the experiments are 
performed 3 times (N=3). 
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4.4.6. RUNX1 inhibits stemness properties in breast cancer cells 
To further investigate the role of RUNX1 in regulating BCSC properties, we 
addressed the capability of RUNX1 to regulate tumorsphere formation from breast 
cancer cells. Tumorsphere formation assays were performed using non-adherent 
plates with non-serum medium. The ectopic expression of RUNX1 in both 
MCF10CA1a and MCF10AT1 cells significantly decreased the number of 
tumorsphere (p < 0.05) (Fig. 4.9C, D). To better understand if RUNX1 represses 
stemness properties in breast cancer, we used two lenti-viruses to establish 
RUNX1 knockdown cell lines in MCF10AT1 cells (Fig. 4.9E).  Depletion of RUNX1 
in these cell lines activated an epithelial to mesenchymal transition with lower E-
cadherin and higher Vimentin expression (Fig. 4.9E). Significantly, the knockdown 
of RUNX1 resulted in increased tumorsphere formation efficiency in MCF10AT1 
cells (51% and 41% respectively) (Fig. 4.9F).  This ability of RUNX1 to repress 
stemness properties was also observed in additional cell lines, including normal-
like MCF10A cells and ER positive luminal-like MCF7 cells (Figure 4.11A, B), 
which suggests that RUNX1 suppression of stemness is a universal phenotype in 
breast cancer cells.    
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Figure 4.11. Loss of RUNX1 promotes stemness in MCF10A and 
MCF7 cells. (A) RUNX1 knockdown in MCF10A cells activates 
tumorsphere formation efficiency. (B) RUNX1 knockdown in MCF107 
cells activates tumorsphere formation efficiency. All the experiments are 
performed 3 times (N=3). 
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Further evidence for the influence of RUNX1 on the cancer stem cell population 
in MCF10AT1 cells was provided by flow cytometry analysis. As shown in Figure 
4.12A, ectopic expression of RUNX1 reduced the CD44high/CD24low subpopulation 
of MCF10AT1 cells from 22.3% to 15.1% (Fig. 4.12A). Consistent with the 
consequence of RUNX1 overexpression, knockdown of RUNX1 significantly 
increased the CD44high/CD24low subpopulation of MCF10AT1 cells by more than 
two-fold (21.9% ns; 45.3% shR1-1; 45.6% shR1-2) (Fig. 4.12B). However ectopic 
expression of RUNX1 in MCF10CA1a cells did not change the percent of the 
CD44high/CD24low cancer stem cell population (Figure 4.13). The highly metastatic 
MCF10CA1a cells have a large percentage of cells (80%) that are 
CD44high/CD24low, indicating that the cells may have lost their plasticity and are 
locked into a mesenchymal phenotype (Figure 4.13). These results indicate that 
RUNX1 functions both to suppress cancer stem cell properties and reduce the 
breast cancer stem cell population.  
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Figure 4.12. RUNX1 reduces BCSC sub-population. (A) Flow 
cytometric analysis of CD44 and CD24 expression in MCF10AT1 cells 
with EV or RUNX1 overexpression. (B) Flow cytometric analysis of CD44 
and CD24 expression in MCF10AT1 cells stably expressing RUNX1 or 
non-silencing shRNAs. All the experiments are performed 3 times (N=3). 
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4.4.7. RUNX1 represses the expression of Zeb1 in breast cancer cells. 
In Figure 4.9A, we observed that decreased RUNX1 expression is coincident with 
activation of Zeb1 in BCSC in MCF10AT1 cells.  Zeb1 is well known for its function 
in promoting EMT, cancer stemness and metastasis in breast cancer (Zhang, Sun 
et al. 2015). Therefore, we tested whether RUNX1 functions by negatively 
regulating Zeb1 expression in breast cancer cells. Zeb1 protein is down regulated 
when RUNX1 is ectopically expressed in MCF10AT1 cells (Fig. 4.14A). This 
RUNX1-mediated Zeb1 repression was confirmed in MCF10AT1 RUNX1 
knockdown cells, where Zeb1 expression is enhanced (Fig. 4.14B). We did not 
Figure 4.13. Overexpression RUNX1 in MCF10CA1a cells does not 
change BCSC population. Flow cytometric analysis of CD44 and CD24 
expression in MCF10AT cells stably expressing non-silencing (Left) or 
RUNX1 (Right) shRNA. All the experiments are performed 3 times (N=3). 
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observe RUNX1 repression of Zeb1 expression in MCF10CA1a cells, which is a 
consequence of very low Zeb1 mRNA levels in MCF10CA1a cells compared to 
MCF10AT1 cells (Figure 4.15). To test whether RUNX1 can directly regulate Zeb1 
in MCF10CA1a cells, we performed ChIP-qPCR for RUNX1 in the Zeb1 promoter 
region in both MCF10AT1 and MCF10CA1a cells (Figure 4.16).  As shown in Fig. 
4.14C, RUNX1 directly binds to the Zeb1 promoter in the two breast cancer cell 
lines relative to two negative control genes ZNF333 and ZNF180.  Upon RUNX1 
overexpression, the binding of RUNX1 is enhanced on Zeb1 promoter, suggesting 
that RUNX1 has potential to directly regulate Zeb1 expression in both pre-
malignant and metastatic breast cancer cell lines.   
In summary, our findings suggest that RUNX1 reduces breast cancer aggressive 
phenotypes both in vivo and in vitro.  Both EMT and cancer stem cell properties 
are repressed by RUNX1 in breast cancer cells. We thus conclude RUNX1-
mediated repression could be through negative regulation of Zeb1 expression in 
breast cancer cells (Fig. 4.14D).  Zeb1 is well known for activating both EMT and 
cancer stem cells in breast cancer. (Zhang, Sun et al. 2015) Therefore RUNX1 
indirectly represses these two cellular processes. It has been shown that RUNX1 
can directly repress EMT in breast cancer (Hong, Messier et al. 2017).  It is 
possible that RUNX1 can directly repress cancer stem cell phenotype in a Zeb1-
independent manner (Fig. 4.14D). This study provides new insight into functional 
mechanisms of the RUNX1 transcriptional regulator in contributing to the stemness 
and the plasticity of breast cancer stem cells.  
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Figure 4.14. RUNX1 negatively regulates Zeb1 expression. (A) 
Western blot analyses show Zeb1 is decreased upon RUNX1 
overexpression in MCF10AT1 cells. (B) Western blot analyses show 
Zeb1 is activated upon RUNX1 knockdown in MCF10AT1 cells. (C) 
ChIP-qPCR confirmation of RUNX1 occupancy at Zeb1. RUNX1 binding 
is increased in RUNX1 overexpression samples. Data obtained with 
antibodies against RUNX1 are normalized to input control and ZNF188 
(NC1) and ZNF333 (NC2), which were used as the negative control as 
RUNX1 are predicted not to bind these genes.  (D) Mechanism on how 
RUNX1 represses tumor growth in breast cancer.  (EC- epithelial-like 
cells; MC-mesenchymal-like cells). All the experiments are performed 3 
times (N=3). 
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Figure 4.15. Zeb1 is expressed at low level in MCF10CA1a cells. 
Zeb1 RNA expression by RT-qPCR of normal mammary-like MCF10A 
cells, MCF10A-derived tumorigenic cell line MCF10AT1, and metastatic 
MCF10CA1a cells shows Zeb1 is expressed at a low level in 
MCF10CA1a cells. 
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4.5 Discussion for Chapter IV: 
We provide multiple lines of evidence that RUNX1 reduces breast cancer cells 
grown in mouse mammary fat pad and inhibits breast cancer stem cell phenotypes. 
RUNX1 levels are decreased in tumors grown in murine mammary fat pads. 
RUNX1 also reduces cell migration and invasion of breast cancer cells in vitro and 
tumor growth in vivo. Moreover, RUNX1 reduces the breast cancer stem cell 
population and tumorsphere formation efficiency, thus indicating that RUNX1 
represses stemness properties in breast cancer. RUNX1 overexpression and 
knockdown studies revealed that RUNX1 mediates the mechanisms of inhibition 
of breast cancer stemness and tumorigenesis through repression of Zeb1 
Figure 4.16. Schematic diagram of ChIP qPCR primers and 
amplicons over Zeb1 for ChIP-qPCR.   
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expression.  Taken together, our findings provide compelling evidence that the loss 
of RUNX1 induces increased cancer stem cells and that RUNX1 overexpression 
can suppress the CSC population, which is responsible for metastasis, treatment 
resistance and tumor recurrence in breast cancer. 
Breast cancer is ranked as the second leading cause of cancer death in 
women after lung cancer (Torre, Bray et al. 2015).  In 2017, approximately 
63,400 cases of female breast carcinoma in situ are expected to be diagnosed 
(Siegel, Miller et al. 2017). Despite the significant advances that have been 
achieved in early detection and treatment of breast cancer, understanding the 
mechanisms of breast cancer progression and metastasis still requires intensive 
study. Recently, using sophisticated next-generation sequencing technology, a 
40 mutation-driver gene list was generated in human breast cancer (Pereira, 
Chin et al. 2016). RUNX1, which is often mutated in breast tumors, is one of 
those genes.  Utilizing the TCGA clinical data sets, we found that reduced RUNX1 
levels in tumor correlate with poor survival of breast cancer patients.  Together 
these clinical findings suggest that RUNX1 may be a promising therapeutic 
biomarker for breast cancer screening and personalized medicine. 
An unresolved question is whether RUNX1 functions to promote or suppress 
tumor growth in breast cancer. Increasing evidence indicates that loss of RUNX1 
function accompanies progression of breast cancer (van Bragt, Hu et al. 2014, 
Chimge, Little et al. 2016, Hong, Messier et al. 2017), supporting the concept that 
RUNX1 suppresses tumor growth. Clinically, RUNX1 expression is decreased in 
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high histological grade tumors compared with low/mid-grade tumors (Kadota, 
Yang et al. 2010).  In the past few years, RUNX1 loss-of-function somatic 
mutations have been identified in several subtypes of breast cancer (Network 
2012)(Banerji, Cibulskis et al. 2012)(Ellis, Ding et al. 2012).  Mechanistically, loss 
of RUNX1 in ER+ breast cancer activates the WNT signaling pathway and ELF5 
expression (van Bragt, Hu et al. 2014)(Chimge, Little et al. 2016) suggesting that 
RUNX1 represses breast cancer progression.  Our previous study showed loss of 
RUNX1 promotes EMT in both normal and breast cancer cells indicating that 
RUNX1 has the potential to inhibit tumor growth (Hong, Messier et al. 2017).  In 
this study, we clearly demonstrated that the level of RUNX1 is decreased during 
tumor growth, and that ectopic RUNX1 expression suppresses tumor growth in the 
mouse mammary fat pad. Together these combined studies and our experiments 
establish that RUNX1 reduces aggressive phenotype in breast cancer.  However, 
we cannot rule out the possibility that RUNX1 may have other functions in breast 
cancer, especially in late stage disease.  For example, in the MMTV-PyMT mouse 
model, the level of RUNX1 is positively correlated with tumor progression (Browne, 
Taipaleenmäki et al. 2015) and regulates genes promoting tumor growth in late 
stage MDA-MB-231 breast cancer cells (Recouvreux, Grasso et al. 2016).  
However, in our study, we found that metastatic MCF10CA1a cells with RUNX1 
overexpression formed smaller tumors in mouse mammary fat pad indicating that 
RUNX1 functions to reduce tumor growth.  These contradictory results suggest 
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that RUNX1 has dual functions (pro- vs anti-tumor growth) in late stage breast 
cancer depending on cellular context.   
The anti-tumor growth activity of RUNX1 in breast cancer is likely through its 
properties in maintaining the normal mammary epithelial phenotype. For example, 
loss of RUNX1 causes the cells to lose their epithelial morphology and activates 
mesenchymal genes in normal-like MCF10A cells (Hong, Messier et al. 2017). 
Furthermore, depletion of RUNX1 in ER positive luminal MCF7 breast cancer cells 
transforms the cells into a partial EMT state (Hong, Messier et al. 2017). It has 
been suggested that partial activation of the EMT promotes plasticity that allows 
reprogramming of the epithelial cell to acquire both migratory and stem-like 
features (Grigore, Jolly et al. 2016).  
    We investigated whether RUNX1 might function by suppressing Zeb1, due to its 
well-known activity in increasing breast cancer stemness and as a marker of EMT. 
Our results show that RUNX1 directly binds to the Zeb1 promoter in both 
MCF10AT1 and MCF10CA1a cells and that binding is enhanced upon RUNX1 
overexpression. In MCF10AT1 cells, RUNX1 negatively regulates Zeb1 
expression at the protein level. Together these findings indicate that the binding of 
RUNX1 on the Zeb1 promoter and the suppression of Zeb1 by RUNX1 reduce 
breast cancer stemness in cells that retain plasticity. Consistent with this 
conclusion, overexpressing RUNX1 in MCF10CA1a cells does not change the 
expression of EMT markers to the same extent that it does in premalignant 
MCF10AT1 cells (Fig. 4.4A). These data and the fact that RUNX1 represses EMT 
	 194	
in normal-like MCF10A cells (Hong, Messier et al. 2017), highlight its critical 
function in repressing tumor initiation and growth in early stage breast cancer. Also 
of significance is that overexpression of RUNX1 in MCF10CA1a cells decreased 
tumor growth in vivo and tumorsphere formation efficiency in vitro, suggesting that 
RUNX1 can reduce aggressive phenotype in late stage breast cancer cells. 
In summary, our findings constitute strong experimental evidence that RUNX1 
functions to reduce aggressive phenotype of breast cancer cells. This study 
provides a novel dimension to understanding how the transcriptional regulator 
RUNX1 contributes to the stemness and the plasticity of breast cancer stem cells. 
Together, these data support a central role for RUNX1 in preventing breast 
cancer progression. Both tight control of RUNX1 expression and RUNX1 
functional integrity are required to prevent breast cancer malignancy. 
Consequently, clinical strategies should consider RUNX1 as a biomarker and 
potentially as a therapeutic candidate.  
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Chapter V Discussion and future direction 
5.1. Results summary 
The results of my dissertation studies have uncovered novel functions of RUNX1: 
a) in the regulation of normal mammary epithelial cells; b) identifying the loss of 
RUNX1 during cancer progression; and c) dysregulated mechanisms caused by 
depletion of RUNX1.  Together these findings demonstrated RUNX1 inhibits the 
breast cancer development. 
     In chapter II of this dissertation, we investigated the consequences of the loss 
of RUNX1 in both mammary epithelial and breast cancer cells. In the normal 
mammary epithelial MCF10A cells, we observed that depletion of RUNX1 changes 
the morphology of cells from epithelial-like to mesenchymal-like, and loss of 
RUNX1 initiates EMT in both normal epithelial and breast cancer cells. We also 
discovered that RUNX1 expression was lost upon induction of EMT by two different 
methods, suggesting that reduction of RUNX1 expression is a hallmark of EMT 
initiation in these cells. Mechanistically, RUNX1 functions through both exogenous 
TGF-b-dependent and -independent mechanisms indicating that RUNX1 is 
involved in multiple signaling pathways. Taken together, our studies revealed for 
that RUNX1 has anti-tumor growth activities in mammary lineage cells. The 
dissertation studies established the concept that RUNX1 preserves the epithelial 
morphology and negatively regulates EMT in both normal mammary epithelial and 
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breast cancer cells. 
In Chapter III of this dissertation, we explored whether RUNX1 regulates other 
cellular activities in normal mammary epithelial cells. To identify those putative 
functions of RUNX1 in MCF10A cells, we performed both global gene expression 
profiling and RUNX1 genome-wide binding analysis. Using high throughput 
sequencing, 1809 novel target genes that are differentially expressed upon loss of 
RUNX1 were identified. The pathway analysis for these genes indicated that 
RUNX1 regulates many aspects of cellular activities including the cell cycle and 
genome stability. We also performed RUNX1-ChIP-seq to study the mechanisms 
of RUNX1 regulated gene expression. Our results demonstrated that in normal-
like mammary epithelial cells, RUNX1 may form the complexes with some of the 
known RUNX1 co-regulatory factors, such as AP1, TEAD4 and STAT5. RUNX1 
may also interact with some factors, that have not previously been identified, such 
as NFIA. Our results also indicate that in MCF10A cells, the primary function of 
RUNX1 is to activate target gene expression. RUNX1 may primarily repress target 
gene expression in an indirect manner.  Using Flow Cytometry analysis, we 
demonstrated that RUNX1 loss results in a significant reduction of mitotic cells, 
with the percentage of mitotic cells reduced from 2.5% in parental and non-
silencing control to 1.4% in shRunx1 cells which is greater than 40% decrease. 
Consistent with G2/M arrest, commonly associated with genome instability, the 
ablation of RUNX1 decreased the expression levels of multiple DNA-repair related 
genes. Moreover, after treating the cells with a DNA-damaging agent, the DNA 
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repair process was compromised in Runx1 depleted MCF10A cells. Overall, this 
chapter discovered functions of RUNX1 in mammary epithelial cells such as 
controlling mitosis that was not previously reported. 
    In Chapter IV of this dissertation, we further elucidated RUNX1 function in breast 
cancer cells in relation to tumor growth. An important component of tumor growth, 
is the contribution of cancer stem cells (CSC). Because CSCs are associated with 
EMT, and RUNX1 is a negative regulator of EMT (Chapter II), we examined the 
cancer stem cell properties upon altering RUNX1 expression. Our results 
demonstrated that RUNX1 suppresses tumorsphere formation efficiency and the 
cancer stem cell population by negatively regulating Zeb1 expression. We 
observed that ectopic RUNX1 expression reduces migration and invasion in vitro 
and tumor growth in vivo, thus establishing RUNX1 reduces aggressive 
phenotypes in breast cancer cells. We therefore show to our knowledge for the 
first time, that RUNX1 inhibits the cancer stem cell phenotype in solid tumors, 
highlighting the potentials of RUNX1 regulating CSC in other epithelial cancers.  
5.2. Significance and clinical impact 
Breast cancer is the most common cancer and the second leading cause of cancer 
death in American women. On average 1 in 8 American women will be diagnosed 
with invasive breast cancer in their lifetime (Siegel, Miller et al. 2016). With the 
advantages of early detection and improved treatments, the 5-year survival  rate 
of breast cancer patients has increased to 90% (Miller, Siegel et al. 2016). 
However, the survival rate for patients with metastatic breast cancer remains low 
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(22%) (Siegel, Miller et al. 2016). Therefore, understanding the mechanisms of 
breast cancer initiation, progression and metastasis remains an important task. 
    In this dissertation, the functional activities of transcription factor RUNX1 in 
normal mammary epithelial and breast cancer cells were examined. The results 
from this dissertation demonstrate that RUNX1 has tumor suppressor potential in 
both mammary epithelial and breast cancer cells.   Loss of RUNX1 expression 
initiates EMT and deregulates cell cycle. Moreover, overexpressing RUNX1 in 
breast cancer cells represses cancer stem cell phenotype and tumor growth in vivo. 
The data from patient samples further suggests that RUNX1 expression and its 
normal function are clinically relevant in breast cancer prognosis. My analyses 
from public data sets showed low RUNX1 expression in patient tumors is 
associated with poor survival. Therefore, we propose that RUNX1 could translate 
into a new prognostic biomarker in breast cancer and potentially be a therapeutic 
target. 
    Mutations of RUNX1 and its partner CBFb account for 24% of adult AML cases 
(Look 1997) and 25% of pediatric ALL cases (Loh, Goldwasser et al. 2006). Thus, 
drug developments targeting the RUNX1 mutation or the interaction between 
RUNX1 and CBFb currently are a priority focus for finding treatments for various 
types of leukemia.  For instance, a small molecule AI-10-49, which selectively 
binds to a CBFβ mutant (CBFβ–SMMHC) and disrupts its binding to RUNX1, 
delays leukemogenesis in mice (Illendula, Pulikkan et al. 2015).  Another 
compound 7.44, a small molecule disrupting RUNX1-ETO tetramerization, also 
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suppresses leukemogenesis both in vitro and in vivo (Schanda, Lee et al. 2017). 
Besides above-mentioned small molecules targeting RUNX1 or CBFb mutation, 
small compounds, such as AI-4-57 and Ro5-3335, which both specifically block 
the Runx-CBFb interaction, inhibit the growth of leukemia cell lines in vitro 
(Cunningham, Finckbeiner et al. 2012, Illendula, Gilmour et al. 2016).  Therefore, 
RUNX1 is a promising target for intervention in leukemia. 
    To date, few efforts have been employed to specifically target RUNX1 in breast 
cancer cells. Therefore, developing small molecules that specifically target RUNX1 
to activate its expression can be a new therapeutic direction for breast cancer 
prevention and intervention, as indicated by our Runx1 repletion studies in mice 
(Fig. 4.5). Recently a study shows that a small molecule T63 activates Runx2 
expression and therefore attenuates the loss of bone mass (Zhao, Chen et al. 
2017).  Same strategy, identifying small molecules promote Runx1 expression, 
could apply to prevent loss of Runx1 induced disease.  
5.3. Open questions and future directions 
In this dissertation, we investigated the importance of RUNX1 in both normal 
epithelial and breast cancer cells. We identified several novel RUNX1 functions 
including repressing EMT and suppressing the cancer stem cell phenotype.  
However more work is needed to paint the full picture of function(s) of RUNX1 in 
normal mammary epithelial cells and in progression of breast cancer. 
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What are the up-steam regulators of RUNX1? 
An interesting direction for future research is to determine the upstream regulator(s) 
of RUNX1. There are many known transcription factor regulatory elements in the 
two RUNX1 promoters, as well as co-regulatory factors, histone modifications and 
enhancers which are found across the RUNX1 gene, all of which contribute to 
regulation of RUNX1 expression.  In hematopoietic cells, RUNX1 is up regulated 
by a RUNX1 intronic cis-regulatory element (+23 RUNX1 enhancer) (Bee, Ashley 
et al. 2009). This enhancer contains conserved motifs that bind various 
hematopoiesis related regulators such as Gata2, ETS, and RUNX1 itself acting in 
an auto-regulatory loop (Nottingham, Jarratt et al. 2007, Bee, Ashley et al. 2009). 
It is unclear whether this auto-regulatory mechanism also operates in mammary 
cells, and if so what factor(s) bind to +23 RUNX1 enhancer? In the mammary gland, 
RUNX1 is precisely regulated as its level fluctuates in pregnancy and lactation (van 
Bragt, Hu et al. 2014, Rooney, Riggio et al. 2017). RUNX1 is highly expressed in 
the basal lineage compared with the luminal lineage, suggesting a mechanism that 
either activates RUNX1 in basal cells or inactivates it in luminal cells (van Bragt, 
Hu et al. 2014).  However, it is unclear what transcription factor(s) control(s) 
RUNX1 expression in mammary cells, especially in basal/ myoepithelial cells. In 
breast cancer, RUNX1 is often mutated and its level is decreased compared with 
normal mammary epithelial cells (Chapter II and Chapter III).  The mechanisms 
driving the loss of RUNX1 expression in breast cancer cells are still unknown, but 
may involve multiple mechanisms including protein degradation by the proteasome, 
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inhibited translation by miRNAs, the removal of an activator, the binding of a 
repressor transcription factor, DNA hypermethylation, and(or) altered histone 
modifications.   
     We performed transcription factor binding prediction analysis on the sequences 
within 1kb upstream of the RUNX1 P1 promoter and identified potential binding 
sites of 66 transcription factors (Fig. 5.1). Among those transcription factors, some 
such as ERa, STAT，GATA1, are well known for their physical interactions with 
Runx1 protein and their roles in breast cancer (Elagib and Goldfarb 2007, Stender, 
Kim et al. 2010, Scheitz, Lee et al. 2012, Li, Ke et al. 2015, Banerjee and Resat 
2016). However, whether these 66 factors are actually functional in the mammary 
lineage, and whether they are positive or negative regulators of RUNX1 requires 
further examination. 
In Chapter II, we showed that TGF-b is one of the upstream regulators of RUNX1 
in mammary epithelial cells. The level of RUNX1 is decreased upon TGF-b 
treatment and overexpressing RUNX1 in TGF-b treated cells reversed the EMT 
phenotype. These data clearly demonstrate that RUNX1 is downstream of the 
TGF-b signaling pathway and that down-regulation of RUNX1 is necessary for the 
activation of TGF-b induced EMT. Estrogen is another upstream regulator of 
RUNX1 (Vivacqua, De Marco et al. 2015), as treating MCF7 cells with 17-b-
estradiol, decreases the level of RUNX1.  However which activators support 
RUNX1 expression in mammary lineage requires exploration; therefore, identifying 
the possible positive regulator(s) in normal mammary epithelial cells is necessary 
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for strategizing to protect RUNX1 expression in mammary gland and for breast 
cancer intervention.   
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What are the co-regulatory partners of RUNX1 in different cellular contexts? 
RUNX1 even with its co-regulatory partner CBF-b, is still not a strong DNA binding 
protein and primarily functions through interacting with diverse transcription factors, 
such as AP-1, GATA-1 and STAT (Pencovich, Jaschek et al. 2011, Scheitz, Lee 
et al. 2012, Chuang, Ito et al. 2013).  Therefore, the complexity of RUNX1 
regulatory mechanisms relies on the composition of its binding partners. The 
Runx1 binding partners are usually transcription factors, thereby giving RUNX1 the 
capability to temporally regulate target gene expression.  Motifs of some 
transcription factors, such as STAT and AP-1, were identified in our motif analysis 
on RUNX1 peaks as co-localizing with RUNX1 motif, suggesting they have the 
potential to form complexes with RUNX1.  Depending on cellular context in 
different subtypes or stages of breast cancer, RUNX1 may form transcription 
regulatory complexes with distinct co-activators or co-repressors. Thus, the 
diversity in binding of cofactors including histone modifiers, may explain the 
contradictory reports that RUNX1 has anti-tumor growth activity in mammary 
Figure 5.1 Potential RUNX1 regulators locate within 1kb upstream 
of RUNX1 promoter.  (A) List of transcription factors with predicted 
binding sites within 1kb upstream of RUNX1 promoter.  (B) Diagram of 
the location of the predicted binding sites of each transcription factor 
within 1kb upstream of RUNX1 promoter. 
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epithelial cells and is tumor-promoting in late stage triple-negative breast cancer 
{Chuang, 2013 #237}.  It would be informative to determine the components of 
RUNX1 transcription complexes by Runx1 immunoprecipitation in different breast 
cancer cell lines representing distinct subtypes and disease stages. 
Does RUNX1 have a function in mitosis? 
In Chapter III, we demonstrated that loss of RUNX1 decreases mitotic population 
in MCF10A cells by more than 40%. Therefore, is RUNX1 required for mitosis? If 
so, what function does RUNX1 play in mitotic cells?  During mitosis, some 
regulatory complexes remain bound to the condensed chromatin for rapid 
reactivation of genes following mitosis which is define as mitotic bookmarking 
(Zaidi, Young et al. 2010).  
    Runx2, another lineage specific Runx factor, is well known for its association 
with RNA Pol I-transcribed ribosomal RNA genes and RNA Pol II-transcribed 
phenotype-specific genes during mitosis (Young, Hassan et al. 2007, Young, 
Hassan et al. 2007). Is RUNX1 also involved in mitotic bookmarking? Nancy 
Speck’s group showed that in RUNX1 deficient hematopoietic stem and progenitor 
cells, ribosome biogenesis is reduced, with lower rRNA and ribosomal protein 
mRNA levels (Cai, Gao et al. 2015). Moreover, from our RNA-seq data, we also 
observed that upon RUNX1 knockdown, the transcription of majority of ribosomal 
proteins is inhibited (Fig.5.2). It will be worth investigating whether RUNX1 is a 
mitotic bookmarking factor in mammary epithelial cells and identify the genes that 
RUNX1 occupies during mitosis. One possible strategy is to perform Runx1-ChIP-
	 205	
seq in the cells blocked in mitosis with Nocodazole.  We can identify the genes be 
bound by Runx1 during mitosis. We can compare the expression of levels of these 
genes during mitosis in both control and RUNX1 depleted cells. It will be interesting 
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to test whether these genes still transcribed /translated properly without RUNX1 
binding during mitosis?  
 
 
What is the mechanism(s) of RUNX1 controlled genome stability? 
Decreased genome stability is a hallmark of cancer (Hanahan and Weinberg 2011). 
In Chapter III, we showed that loss of RUNX1 may lead to genome instability as 
DNA damage repair is slowed down in RUNX1 depleted cells. The exact 
mechanism(s) of RUNX1 controlled genome stability requires further exploration.  
Many mechanisms are involved to drive genome instability at both the 
chromosomal and nucleotide levels (Lee, Choi et al. 2016). Genomic instability at 
the nucleotide level is frequently represented in the hyper-mutation phenotype 
(Roberts and Gordenin 2014). Most of the mutations are caused by the defect of 
DNA repair pathways (Lee, Choi et al. 2016).   
Nevertheless, sequencing data from cancer patients have identified the 
existence of mutations densely clustered in short DNA segments which cannot be 
explained by DNA repair defect (Nik-Zainal, Alexandrov et al. 2012)(Roberts, 
Sterling et al. 2012).  Later, it was identified that members of Apolipoprotein B 
editing complexes (APOBECs) are cytidine deaminases (Conticello 2008) that are 
Figure 5.2 Heat map of changes in ribosome protein mRNAs. Heatmap 
of changes in ribosome protein mRNAs from control (NS, EV) or shRunx1 
(shRunx1-1, shRunx1-2) MCF10A cells.  
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responsible for generating this pattern of mutation (Roberts, Sterling et al. 2012), 
which is wide-spread in human cancers, including breast cancer (Burns, Lackey et 
al. 2013, Roberts, Lawrence et al. 2013, Kanu, Cerone et al. 2016).  HIV-1 protein 
Vif down regulates the human APOBEC3 family by targeting them for degradation 
(Wiegand, Doehle et al. 2004), which requires CBFb (Zhang, Du et al. 2011, Kim, 
Kwon et al. 2013).  Moreover CBFb is a positive regulator for APOBEC3 
transcription, as knockdown of CBFb decreases APOBEC3 mRNA (Anderson and 
Harris 2015). In human breast cancer, RUNX1 levels are decreased, which may 
generate free-state CBFb. It is possible that the free-state or increased CBFb 
promotes APOBEC3 expression and induces genome instability by generating 
mutations. Thus, RUNX1 mediated APOBEC3 repression may be a new axis for 
controlling genome stability in breast cancer. 
Is RUNX1 involved in Immune suppression? 
In the past few years, new findings have led to increased attention in the 
mechanisms by which cancer cells with EMT phenotype might contribute to 
immune suppression (reviewed in (Terry, Savagner et al. 2017)).  Multiple routes 
have been examined on the mechanisms of EMT induced tumor immune escape 
(Terry, Savagner et al. 2017). For instance, the EMT program can medicate cancer 
cell immune resistance to natural killer cells(Terry, Buart et al. 2017). Natural killer 
cells are the effector lymphocytes of the innate immune system, repressing tumor 
growth during cancer initiation and progression(Terry, Savagner et al. 2017). The 
EMT program can also activate immunosuppressive cytokines or immune 
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checkpoint ligands to modulate efficacy of immune response and its duration. For 
instance in triple-negative breast cancer, 20% of tumors activate the expression of 
one such immune checkpoint ligand, programmed cell death ligand-1 (PD-L1) 
(Wimberly, Brown et al. 2015) (Mittendorf, Philips et al. 2014) , which binds with its 
receptor PD-1 in T-cells. The binding of PD-1 and PD-L1 inhibits T-cell cytotoxic 
activity, resulting in a T-cell exhaustion state (Zou, Wolchok et al. 2016).  Antibody 
blocking PD-1/PD-L1 signal clinically restores T-cell activities and represses tumor 
growth (Alsaab, Sau et al. 2017) . To date, nivolumab or pembrolizumb (anti-PD-1 
antibody) and atezolizumab (anti-PD-L1 antibody) have been approved by the FDA 
to treat various metastatic cancers (Alsaab, Sau et al. 2017).  In cancer, several 
EMT signal pathways, such as Zeb1 and TGF-b, can drive PD-L1 expression as 
an immune escape mechanism (Chen, Gibbons et al. 2014, Chen and ten Dijke 
2016). 
   In chapter II, we demonstrated that RUNX1 blocks the initiation of EMT and we 
hypothesize that RUNX1 represses the immune surveillance both in the immune 
system and in cancer cells.  As the master regulator of hematopoiesis, RUNX1 is 
essential for T-cell maturation (reviewed in (Collins, Littman et al. 2009, Hsu, 
Shapiro et al. 2016, Ebihara, Seo et al. 2017)). Without RUNX1, development of 
T-cells is blocked resulting in the loss of functional nature killer T cells (Egawa, 
Eberl et al. 2005, Egawa, Tillman et al. 2007). Recently, it has been shown that 
Runx3 is a central regulator of CD8+ T cells by promoting T cell differentiation and 
accumulating matured CD8+ T cells in tumors (Milner, Toma et al. 2017). Given 
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the fact that both Runx1 and Runx3 is up-regulated and required for T-cell 
maturation (Yu, Zhang et al. 2017).  Runx1 may be also involved in resident 
lymphocytes in tumors.  Meanwhile, in cancer cells, our preliminary data indicate 
that RUNX1 functions as a negative regulator of PD-L1 and other immune 
checkpoint ligands.  In our MCF10A shRunx1 RNA-seq data, we found that loss of 
RUNX1 activates both PD-l1 and B7H4, another immune checkpoint ligand. 
However, it is unclear whether RUNX1 directly or indirectly regulates expression 
of these two ligands.  Taken together, these data implicate that RUNX1 is a key 
component to repress immune escape and its exact function requires further 
research. 
Is RUNX1 a regulator of long noncoding RNAs (lncRNAs)? 
Long noncoding RNAs are greater than 200 nucleotides in length and have no 
protein coding capacity.  They are often observed to be deregulated in a variety of 
cancer types.  Several lncRNAs have been well document for their function during 
breast cancer progression (reviewed in (Cerk, Schwarzenbacher et al. 2016, Wang, 
Liu et al. 2016) ).   
    Strikingly from our RNA-seq data, we observed that RUNX1 significantly altered 
the expression of several lncRNAs including NEAT1, MALAT1, XIST, HOTAIR, 
HOTAIRM1, GAS5 and ZFAS1 (Tabel 5.1). The expression patterns of these 
lncRNAs upon loss of RUNX1 are consistent with their patterns upon breast cancer 
progression. RUNX1 genomic binding analysis shows that RUNX1 directly binds 
to the promoters of many of these lncRNAs, such as NEAT1 and MALAT1, 
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suggesting transcriptional regulation by RUNX1. This may be another unidentified 
aspect of RUNX1 anti-tumor growth activity in breast cancer. It will be interesting 
to determine the extent to which RUNX1 plays a regulatory role in controlling 
lncRNA expression and how it relates to breast cancer progression.  To test this, I 
will knockdown oncogenic lncRNA by Gapmer or overexpress anti-tumor lncRNA 
by CrisprA in RUNX1-depleted cells and examine whether phenotypes induced by 
loss of RUNX1 are attenuated by specific lncRNA. 
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Table 5.1 List of LncRNAs expression of which is changed upon 
RUNX1 knockdown in MCF10A cells and their involvement in 
human breast cancer. 
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5.4.  Concluding Remarks 
This thesis describes the function of RUNX1 in both mammary epithelial cells and 
breast cancer cells. In mammary epithelial cells, RUNX1 maintains the epithelial 
phenotype and loss of RUNX1 promotes EMT. Additionally, our results 
demonstrate the anti-tumor growth function of RUNX1 in breast cancer cells by 
inhibiting the cancer stem cell population. In conclusion, my thesis work provides 
novel and significant insight into the mechanisms by which RUNX1 prevents 
transition of the mammary epithelium to breast cancer. This work impacts our 
understanding of Runx biology, mammary epithelial biology and breast cancer. Our 
findings pave the way for future investigation of the regulation of RUNX1 in other 
epithelial cancers. 
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